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Abstract 
Deubiquitinases (DUBs), the enzymes that catalyze the removal of ubiquitin moieties 
from target proteins, regulate a wide range of cellular processes and are potential targets 
for cancer therapy. Our knowledge on the basic biology of these important enzymes is 
still very limited. In this Thesis we have focused on three human DUBs (USP1, USP12 
and USP46) that share a common regulatory mechanism: they are activated by the 
cofactor UAF1. We have explored several aspects of the function and regulation of 
these three DUBs to clarify standing controversies and to uncover novel details.  
Our results show that phophorylation of USP1 at serine 313 is not necessary for UAF1 
binding, neither for its catalytic activity. We also provide evidence that USP1 
autocleavage occurs most likely in cis. Importantly, we map the UAF1-binding site of 
USP1, USP12 and USP46 to their so-called “Fingers” subdomain, and contribute to 
identify single residues that are critical for the interaction between these DUBs and their 
cofactor. Using a panel of functional tests, we show for the first time that cancer-related 
mutations in USP1 can alter its function and regulation. Regarding the potential role of 
the USP1/UAF1 complex as a target in cancer, we observed overexpression of USP1 
and UAF1 in pancreatic tumors and derived cell lines, and our data suggest that the 
USP1 inhibitor ML323 can increase oxaliplatin sensitivity in relatively resistant 
pancreatic cancer cell lines.  
In this Thesis we also significanlty expand the repertoire or potential USP1 substrates. 
By appliying a novel approach, termed bioUb, and label-free quantification (LFQ)-based 
proteomics, we have identified 10 proteins whose ubiquitination level increases when 
USP1 is silenced.  
Finally, regarding USP12 and USP46, our data suggest that these enzymes may 
differently bind to their common cofactor WDR20, and to at least another interactor 
(DMWD). This differential binding appears to be mediated by the presence/absence of a 
4 amino acid motif (MEIL) at their N-terminus, and may contribute to explain the 
previously observed functional differences between these two highly similar enzymes. 
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1. Introduction 
Posttranslational modifications (PTM) are important regulatory events that influence the 
properties of most cellular proteins including their activity, their interactions with other 
proteins and their subcelullar localization. Proteins can be modified, for example, by 
methylation, acetylation, hydroxylation, phosphorylation or conjugation to ubiquitin 
(Ub) and ubiquitin-like (UBL) proteins. Ubiquitin conjugation has emerged as a crucial 
regulator of practically all aspects of cell biology. 
1.1. PROTEIN UBIQUITINATION/DEUBIQUITINATION 
For a long time, most intracellular proteins were thought to be long-lived. This view 
remained virtually unchallenged until ubiquitin and the process of ubiquitination linked 
to the degradation of proteins in the proteasome were discovered (Goldstein et al., 1975; 
Hershko, 1983). 
The conjugation of ubiquitin is one the most common posttranslational modifications of 
proteins, and it is implicated in modulating many aspects of protein stability and 
function. Ubiquitin, a highly conserved 76 amino acid polypeptide, is covalently 
attached by its C-terminal dyglicine motif to either the N-terminal methionine or, most 
frequenlty, to a lysine of the target substrates (Figure 1). 
 
Figure 1: Ubiquitin linkage. The ubiquitin molecule can be conjugated by its C-
terminal dyglicine motif (GG, red) to a specific lysine (K) residue on the target 
substrate. 
The attachment of ubiquitin to a substrate is a multi-step enzymatic cascade involving 
three enzymes (Hershko et al., 1983) (Figure 2). In the first step, ubiquitin is activated 
by an E1 ubiquitin-activating enzyme in an ATP-dependent reaction. In the second step, 
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the activated ubiquitin is transferred to the active site of an E2 ubiquitin-conjugating 
enzyme. Finally, an E3 ubiquitin ligase catalyzes the ligation of ubiquitin to the target 
protein. 
 
Figure 2: The ubiquitination pathway. Ubiquitination is mediated by the 
sequential action of three enzymes: E1 (ubiquitin-activating enzyme), E2 
(ubiquitin-conjugating enzyme) and E3 (ubiquitin ligase). 
In humans, two E1s, around 35 E2s and several hundred E3 enzymes exist, thus, 
reflecting the wide variety of cellular functions that are modulated by ubiquitination. It 
must be noted that in addition to ubiquitin, mammalian cells encode approximately 20 
ubiquitin-like proteins (UBLs) that may be conjugated to target proteins via enzymatic 
cascades comparable to that of ubiquitination (Veen and Ploegh, 2012). These UBLs 
include, among others, small ubiquitin-like modifier (SUMO), neuronal-precursor-cell-
expressed developmentally downregulated protein 8 (NEDD8) and interferon-
stimulated gene 15 (ISG15). UBLs have variable sequences, but display three-
dimensional structure similar to ubiquitin. 
Protein ubiquitination is a highly versatile process due to the possibility of generating 
different types of ubiquitin chains (Figure 3). Thus, ubiquitination may occur on a single 
one or on several lysine/s of the target protein, resulting in monoubiquitination or 
multiubiquitination, respectively (Figure 3A) (Petroski and Deshaies, 2003, 2005). In 
addition, in the process of homotypic polyubiquitination (Figure 3B), further ubiquitin 
moieties can be sequentially attached to one of the seven internal lysine residues of 
ubiquitin (K6, K11, K27, K29, K33, K48 or K63) (Pickart and Fushman, 2004), or 
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ubiquitin chains can be assembled in linear configuration through the amino group at 
the N-terminus (Kirisako et al., 2006). Finally, several studies have described the 
existence of the so-called heterotypic polyubiquitination (Ikeda and Dikic, 2008) 
(Figure 3C), which involves the formation of mixed or branched ubiquitin chains, and 
could also include combinations of different UBLs, such as ubiquitin-SUMO hybrid 
chains (Guzzo and Matunis, 2013). 
 
Figure 3: Schematic representation of the different types of ubiquitin 
modifications and their functional role. The diversity of ubiquitin linkage and 
chain types regulates the fate of the protein substrates. Adapted from (Wong and 
Cuervo, 2010). 
The diversity of ubiquitin linkages is essential for determining the fate of cellular 
proteins. Monoubiquitination can regulate endocytosis, protein transport and DNA 
repair among other functions (Hicke, 2001). Multiubiquitination is important for 
receptor endocytosis (Haglund et al., 2003). K48-linked polyubiquitination targets 
proteins for degradation in the proteasome (Chau et al., 1989), whereas K63-linked 
polyubiquitination is required for proteasome-independent functions such as DNA 
damage tolerance, vesicle trafficking and signal transduction (Haglund and Dikic, 
2005). Until recently, only K48- and K63-linked chains have been extensively studied 
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and the outcome of other linkage types, such as K29 or K33, is still poorly 
characterized. The functions so far assigned to these atypical ubiquitin linkages 
(summarized in Figure 3B) are very diverse (Kulathu and Komander, 2012). 
Like other PTMs, such as phosphorylation or methylation, ubiquitination is a reversible 
process (Figure 4). Deubiquitinating enzymes or deubiquitinases (DUBs), oppose the 
activity of E3 ligases by removing ubiquitin moieties from protein substrates. DUBs 
catalyze the hydrolysis of the isopeptide bond between ubiquitin and the target protein 
or between ubiquitin moieties in a polyubiquitin chain. (Reyes-Turcu et al., 2009) 
(Figure 4). 
Fulfilling an analogous role to DUBs, there are also deconjugating enzymes for other 
UBLs, such as SUMO-specific proteases (SENPs) (Mukhopadhyay and Dasso, 2007), 
NEDD8-specific proteases (NEDP1) (Mendoza et al., 2003) and ISG15-specific 
proteases (UBP43) (Malakhov et al., 2002). 
 
Figure 4: Deubiquitination pathway. Deubiquitinating enzymes (DUBs) catalyze 
the removal of ubiquitin moieties from ubiquitinated substrates. 
The dynamic balance between the activity of ubiquitin E3 ligases and DUBs determines 
the final ubiquitination status of the substrate, and this balance must be carefully 
regulated to ensure cellular homeostasis. In this regard, the 
ubiquitination/deubiquitination processes play an essential role in critical cellular 
functions such as gene expression (Geng et al., 2012), cell cycle progression (Nakayama 
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and Nakayama, 2006), apoptosis (Vucic et al., 2011) and DNA repair (Ulrich and 
Walden, 2010). Dysregulations in protein ubiquitination/deubiquitination have been 
found to be involved in several human diseases, such as neurodegenerative disorders 
(Atkin and Paulson, 2014) and cancer (Satija et al., 2013). These findings provide 
opportunities for new therapeutic approaches. For example, targeting the ubiquitin-
proteasome pathway using the proteasome inhibitor bortezomib, has proven to be an 
effective strategy in the treatment of multiple myeloma (Chen et al., 2011; Richardson 
et al., 2003). More recently, the enzymes that conform the 
ubiquitination/deubiquitination machinery have begun to be studied as potential targets 
in cancer therapy (Hoeller and Dikic, 2009). In this regard, E3 ligases were initially the 
focus of these studies, and E3 inhibitors are already undergoing clinical trials (Mattern 
et al., 2012). On the other hand, several small molecule DUB inhibitors have shown 
therapeutic potential in preclinical trials (Mattern et al., 2012). 
The development of DUBs as therapeutic targets for cancer and other diseases requires 
a more detailed understanding of the function and regulation of these enzymes. 
1.2. HUMAN DEUBIQUITINATING ENZYMES (DUBs) 
The human genome encodes nearly 100 putative DUBs, although only 79 of them are 
predicted to be active enzymes (Nijman et al., 2005a). 
1.2.1. Cellular functions of DUBs 
The major cellular functions of DUBs are illustrated in Figure 5. A first function is the 
processing of ubiquitin precursors (Figure 5 a). Ubiquitin is expressed from several 
genes as a linear fusion of multiple ubiquitin moieties or fused with ribosomal proteins. 
The generation of a pool of free ubiquitin units in cells requires DUB activity. A second 
function consists on the removal of degradative or non-degradative ubiquitin tags from 
proteins. By removing the ubiquitin tags from modified substrates, DUBs may reverse 
ubiquitin signaling or rescue a substrate from degradation (Figure 5 b,c). A third 
function relates to the recycling of ubiquitin moieties from those ubiquitinated proteins 
that undergo proteasomal degradation. This activity of DUBs is critical to maintain the 
pool of free ubiquitin (Figure 5 d,e) (Swaminathan et al., 1999; Verma et al., 2002). 
Finally, by helping to exchange one type of ubiquitin modification for another, DUBs 
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contribute to edit the length and topology of ubiquitin tags, and can thereby alter the 
fate of the ubiquitinated substrate (Figure 5 f) (Heyninck and Beyaert, 2005; Komander 
et al., 2009). 
 
Figure 5: Schematic diagram of DUBs functions. Adapted from (Komander et al., 
2009). 
1.2.2. Domain architecture and classification of DUBs  
DUBs are modular proteins. Besides their active site-containing core catalytic domain, 
they may contain additional inserted sequences as well as N- and/or C-terminal 
extensions. These additional amino acid sequences contribute to modulate the substrate 
specificity, protein-protein interactions, and subcellular localization of the enzymes, and 
may include, among others, motifs that recognize and non-covalently bind ubiquitin, 
such as the ubiquitin-binding domain (UBD), the ubiquitin-interacting motif (UIM) or 
the ubiquitin-associated motif (UBA) (Hurley et al., 2006), as well as ubiquitin-like 
domains (ULD) (Zhu et al., 2007). 
Based on the structure of their catalytic domains, DUBs have been classified in five 
subfamilies: ubiquitin-specific proteases (USPs), ovarian-tumor proteases (OTUs), 
Machado-Joseph disease domain proteases (MJDs), ubiquitin C-terminal hydrolases 
(UCHs), and JAB1/MPN/Mov34 metalloproteases (JAMMs) (Nijman et al., 2005a) 
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(Figure 6). The first four families are cysteine proteases whose active site contains a so-
called catalytic triad formed by cysteine, histidine and aspartate/asparagine residues. In 
contrast, JAMMs are zinc-dependent metalloproteases that contain histidine, aspartate 
and serine residues in their catalytic site (Komander, 2010; Nijman et al., 2005a). 
The USP subfamily represents the largest and more diverse group of human DUBs, with 
more than sixty members (Komander et al., 2009; Nijman et al., 2005a; Quesada et al., 
2004). 
 
Figure 6: DUB classification. Human DUBs are classified in five subfamilies: USP, 
OTU, UCH, MJD and JAMMs. 
1.3. THE USP SUBFAMILY OF DUBs 
1.3.1. General structural features and ubiquitin chain specificity of 
USPs 
The DUBs belonging to the USP subfamily share a common structural fold of their 
catalytic domain, termed the USP fold (Dharadhar et al., 2016; Hu et al., 2002; 
Komander et al., 2009; Li et al., 2016; Reyes-Turcu et al., 2009). 
The USP fold resembles an open right hand that contains three well-defined 
subdomains, referred to as the “Thumb” “Palm” and “Fingers” (Figure 7). The “Thumb” 
subdomain is principally composed of α-helices and comprises the Cys Box, a region 
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that contains the active site cysteine. The “Palm” subdomain is formed by both β-
strands and α-helices and contains the other two catalytic amino acids: histidine and 
aspartate (or asparagine) residues. The catalytic core is located at the interface between 
the “Thumb” and “Palm” subdomains. This interface generates a cleft where the active 
site residues and the C-terminal tail of ubiquitin are accommodated (Hu et al., 2002, 
2005; Komander et al., 2009; Renatus et al., 2006). The front side of the “Fingers” 
subdomain is the primary interaction site for ubiquitin. In several USPs, the “Fingers” 
subdomain contains a conserved Cys-X-X-Cys zinc-coordinating motif (Hu et al., 2002, 
2005). Besides mediating ubiquitin binding, the “Fingers” subdomain may play an 
important role in the regulation of certain USPs, as described in detail in section 4.2.2.  
 
Figure 7: Structural characteristics of the USP catalytic domain. As a 
representative example, the structure of the catalytic domain of USP7 is shown on 
the left. The drawing on the right illustrates the “open right hand” shape that 
characterizes the USP domain. The “Thumb”, “Palm” and “Fingers” subdomains 
are indicated. The catalytic site is depicted in brown and the Zn binding site is 
represented in light purple. An ubiquitin molecule bound to “Fingers” subdomain 
is shown in grey. Adapted from (Faesen et al., 2012). 
Despite their structural similarities, the catalytic domain of different USPs shows only 
limited amino acid sequence conservation. A detailed sequence alignment analysis (Ye 
et al., 2009) revealed that the USP core domain can be divided into six relatively-well 
conserved boxes (boxes 1–6) (Figure 8), but, several USPs, contain additional non-
conserved domains of variable length inserted between the boxes. As a result of the 
presence of these insertions, the size of the catalytic domain may vary considerably 
between different USPs. It has been proposed that these so-called inserted domains play 
regulatory roles (Ye et al., 2009). 
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Figure 8: Structure and box annotations of USP7, a representative example of 
the USP family. A. Schematic illustration and ribbon representation of USP7 
catalytic domain. The conserved boxes 1-6 are depicted in different colors B. 
Ribbon representation where the insertion points for non-conserved amino-acid 
segments are highlighted in red. Adapted from (Ye et al., 2009). 
In comparison to DUBs belonging to other subfamilies, USPs are in general relatively 
promiscuous regarding the type of ubiquitin linkage they can cleave. Thus, whereas 
OTUs exhibit strong linkage preferences for specific di-ubiquitin topoisomers and many 
JAMMs are K63-specific (Bremm et al., 2010; Cooper et al., 2009; Faesen et al., 2011; 
Komander et al., 2009; Wang et al., 2009), some USPs, like USP4 and USP16, seem to 
be able to hydrolyze all ubiquitin topoisomers, including linear-linked ubiquitin chains 
(Faesen et al., 2011). 
1.3.2. Regulation of USP catalytic activity  
The catalytic activity of USPs is regulated by several mechanisms, including substrate-
induced conformational rearrangement of the catalytic site, posttranslational 
modifications (PTMs) and binding to activating cofactors. 
Upon binding to their ubiquitinated substrates, several USPs undergo different 
conformational changes that promote their catalytic activity. These changes may consist 
on the alignment of the catalytic triad in a productive conformation, as in USP7 (Hu et 
al., 2002), the displacement of a loop that blocks the catalytic site, as in USP14 (Hu et 
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al., 2002), or a movement of the “Fingers” subdomain to properly fit the globular body 
of the ubiquitin, as in USP8 (Avvakumov et al., 2006). 
On the other hand, a variety of posttranslational modifications may regulate the catalytic 
activity of some USPs. A prominent example is the Akt-mediated phosphorylation of 
USP14 , which activates its deubiquitinating activity (Xu et al., 2015). 
Finally, a small subset of USPs requires binding to a cofactor to become catalytically 
active. The most prominent example of this regulatory mechanism is the activation of 
USP1, USP12 and USP46 by the WD-repeat containing protein WDR48/UAF1. These 
three USPs have a very low intrinsic deubiquitinating activity that is dramatically 
enhanced upon biding to the cofactor (Cohn et al., 2007, 2009). The work described in 
this Thesis focuses on different aspects of the function and regulation of the 
deubiquitinase complexes that USP1, USP12 and USP46 form with their cofactor 
WDR48/UAF1. 
1.4. WDR48/UAF1, AN ACTIVATING COFACTOR OF USP1, 
USP12 AND USP46 
The gene encoding WDR48/UAF1 is located on the 3p22.2 chromosomal region. A 
partial cDNA coding for a 607 amino acid protein (KIAA1449) was first identified in 
2000 (Nagase et al., 2000) . In 2002, Park and co-workers cloned the full-length cDNA 
encoding a 677 amino acid protein with a predicted molecular weight of 76.21 kDa, 
which they called p80 (Park et al., 2002). The officially recommended name for this 
protein is WDR48 (http://www.uniprot.org/uniprot/Q8TAF3). However, this protein is 
most commonly referred to as USP1-associated factor 1 (UAF1) in the scientific 
literature. For this reason, the name UAF1 will be hereafter used in this Thesis. 
1.4.1. UAF1 domain structure 
UAF1 belongs to the WD repeat (WDR) domain-containing protein family. This family 
is characterized by the presence of several copies of an approximately 40 residues-long 
sequence motif containing Trp-Asp repeats. UAF1 contains eight WD repeats. The 
structure of UAF1 reveals three different domains (Figure 9): repeats WD1-WD7 form 
the β-propeller domain, a domain shaped as a toroid with a narrow central pore, whereas 
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the WD8 repeat is included into the so-called ancillary-domain. On the other hand, the 
C-terminus of UAF1 contains a SUMO-like domain (SLD) with two subdomains (SLD1 
and SLD2). The SLD adopts a coiled-coil conformation (Yin et al., 2015), although the 
structure of some regions of this domain remains unsolved in the currently available 
models. The SLD of UAF1 has been uncovered to be involved in the substrate 
recruitment (Yang et al., 2011).  
 
Figure 9: Structure of UAF1. A. Schematic representation of UAF1 domain 
structure: The β-propeller domain (green) with the WD repeats 1-7, the ancillary 
domain containing WD8 (orange) and the SUMO-like domain (blue) with the SLD1 
and SLD2 subdomains are indicated. B. Three-dimensional structure of UAF1. The 
three domains, as well as the N-and C-termini are indicated, and the WD repeats 
are numbered. Panel B is adapted from (Yin et al., 2015). 
1.4.2. UAF1 function 
UAF1 was originally identified as a cellular protein targeted by the herpesvirus saimiri 
Tip protein during viral infection (Park et al., 2002). UAF1 has been subsequently 
found to bind other viral proteins, such as the E1 helicase of Human papillomavirus 
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(HPV) (Côté-Martin et al., 2008) or the EBNA3C protein of Epstein-Barr virus (EBV) 
(Ohashi et al., 2015) and to play a role in viral pathogenesis. 
However, the best-characterized function of UAF1 is as a regulator of USP1, USP12 
and USP46. UAF1 binding increases the stability of USP1, USP12 and USP46 (Cohn et 
al., 2007, 2009). In addition, UAF1 acts as a cofactor that stimulates the catalytic 
activity of these three enzymes (Cohn et al., 2007, 2009). The low intrinsic enzymatic 
activity of these DUBs is increased by up to 30 fold upon complex formation with 
UAF1 (Cohn et al., 2007; Faesen et al., 2011; Yin et al., 2015). By activating these 
DUBs, UAF1 contributes to regulate the ubiquitination level of several substrate 
proteins, and thus plays a role in a variety of cellular processes, which will be described 
in detail in sections 1.5.2. and 1.6.2. 
Two different mechanisms have been proposed for UAF1-mediated stimulation of 
USPs. On one hand, UAF1 binding has been reported to induce a structural 
rearrangement of the DUB active site that allosterically increases catalytic turnover (Li 
et al., 2016; Villamil et al., 2012a). An alternative model proposes that activation relies 
mainly on UAF1-dependent stabilization of the DUBs, without significant 
rearrangements in their structure (Dharadhar et al., 2016; Yin et al., 2015). Of note, 
binding to UAF1 does not modify the affinity of the DUBs for their substrates (Yin et 
al., 2015). 
1.5. THE USP1/UAF1 DEUBIQUITINASE COMPLEX 
The first deubiquitinase found to be activated by UAF1 was USP1 (Cohn et al., 2007). 
USP1 is a 785 amino acid protein with a predicted molecular weight of 88.2 KDa 
(Fujiwara et al., 1998), encoded by a gene located on chromosomal region 1p31.3. As 
detailed below, the USP1/UAF1 complex plays important roles in several aspects of the 
cellular response to DNA damage, and represents a potential target in cancer therapy.  
1.5.1. Domain structure and functional motifs in USP1  
USP1 bears one of the largest catalytic domains within the USP subfamily due to the 
presence of inserted domains between boxes 2 and 3 and between boxes 5 and 6 (Ye et 
al., 2009). The catalytic domain of USP1 contains an N-terminal Cys box bearing the 
 
17 
Introduction
  
catalytic residue C90 and a C-terminal His box bearing the catalytic residues H593 and 
D751. (Fujiwara et al., 1998; Villamil et al., 2012a) (Figure 10). Although the three-
dimensional structure of USP1 has not yet been solved, a modeled structure suggests 
that these three amino acids, which constitute the catalytic triad, are close to each other 
forming the catalytic core of the enzyme (Villamil et al., 2012b). Mutation of any of 
these residues significantly decreases the catalytic activity of USP1 (Villamil et al., 
2012a). 
As indicated in Figure 10, several sequence motifs that contribute to modulate USP1 
function have been identified in the inserted domains. The inserted domain between 
boxes 2 and 3 contains a degradation motif (degron) (Cotto-Rios et al., 2011a), a 
phosphorylation site (S313) (Cotto-Rios et al., 2011b; Villamil et al., 2012b) and two 
nuclear localization signals (NLSs) (Garcia-Santisteban et al., 2012). The inserted 
domain between boxes 5 and 6 includes an autocleavage site (G670-G671) (Huang et 
al., 2006). The relevance of these elements in the regulation of USP1 will be described 
in detail below. 
 
Figure 10: Functional motifs in USP1 Schematic representation of USP1 protein 
showing the position of the amino acids that constitute the catalytic triad C90, 
H593 and D751 (black arrowheads). An insertded domain between boxes 2 and 3 
contains a degron motif (green), the serine 313 phosphorylation site (red “P”) and 
two NLSs (dark blue). An inserted domain between boxes 5 and 6 contains a 
diglycine autocleavage site (pink). 
1.5.2. The role of the USP1/UAF1 complex in the response to DNA 
damage 
Living organisms can be exposed to a variety of endogenous and exogenous DNA-
damaging agents that generate genomic lesions. To preserve genome integrity, cells 
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have evolved a complex array of mechanisms to detect, signal and repair these lesions, 
which collectively constitute the so-called DNA damage response (DDR) (Jackson and 
Bartek, 2009). During the DDR, multiple repair factors relocalize into nuclear foci at the 
sites of damage (Lukas et al., 2004). Recruitment of these factors is regulated by a 
complex interplay of protein post-translational modifications (Zhao et al., 2014). In 
particular, ubiquitination has been shown to crucially regulate different DNA repair 
processes, such as translesion synthesis (TLS), the Fanconi anemia (FA) pathway and 
double-strand break (DSB) repair (Ulrich and Walden, 2010) (Figure 11). 
 
Figure 11: Ubiquitination in the DNA damage response. Following DNA double 
strand breaks (DSBs), histone H2AX is phosphorylated and recruited to the 
damage site. Next, downstream DNA repair factors, such as BRCA1 and 53BP1, are 
recruited in an ubiquitin-dependent manner to damage foci. In the response to 
interstrand DNA cross-link (ICL) lesions, Translesion Synthesis (TLS) and Fanconi 
Anemia (FA) pathways can be activated by ubiquitination of PCNA and 
FANCD2/FANCI, respectively.  
DSBs are potentially hazardous chromosomal lesions. Two predominant pathways have 
evolved to repair DSBs: nonhomologous DNA end joining (NHEJ) and homologous 
recombination (HR). NHEJ operates by a direct ligation of the broken DNA ends, 
whereas HR involves repair of DSBs by duplicating the genetic information from the 
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sister chromatid. The balance between these pathways is essential for the successful 
maintenance of the genomic integrity. The first step following DNA damage, is the 
phosphorylation of histone H2AX (γ-H2AX) and its subsequent recruitment to damage 
foci. Then multiple repair factors, such as Breast cancer 1 (BRCA1) and p53-binding 
protein 1 (53BP1), relocalize into nuclear damage foci (Lukas et al., 2004). Recruitment 
of these factors is crucially regulated by ubiquitination (Ulrich and Walden, 2010). 
Genetic evidence suggests that BRCA1 and 53BP1 are the responsible for the choice 
between HR and NHEJ, respectively (Bouwman et al., 2010; Chapman et al., 2012).  
The role of the ubiquitin conjugation machinery in the DNA damage response has been 
relatively well studied, but considerably less is known about the role of DUBs in these 
processes. In this regard, USP1 was one of the first DUBs identified as a DDR 
regulator. In particular, the USP1/UAF1 complex, regulates the Fanconi anemia (FA) 
pathway by deubiquitinating Fanconi anemia complementation group 2 (FANCD2) and 
Fanconi anemia complementation group I (FANCI) (Nijman et al., 2005b), as well as 
the process of translesion synthesis (TLS) by deubiquitinating Proliferating cell nuclear 
antigen (PCNA) (Huang et al., 2006). In addition USP1/UAF1 has been shown to 
promote HR-mediated DNA repair (Cukras et al., 2016; Liang et al., 2016; Murai et al., 
2011).  
Fanconi anemia (FA) is a rare genetic disease characterized by congenital 
malformations, progressive bone marrow failure, genomic instability, hypersensitivity 
to DNA cross-linking agents, such as mytomicin C (MMC) or cisplatin, and increased 
susceptibility to cancer (Kee and D’Andrea, 2012). To date, nineteen genes that encode 
Fanconi anemia complementation (FANC) group proteins have been identified. The 
products of these genes participate in a complex pathway that repairs interstrand DNA 
crosslinks (ICLs). Following DNA damage, eight FANC proteins 
(FANCA/B/C/E/F/G/L/M) form a multisubunit E3 ligase complex, termed the FA core 
complex. The FA core complex monoubiquitinates two other FA proteins, FANCD2 (at 
residue K561) and FANCI (at residue K523). Monoubiquitinated FANCD2 
(UbFANCD2) and FANCI (UbFANCI) are subsequently translocated to DNA damage 
sites and recruit downstream DNA repair proteins (FANCD1J/N/O/P) (Kim and 
D’Andrea, 2012). USP1 regulates the FA pathway by deubiquitinating UbFANCD2 and 
UbFANCI, thus reversing the activation of the pathway (Figure 12; left panel). The 
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importance of a timely inactivation of FA pathway by USP1 is demonstrated by the 
observation that USP1 or UAF1 gene knockout in murine models or DT40 chicken cells 
results in a phenotype that resembles the phenotype of human patients with FA (Kim et 
al., 2009; Murai et al., 2011; Oestergaard et al., 2007; Park et al., 2013). 
In addition to the FA pathway, USP1 also participates in translesion synthesis (TLS). 
TLS is a DNA damage tolerance mechanism that involves DNA replication by 
specialized DNA polymerases, called TLS polymerases (Waters et al., 2009). Following 
DNA damage that stalls the progression of the replication fork, PCNA is 
monoubiquitinated at K164 by RAD6 and RAD18 E3 ligases (Hoege et al., 2002). 
Monoubiquitinated PCNA (UbPCNA) promotes a switch between the classical 
replicative polymerases and the TLS polymerases, which can bypass the lesion and 
continue replication (Fox et al., 2011). However, TLS polymerases have a lower 
fidelity, and thus, TLS is a highly mutagenic process that needs to be tightly regulated. 
Central to this regulation, USP1 deubiquitinates UbPCNA, thus contributing to prevent 
unscheduled recruitment of error-prone TLS polymerases (Huang et al., 2006) (Figure 
12; middle panel). 
Finally, USP1/UAF1 promotes homologous recombination by an as yet unknown 
mechanism that appears to involve the suppression of the NHEJ pathway (Murai et al., 
2011). This function has been reported to be, at least in part, mediated by interaction of 
UAF1 with RAD51-associated protein 1 (RAD51AP1) in a manner that could be 
independent from USP1 (Cukras et al., 2016; Liang et al., 2016) (Figure 12; right panel). 
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Figure 12: Summary of the roles of the USP1/UAF1 complex in the DNA damage 
response. USP1/UAF1 regulates DNA repair by reverting the monoubiquitination 
of FANCD2/FANCI in the Fanconi anaemia (FA) pathway and of PCNA in the 
translesion synthesis (TLS) pathway. In addition, the USP1/UAF1 complex 
promotes the repair of DNA damage via homologous recombination (HR) by the 
interaction of UAF1 with RAD51AP1. 
To conclude, it is important to note that the function of USP1/UAF1 in the nucleus 
extends beyond its DDR-related roles, to include deubiquitination of inhibitors of DNA 
binding (ID) proteins (Williams et al., 2011). ID proteins, which are expressed in 
several undifferentiated and proliferative cells, negatively regulate basic-helix-loop-
helix (bHLH) transcription factors and thus, inhibit cell differentiation. By 
deubiquitinating and stabilizing ID proteins, USP1/UAF1 contributes to maintain stem 
cell features in osteosarcoma (Williams et al., 2011). It can be reasonably assumed that 
the USP1/UAF1 complex may have still unknown substrates and carry out additional 
cellular functions that remain to be elucidated. To explore this possibility, we have used 
a novel proteomics-based strategy, termed bioUb (Franco et al., 2011) to search for 
potential novel USP1/UAF1 targets, as described in section 3.7.1. 
1.5.3. Regulation of the USP1/UAF1 complex 
In addition to the catalyitic activation of USP1 that results from binding to UAF1, 
several other regulatory mechanisms converge to determine the levels, localization and 
activity of USP1, ensuring that the function of the USP1/UAF1 complex is carried out 
in a properly controlled spatio-temporal manner. These mechanisms include cell cycle-
regulated expression, autocleavage/degradation, phosphorylation, and subcellular 
localization. 
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Transcription of the USP1 gene is cell cycle-regulated: USP1 mRNA levels are low 
during G1 and reach a peak during S phase (Nijman et al., 2005b). The levels of USP1 
protein are also regulated in a cell cycle-dependent manner by proteasomal degradation. 
In this respect, USP1 contains a degradation motif (degron) comprising amino acids 
295-342 which is recognized by the Anaphase Promoting Complex/CyclosomeCdh1 
(APC/CCdh1) E3 ligase in G1, leading to USP1 degradation (Cotto-Rios et al., 2011a). 
APC/CCdh1-induced degradation of USP1 can be further regulated by two different 
mechanisms. On the one hand, Cyclin-dependent kinase 1 (Cdk1)-mediated 
phosphorylation of USP1 at serine 313 could mask the degron motif and thus prevent 
USP1 degradation in M phase (Cotto-Rios et al., 2011b). On the other hand, calpains 
may indirectly prevent APC/CCdh1-induced degradation of USP1 by activating Cdk5, a 
Cdh1 inhibitor (Cataldo et al., 2013). 
Besides the cell cycle-related oscillations in USP1 levels, the activity of the 
USP1/UAF1 complex needs to be tightly regulated in response to genotoxic lesions. 
Thus, activation of FA and TLS pathways require the downregulation of USP1/UAF1 
function in order to avoid FANCD2/FANCI and PCNA deubiquitination. In this regard, 
USP1 transcription is stopped upon DNA damage by a mechanism involving the p21 
cyclin-dependent kinase inhibitor (Rego et al., 2012). In addition, exposure to genotoxic 
agents promotes autocleavage of the USP1 protein at the G670/G671 diglycine motif 
(Huang et al., 2006) (Figure 10). This cleavage event generates an N-terminal fragment 
(residues 1-671) and a shorter C-terminal fragment (672-785) of USP1, which are 
eventually degraded by the proteasome. USP1 autocleavage is thought to represent an 
important regulatory mechanism for USP1/UAF1 function. However, several aspects of 
this mechanism remain to be elucidated.  
The function of the USP1/UAF1 complex can be also regulated by phosphorylation of 
USP1. The most relevant phosphorylation site in USP1 appears to be the serine residue 
at position 313. Besides the effect of this modification on APC/CCdh1-induced USP1 
degradation described above, S313 phosphorylation has been reported to regulate UAF1 
binding. Using in vitro pull-down assays with purified recombinant proteins, Villamil et 
al, mapped the UAF1-binding region of USP1 to the non-conserved inserted domain 
between boxes 2 and 3 of USP1 (amino acid segment 235-408), which contains the 
S313 residue. They reported that this residue needed to be phosphorylated for the 
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USP1/UAF1 interaction to occur (Villamil et al., 2012b) (Figure 13). In contrast to these 
findings, our group had previously mapped the UAF1-binding region of USP1 to the 
amino acid segment 420–520 using cell-based assays (Garcia-Santisteban et al., 2012). 
This segment does not include the S313 phosphorylation site (Figure 13), and thus our 
findings raised questions about how modification of this residue could modulate 
USP1/UAF1 interaction. One of the aims of this Thesis has been to clarify these 
conflicting results, and to determine to what extent S313 phosphorylation contributes to 
USP1/UAF1 interaction.  
 
Figure 13: Schematic representation of USP1 showing the two reported UAF1 
binding sites. The UAF1 binding site reported by Villamil et al. (including the 
serine 313 phosphorylation site) is highlighted in yellow. The UAF1 binding site 
reported by Garcia-Santisteban et al. is coloured in green. 
Finally, the subcellular localization of the USP1/UAF1 complex is largely determined 
by two nuclear localization signals (NLSs) in USP1 (Garcia-Santisteban et al., 2012). In 
contrast to USP1, which is located in the nucleus, UAF1 is a cytoplasmic protein when 
expressed alone (Figure 14A). Our current data support a model in which USP1 and 
UAF1 form a complex in the cytoplasm that is subsequently relocated to the nucleus 
(Garcia-Santisteban et al., 2012) (Figure 14B). Thus, UAF1 enters the nucleus via a 
piggyback mechanism mediated by USP1 NLSs. Importantly, the nuclear relocation of 
UAF1 that results from USP1 co-expression provides a clear readout to analyze 
USP1/UAF1 complex formation in cells (Figure 14C) and can be easily applied to 
evaluate the ability of different USP1 or UAF1 mutants to interact with each other. 
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Figure 14: Two NLSs in USP1 mediate the nuclear localization of USP1/UAF1. A. 
Confocal images of 293T cells co-expressing Xpress-UAF1 with an empty GFP 
vector or with GFP-USP1. Xpress-UAF1 (red) relocates to the nucleus when co-
expressed with GFP-USP1 (green), but remains in the cytoplasm when co-
expressed with GFP. B. Model illustrating the import of the USP1/UAF1 complex 
to the cell nucleus. USP1 (green) and UAF1 (red) form a complex in the cytoplasm 
that is subsequently transported into the cell nucleus through active nuclear 
import mediated by the interaction between USP1 NLSs and importins (imp). C. 
UAF1 nuclear relocation assay. The interaction between USP1 and UAF1 complex 
can be observed in cells as a relocation of UAF1 to the nucleus. Panels B and C are 
taken from (Garcia-Santisteban et al., 2012). 
1.5.4. USP1 alterations in cancer  
The DUBs that participate in the DNA damage response are increasingly gaining 
interest from the point of view of anticancer therapy. Given the crucial role of USP1 in 
this process, it is reasonable to assume that aberrant expression or mutational alteration 
of this DUB might contribute to cancer development. 
USP1 mRNA levels are significantly altered in different human tumor types. In 
particular, USP1 is often overexpressed in cervical and gastric cancer, melanoma and 
sarcoma (García-Santisteban et al., 2013). On the other hand, although USP1 gene 
mutations are not a frequent event in human tumors, the Catalogue Of Somatic 
Mutations in Cancer (COSMIC) database (http://cancer.sanger.ac.uk/cosmic) includes 
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more than 100 USP1 gene mutations. Most of these mutations are missense 
substitutions (Figure 15), whose functional effect has not yet been tested (Forbes et al., 
2011). We present a functional characterization of a subset of cancer-related USP1 
mutants in section 4.3.2.  
 
Figure 15: Types of cancer-associated mutations in USP1. Distribution of cancer-
associated USP1 mutations reported in the COSMIC mutation database.  
1.5.5. The USP1/UAF1 complex as a therapeutic target in cancer 
A mainstay of conventional cancer therapy is the use of platinum-based genotoxic 
drugs, such as cisplatin or oxaliplatin. However, the DNA damage induced by these 
agents may lead to the activation of DNA repair pathways, which may act as escape 
routes resulting in resistance of cancer cells to the chemotherapy (Housman et al., 
2014). 
Importantly, interfering with USP1 function has been shown to increase sensitivity to a 
variety of chemotherapeutic agents in several model systems (Kim et al., 2009; Murai et 
al., 2011). These observations have led to propose that targeting the USP1/UAF1 
complex might be a relevant approach to overcome resistance to commonly used 
chemotherapeutic drugs (Jackson and Durocher, 2013).  
Several small molecule inhibitors that block the activity of USP1/UAF1 complex have 
been reported over the last years.  
In 2011, a high throughput screening (HTS), lead to the identification of pimozide and 
GW7647 (Chen et al., 2011). In 2013, a similar screening identified SJB2-043, which 
inhibited the growth of leukemic cells (Mistry et al., 2013). In 2014, ML323, the most 
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selective USP1/UAF1 inhibitor reported to date was developed (Dexheimer et al., 
2014). Finally, this year, a compound called SJB3-019A has been shown to inhibit 
USP1 and to decrease cell viability in myeloma cells (Das et al., 2017). Remarkably, 
pimozide, GW7647 and ML323 have been shown to reverse the resistance of non-small 
cell lung cancer (NSCLC) cells to cisplatin (Chen et al., 2011). These data suggest that 
combining USP1 inhibitors with platinum-based drugs can be a valid therapeutic 
strategy in cancer treatment. However, besides NSCLC, there is no information about 
the potential effects of this combination in other cancer types. In section 4.3.3.3. we 
present data on the effect of the combination of ML323 with oxaliplatin in cellular 
models of pancreatic cancer. 
It is important to note that all the compounds described above are small-molecules that 
directly block the catalytic activity of USP1. Taking into account that USP1 enzymatic 
activity requires UAF1 binding, disruption of the USP1/UAF1 interaction could be an 
alternative strategy to inhibit USP1 for therapeutic purposes. As a first step to explore 
this possibility, a more detailed characterization of the USP1/UAF1 binding interface is 
necessary. In section 4.2.3. we describe our efforts to fine-map the amino acid residues 
that contribute to USP1/UAF1 interaction. 
1.6. THE USP12/UAF1 AND USP46/UAF1 DEUBIQUITINASE 
COMPLEXES 
The USP12 gene is located in 13q12.13 and the USP46 gene is located in 4q12. These 
genes encode very similar proteins, USP12 (370 amino acids) and USP46 (366 amino 
acids), with 88% amino acid sequence identity. As described above for USP1, binding 
to UAF1 significantly enhances the catalytic activity of USP12 and USP46 (Cohn et al., 
2009). However, full activation of these two enzymes, requires a second cofactor, 
termed WD-repeat containing protein 20 (WDR20) (Dahlberg and Juo, 2014; Kee et al., 
2010). 
1.6.1. Domain structure and functional motifs of USP12 and USP46 
USP12 and USP46 lack the inserted domains that are present in USP1, and are therefore 
shorter proteins. The three-dimensional structures of USP46 and USP12 have been 
recently solved (Dharadhar et al., 2016; Li et al., 2016; Yin et al., 2015). These DUBs 
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contain the catalytic triad that characterizes the USP family (Figure 16A), and the 
structure of their catalytic domains shows the distinctive open right hand conformation 
with the “Fingers”, “Thumb” and “Palm” subdomains (Figure 16B). There is still very 
limited information on the specific sequence motifs that contribute to their function, 
regulation or localization. 
 
Figure 16: USP12 and USP46 domains and structure. A. Schematic representation 
of USP12 and USP46 showing the position of the residues that form the catalytic 
triad (USP12 C48/H317/D332 and USP46 C44/H313/D327). The N-terminal Cys 
box and the C-terminal His box domains are indicated in orange. B. Structural 
representation of free USP12 (left) and ubiquitin bound USP46 (right) showing the 
conserved open right hand conformation of the “USP fold”. The Zn atom is 
illustrated as a pink circle (Taken from NCBI Structure).  
1.6.2. Cellular functions of the USP12 and USP46 
As it might be expected from the high amino acid sequence similarity between USP12 
and USP46, they share some substrates and participate in common cellular processes 
(summarized in Figure 17). For example, USP12 and USP46 regulate embryonic 
development in a Xenopus model by deubiquitinating histones H2A and H2B (Joo et al., 
2011). In addition, both DUBs negatively regulate the Akt signaling pathway by 
stabilizing the Pleckstrin Homology domain Leucine rich repeat Protein Phosphatases 
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(PHLPPs) (Gangula and Maddika, 2013; Li et al., 2013), and thus play a crucial role in 
cell survival, proliferation, migration and cell death. 
Remarkably, each of these DUBs has also specific substrates and regulates specific 
processes. On one hand, USP12 regulates Notch signaling by stabilizing the 
nonactivated form of the Notch receptor NotchR (Moretti et al., 2012), T-cell receptor 
(TCR) signaling by stabilizing the TCR signaling complex (Jahan et al., 2016), and 
androgen receptor (AR) signaling by stabilizing the AR protein (Burska et al., 2013; 
McClurg et al., 2014). On the other hand, USP46 may contribute to modulate synaptic 
transmission in the brain by deubiquitinating and regulating the turnover of neuronal 
glutamate receptors (GluR) and AMPA receptors (AMPAR) (Dahlberg and Juo, 2014; 
Huo et al., 2015). 
 
Figure 17: Summary of the substrates and cellular roles of USP12 and USP46. 
Common substrates are outlined in green and disparate substrates are outlined in 
red. 
1.6.3. Regulation of USP12 and USP46 by UAF1 and WDR20 
In the original report describing the USP12/UAF1 and USP46/UAF1 interactions, it was 
noted that these DUBs were activated by UAF1 to a lesser degree than USP1 (Cohn et 
al., 2009). It was later found that a second WD-repeat containing protein, WDR20, 
interacts with USP12 and USP46, but not with USP1, and further enhances the catalytic 
activity of these two enzymes (Figure 18A) (Dahlberg and Juo, 2014; Kee et al., 2010). 
WDR20 is a 569 amino acid protein containing a β-propeller domain architecture 
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formed by five WD repeats (Figure 18B). WDR20 has been proposed to regulate the 
activity of these enzymes through an allosteric mechanism, without altering their 
substrate affinity (Li et al., 2016). 
The three-dimensional structure of a ternary USP12/UAF1/WDR20 complex (Li et al., 
2016) has recently been solved, providing novel insights into its regulation. WDR20 is 
closely engaged with the USP12 “Palm” subdomain (Figure 18C). The proposed model 
for USP12 activation by UAF1 and WDR20 suggests that UAF1 helps adjusting the 
topology of the Ub tail to USP12 active site, whereas WDR20 regulates the 
conformation of the catalytic cleft (Li et al., 2016). The structure of a USP46/UAF1 
complex has been reported (Yin et al., 2015), but the structure of a ternary 
USP46/UAF1/WDR20 complex remains to be solved. 
 
Figure 18: USP12 forms a trimeric complex with UAF1 and WDR20 to achieve full 
catalytic activity. A. Schematic representation of the level of enzymatic activity of 
free USP12, USP12/UAF1 complex and USP12/UAF1/WDR20 complex. B 
Schematic representation of the WDR20 protein showing the β-propeler domain 
with five WD repeats (blue). C. Three dimensional structure of the 
USP12/UAF1/WDR20 complex. Structures are taken from NCBI Structure. 
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In addition to UAF1 and WDR20, a global proteomics analysis identified several 
proteins that interact with both USP12 and USP46 (Sowa et al., 2009). Reported 
common interactors of these DUBs included PHLPP, PHLPPL and DMWD. In our 
view, it is remarkable that USP12 and USP46, being very similar proteins and sharing 
many interactors, are nevertheless able to carry out disparate cellular functions, as 
described above. The molecular mechanisms that may underlie their functional 
differences are still unknown, but they could be related to a differential interaction of 
these DUBs with their regulatory cofactors or with other cellular proteins. A series of 
experiments carried out to test this possibility is described in section 4.5. 
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2. Hypotheses and aims 
The work presented in this Thesis deals with three human deubiquitinases USP1, 
USP12 and USP46, whose enzymatic activity is regulated by the cofactor UAF1. Most 
of the work focuses on USP1. 
Over the last years, our knowledge about the role of USP1 as a crucial regulator of the 
DNA damage response has significanlty increased. However, several aspects of the 
basic biology of this enzyme, including its regulation, remain to be fully characterized. 
We began this work (see aim 1) by trying to shed further light on three important 
regulatory mechanisms of USP1 (phosphorylation, autocleavage and UAF1 binding), 
and to clarify the controversies that have arisen regarding some of them.  
USP1 is emerging as a potential therapeutic target in the treatment of cancer. However, 
there is no information about the functional effects of USP1 mutations detected in 
human tumors. We hypothesized that certain cancer-related missense mutations in 
USP1 could affect its binding to UAF1, autocleavage or function (see aim 2). On the 
other hand, USP1/UAF1 inhibitors, such as ML323, reverses resistance of cancer cells 
to chemotherapy, but ML323 has so far only been tested in NSCLC. We hypothesized 
that ML323 could show therapeutic potential in other tumor models, such as pancreatic 
cancer cells (see aim 3). 
Finally, since only a limited number of bona-fide targets of USP1 (PCNA, 
FANCD2/FANCI and ID proteins) have been identified to date, we hypothesized that 
there would be USP1 substrates that remain to be identified (see aim 4). 
On the other hand, USP12 and USP46 are two very similar proteins (88% amino acid 
sequence identity) whose enzymatic activity is regulated by UAF1 and WDR20. 
Remarkably, these enzymes participate in disparate cellular processes, but the 
mechanisms that may underlie these functional differences are unknown. We 
hypothesized that these mechanisms could be related to a differential interaction of 
USP12 and USP46 with their cofactors or with other cellular proteins (see aim 5). 
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Thus, the five aims of this Thesis are as follows: 
Aim 1. To characterize in detail three aspects of the USP1 regulation that are 
controversial and/or not completely understood: phosphorylation, autocleavage and 
interaction with UAF1.  
Aim 2. To investigate the functional consequences of several cancer-related missense 
mutations in USP1. 
Aim 3. To evaluate the effect of the USP1 inhibitor ML323, in cellular models of 
pancreatic cancer, as a single agent and in combination with the chemotherapeutic drug 
oxaliplatin. 
Aim 4. To identify novel USP1 substrates using the bioUb system followed by mass 
spectrometry. 
Aim 5. To investigate potential differences in the binding of USP12 and USP46 to their 
cofactors and other cellular proteins. 
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3. Materials and Methods 
3.1. BIOINFORMATICS TOOLS 
3.1.1. Sequence alignment and 3D structure modeling 
Multiple sequence alignments were carried out using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) (Larkin et al., 2007) or Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) (Sievers and Higgins, 2014). 
The figures showing the modeled structure of USP1 and USP46 catalytic domains were 
prepared with SWISS-MODEL (https://swissmodel.expasy.org/) or PyMOL 
(https://www.pymol.org/) using the USP7 structure 1NB8 (Hu et al., 2002) as template. 
The figures showing the three-dimensional structure of USP12, USP46-ubiquitin and 
USP12-WDR20-UAF1 were taken from NCBI (Structure) 
(https://www.ncbi.nlm.nih.gov/Structure) and correspond to structures 5K16, 5CVM 
and 5K1C. 
3.1.2. COSMIC mutation database 
In order to search for USP1 alterations in cancer, the publicly available COSMIC 
(Catalogue of Somatic Mutations in Cancer) database 
(http://cancer.sanger.ac.uk/cosmic) was used. This database describes over 136000 
coding mutations in almost 542000 tumor samples (Forbes et al., 2011). 
3.2. CLONING AND MUTAGENESIS 
Several plasmids used in the Thesis were kindly provided by other researchers. A list of 
these plasmids and their original creators is provided as Supplementary table 1. On the 
other hand, the plasmids encoding GFP-USP1C90S, UAF1-mRFP, NLS-USP1(420-520)-
GFP and YFP-USP1(del420-520) were previously generated by our group and have 
been described before (Garcia-Santisteban et al., 2012). Here we will describe the 
construction of the plasmids created for this Thesis, which are listed in Supplementary 
table 2. 
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3.2.1. “Classical”-restriction enzyme-based cloning 
Vector and insert were prepared separately, digested with the same restriction enzymes, 
ligated and used to transform chemically competent bacteria. 
3.2.1.1. Vector preparation 
1.5-2 µg of the closed circular plasmid DNA were double digested with the desired 
restriction enzymes for 2 hours at 37ºC. If a different reaction buffer was required for 
each enzyme, a sequential digestion was performed: first, DNA was digested with one 
enzyme, purified using the QIAquick PCR Purification Kit (Qiagen), and subsequently 
digested with the other enzyme. 
For purification with the QIAquick PCR Purification Kit, 5 volumes of Buffer PB were 
mixed with 1 volume of DNA, placed in a QIAquick column and centrifuged for 1 
minute at 13000 rpm. Flow-through was discarded, and the column was washed by 
adding 700 µl Buffer PE and centrifuging twice for 1 minute at 13000 rpm. After 
placing the column in a clean microcentrifuge tube, H2O was added, incubated for 5 
minutes, and centrifuged for 1 minute at 13000 rpm to elute the DNA. All 
centrifugations were carried out at room temperature. 
To prevent vector self-ligation, digested vectors were dephosphorylated for 2 hours 
using alkaline phosphatase (AP, Roche), which removes the terminal 5’-phosphate 
residues from single- or double-stranded DNA. The dephosphorylation step was 
repeated two or three times. Finally, 2 µl of 0.5 M EDTA were added to the 
dephosphorylation reaction and incubated for 10 minutes at 75°C to inactivate the AP. 
Digested and dephosphorylated vectors were purified using the QIAquick PCR 
Purification Kit (Qiagen) as described above, and eluted in 30 µl H2O. 
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3.2.1.2. Insert preparation 
Three different methods were used to prepare the inserts: 
3.2.1.2.1. Insert preparation by restriction enzyme digestion (subcloning) 
In those cases where the restriction enzyme sites were compatible, and the reading 
frame unaltered, the insert was excised from the original plasmid using restriction 
enzyme digestion. Briefly, the original plasmid was digested with the appropriate 
restriction enzymes for 2 hours at 37°C as described above. Next, digested DNA was 
separated in a 1.5% agarose gel made in 1XTAE with ethidium bromide. DNA was 
loaded onto the gel and run at 100 V for 15-25 minutes. The GeneRuler 1 kb DNA 
ladder plus (Thermo Fisher Scientific) was used as a marker. DNA was visualized using 
a UV transilluminator and the band corresponding to the insert was excised from the gel 
and purified using the QIAquick Gel Extraction Kit (Qiagen). The gel slice was 
dissolved in 3 volumes of Buffer QG by incubating at 50°C for 10 minutes. After 
adding 1 volume of isopropanol, the mixture was placed in a QIAquick column and 
centrifuged for 1 minute at 13000 rpm. The flow-through was discarded, 500 µl Buffer 
QG were added, and the column was centrifuged again for 1 minute at 13000 rpm. 
Flow-through was discarded, and washing and DNA elution steps were carried out as 
described in section (3.2.1.1).  
3.2.1.2.2. Insert preparation by PCR 
To prepare inserts by PCR, the template DNA was amplified with specific forward and 
reverse primers bearing the desired restriction sites. If needed, epitope tags or sequences 
required for the proper expression of the protein in eukaryotic cells were incorporated in 
the primers. These sequences include a Kozak sequence and a start codon (ATG) in the 
forward primer to ensure the initiation of the translation process, and a stop codon in the 
reverse primer to finish translation in those cases where a C-terminal tag was not 
present. The complete list of primers is provided in Supplementary table 3. 
Forward and reverse primers were used to amplify the DNA template following the 
PCR reaction A and program A (section 3.9.1). The correct size of the PCR product was 
checked in an agarose gel. PCR products were purified using QIAquick PCR 
Purification Kit (Qiagen) as described above. Purified PCR products were digested for 2 
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hours at 37°C, purified again using the QIAquick PCR Purification Kit and eluted in 30 
µl H2O. 
3.2.1.2.3. Insert preparation by using gBlocks 
gBlocks (Integrated DNA Technologies) are custom double-stranded DNA fragments 
(up to 3 kb). Several inserts were purchased as gBlocks. Upon arrival, gBlocks were 
digested for 2h at 37°C, purified using the QIAquick PCR Purification Kit and eluted in 
30 µl H2O.  
3.2.1.3. Ligation of vector and insert and transformation of E. coli DH5α  
bacteria 
The digested vector and insert were run in an agarose gel to check their correct size and 
ratio. A ligation reaction was prepared maintaining a 3:1 insert:vector ratio. 10X 
reaction buffer (Fermentas), 10 mM ATP (Sigma), T4 DNA Ligase (Fermentas) and 
H2O up to a volume of 10 µl was added. The ligation mixture was incubated overnight 
at 4°C.  
Chemically competent Escherichia coli DH5α bacteria were transformed with ligated 
DNA. Briefly, DH5α competent bacteria were thawed on ice. For a single 
transformation, 40 µl of bacterial suspension was mixed with 10 µl of ligation product 
in a thin-walled microtube, and incubated for 1 hour on ice. After heat-shock (37°C for 
20 seconds), the tube was placed on ice for 5 minutes. Bacteria/DNA mix was added to 
a 15 ml tube containing 500 µl LB-medium and incubated at 37°C and 220 rpm in a 
shaker for 1 hour. Finally, all the suspension (≈550 µl) was plated on an LB agar plate 
containing the appropriate antibiotic and incubated at 37°C overnight. 
Next day, well-isolated colonies were picked from LB agar plates using a sterile 
toothpick, and grown overnight at 37°C and 220 rpm in 10 ml of LB medium containing 
the appropriate antibiotic. 
3.2.2. Gibson assembly cloning 
Gibson assembly is a cloning method that does not require the presence of compatible 
restriction enzyme ends in vector and insert. This method facilitates the joining of 
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multiple overlapping DNA fragments in a single-tube using a series of isothermal 
enzymatic reactions (Gibson et al., 2009). An overview of the Gibson Assembly 
Cloning Method is illustrated in Figure 19. 
 
Figure 19: Overview of the Gibson Assembly Cloning Method. DNA fragments 
with overlapping ends are mixed with a Gibson Assembly master mix that includes 
three different enzymatic activities in a single buffer: the exonuclease that chews 
back 5´ends facilitating the annealing of fragments with overlapping region, the 
DNA polymerase that extends 3´ends and the DNA ligase that seals nicks in the 
assembled DNA. 
Gibson assembly using the commercially available Gibson Assembly Cloning Kit (New 
England Biolabs) was carried out to clone the YFP-DMWD plasmid. Two separate, 
overlapping, DNA fragments that together encoded full-length DMWD cDNA were 
ordered as gBlocks (IDT). 160 ng of the two DNA fragments and 100ng of linearized 
pEYFP vector were mixed with 10 µl of 2X Gibson Assembly Master Mix in a final 
volume of 20 µl. The assembly reaction was incubated at 50ºC for 20 minutes and then 
used to transform competent NEB5α E. coli bacteria, essentially as described above for 
DH5α bacteria.  
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Single colonies were picked from LB agar plates and grown overnight at 37°C and 220 
rpm in 10 ml of LB medium containing the appropriate antibiotic. 
3.2.3. Site-directed mutagenesis 
The QuikChange Site-Directed Mutagenesis Kit (Stratagene) was used to generate point 
mutants. The list of mutants prepared using this strategy is provided in Supplementary 
table 4. The basic procedure, represented in Figure 20, uses a plasmid as DNA template 
and two synthetic primers containing the desired mutations (the complete list is 
provided in Supplementary table 5) These primers, each complementary to opposite 
strands of the plasmid, are extended by PCR, to generate a mutated plasmid. Next, the 
PCR product is treated with DpnI (a restriction endonuclease specific for methylated 
DNA) to digest the parental non-mutated DNA template and transformed into 
competent bacteria. 
 
Figure 20: Schematic representation of the site-directed mutagenesis strategy. A 
pair of mutagenic primers (green and purple arrows) containing the desired point 
mutation(s) (red crosses) are used in a PCR reaction to generate mutated plasmids 
(green and purple). Parental non-mutated plasmids (blue and orange) are 
digested with DpnI. Finally, competent bacteria are transformed with the 
digestion product. 
An optimized method (Zheng et al., 2004) was used for the design of mutagenic primers 
to minimize primer dimerization during PCR. The melting temperature (Tm), which 
optimally should be higher than 81°C, was calculated with the following formula: 
𝑻𝒎 = 𝟖𝟏.𝟓 + 𝟎.𝟒𝟏 × (%𝑮𝑪) − 𝟔𝟕𝟓𝑵 −  % 𝒎𝒊𝒔𝒎𝒂𝒕𝒄𝒉 
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PCR reaction and program B (section 3.9.1) were used to amplify the template DNA 
with the pair of mutagenesis primers. Next, 2 µl DpnI were added to the PCR reaction 
and incubated at 37°C for 5 minutes to digest parental non-mutated DNA. Finally, 
XL10-Gold ultracompetent bacteria were transformed with the digestion product. For a 
single transformation, 45 µl of bacterial suspension were mixed with 2 µl β-
mercaptoethanol in a 15 ml tube, incubated for 2 minutes on ice, and 2 µl of the PCR-
digestion product were added and incubated for further 30 minutes on ice. After heat-
shock (42°C for 30 seconds), the tube was placed on ice again for 2 minutes. Next, 500 
µl of pre-warmed LB-medium were added, and incubated at 37°C and 220 rpm for 1 
hour in a shaker. Finally, all the suspension (≈550 µl) was plated onto an agar plate 
containing the appropriate antibiotic and incubated at 37°C overnight. Picking of 
bacterial colonies and DNA isolation were carried out as described above. 
If multiple mutations needed to be simultaneously introduced (e.g. to generate Xpress-
UAF12M, bearing K214E and W256A mutations), the QuikChange Multi Site-Directed 
Mutagenesis Kit (Stratagene) was used. The method is essentially as described above, 
but in this case, two different forward primers, one per mutation, are employed (PCR 
reaction and program C, section 3.9.1.). 
3.2.4. Plasmid isolation and DNA sequencing 
Bacterial suspensions were centrifuged at 3500 rpm for 10 minutes and QIAprep Spin 
Miniprep Kit (Qiagen) was used to isolate plasmid DNA. The pellet was resuspended in 
250 µl of Buffer P1 and transferred to a clean tube. The same volume of Buffer P2 was 
added and tubes were gently inverted 8-10 times to lyse bacteria. Next, 350 µl of Buffer 
N3 were added and tubes were inverted again 8-10 times. After centrifuging for 10 
minutes, the supernatant (≈700 µl) was transferred to a QIAprep spin column and 
centrifuged for 1 minute. Flow-through was discarded and the column was washed 
adding 500 µl Buffer PB and centrifuging again for 1 minute. The column was washed 
again with Buffer PE containing ethanol, and centrifuged twice for 1 minute to remove 
residual buffer. Finally, the column was placed in a clean microcentrifuge tube, 70 µl 
H2O were added, incubated for 5 minutes, and centrifuged for 1 minute to elute DNA. 
All centrifugations, except the first one, were performed at 13000 rpm using a standard 
table-top microcentrifuge at room temperature. 
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All the new plasmids generated were confirmed by DNA sequencing at StabVida. The 
primers used for sequencing are listed in Supplementary table 6. 
3.3. CELL CULTURE 
3.3.1. Cell lines and cell culture conditions 
Cell lines were maintained as monolayer cultures in Dulbecco’s modified Eagle’s 
medium (DMEM) or Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S) 
(Thermo Fischer Scientific) at 37°C in a humidified atmosphere containing 5% CO2. 
HeLa cervical adenocarcinoma, Human Embrionic Kidney 293T (HEK293T), hereafter 
called 293T cells and Hs766T pancreatic cancer cell lines were cultured in DMEM, 
whereas non-transformed HPDE and HPNE cell lines and the pancreatic cancer cell 
lines PDAC-1, PDAC-2, PDAC-3, PDAC-4, PDAC-5, BxPC-3, PANC-1, SU8686, 
CEPAC-1, HPAC, CAPAN-1, ASPC-1, MIAPaCa-2, HAF-II, PL45, SUIT 2.028, SUIT 
2.027 and PP161 were cultured in RPMI 1640.  
Cells growing in culture flasks were harvested when they reached confluency (twice or 
thrice a week). Briefly, old media was removed and cells were washed once with 
phosphate buffered saline (PBS). Cells were detached by incubation with trypsin-EDTA 
solution (Thermo Fischer Scientific) for about 2 minutes at 37°C, and resuspended in 
culture medium containing serum to inhibit further trypsin activity. The volume of cell 
suspension required to obtain the desired confluency was transferred to a new culture 
flask containing fresh medium.  
3.3.2. Cell seeding 
Prior to each experiment, cells were harvested (as described above) and depending on 
the cell line and type of experiment, a different number of cells was seeded onto 
different culture plates Table 1. 
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Table 1: Number of cells seeded per well or plate for the different types of 
experiment. 
 
For immunofluorescence or live cell microscopy experiments cells were seeded at 60-
80% confluency onto sterile glass coverslips in 12-well culture plates (Costar) or in 35 
mm ibiTreat µ-dish slides (Ibidi), respectively. 
For the rest of experiments the cell number was determined using a cell counting 
chamber. Briefly, the counting chamber was filled with an aliquot of cell suspension 
diluted in trypan blue solution. Only viable cells (non-stained with trypan blue) were 
counted. A total of four squares were counted, and cells touching only the upper and left 
lines of each square were considered to avoid counting the same cell twice. An average 
of the counts was multiplied by 104 and by the trypan blue dilution to give the number 
of cells/ml in the suspension. 
3.3.3. Transfection 
3.3.3.1. DNA transfection 
Twenty four hours after cell seeding, DNA transfection was performed using 
XtremeGENE 9 (XTG9) reagent (Roche). The transfection reagent was mixed with 
antibiotic- and serum-free DMEM, added drop by drop into a tube containing the 
plasmid DNA(1:2 DNA/XTG9 ratio). The DMEM/transfection reagent/DNA tube was 
gently mixed, incubated for 25 minutes at room temperature and added drop by drop to 
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the cells whilst gently rocking the plate. Depending on the surface area (type of plate), 
different amounts of DNA, DMEM, transfection reagent and growth medium were used 
(Table 2). 
Table 2: Conditions for DNA transfection using XtremeGENE9 (XTG9) depending 
on the type of plate. 
 
3.3.3.2. siRNA transfection 
Transfection of small interfering RNAs (siRNAs) was performed using Lipofectamine 
RNAiMAX transfection reagent (Thermo Fisher Scientific) following manufacturer´s 
recommendations. Briefly, transfection reagent was mixed with Opti-MEM Reduced 
Serum Medium (Thermo Fisher Scientific) and incubated for 2 minutes at room 
temperature. The transfection reagent/Opti-MEM mix was added dropwise into a tube 
containing siRNA diluted in Opti-MEM. The mixture was incubated for 20 minutes at 
room temperature and added to the cells whilst rocking the plate. For USP1 knockdown 
we used a pool of three commercial siRNAs from Ambion (Thermo Fisher Scientific) 
(s14723, s14724, and s14725) (10 µM). As a control, a siRNA oligonucleotide with no 
sequence specificity for any human RNA (siCTRL) was used (Thermo Fisher 
Scientific) (4390843) (10 µM). Depending on the type of plate, different amounts of 
siRNA, Opti-MEM, transfection reagent and growth medium were used (Table 3). 
Table 3: Conditions for siRNA transfection using Lipofectamine RNAiMAX 
depending on the type of plate. 
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3.3.4. Drug treatments 
The following drugs were used in this Thesis: hydroxyurea (HU), a drug that arrests 
DNA replication, was used to induce monoubiquitination of PCNA; neocarzinostatin 
(NCS), a DNA damaging agent that produces DNA double-strand breaks, was used to 
induce the recruitment of 53BP1 and conjugated ubiquitin to DNA damage foci; the 
USP1 inhibitor ML323, and a platinum-based drug oxaliplatin. 
Cells were treated for the time periods indicated in each experiment by replacing the 
growth medium with medium containing the desired drug at the concentration shown in 
Table 4. 
Table 4: List of drugs used in this study. The drug, company, reference, stock and 
final concentrations (conc.) are indicated. *ML323 and oxaliplatin final 
concentrations varied depending on the experiment; see sections 3.3.5 and 
section 3.5.1 for details. 
 
3.3.5. Sulforhodamine B (SRB) cell viability assay 
Cell viability was measured using the Sulforhodamine B (SRB) assay (Vichai and 
Kirtikara, 2006). Exponentially growing pancreatic cancer cells were seeded in 96-well 
plates, and 24 hours later were treated with oxaliplatin (0.0048, 0.019, 0.039, 0.078, 
0.15, 0.31, 0.62 and 1.25 µM), the USP1 inhibitor ML323 dissolved (0.39, 0.78, 1.5, 
3.1, 6.25, 12.5, 25 and 100 µM) or a combination of both drugs. The corresponding 
controls were incubated with growth medium without drugs, and their viability was 
considered as 100%. After 72 hours of drug exposure, the SRB assay was performed. 
Cells were fixed with ice-cold 50% (w/v) trichloroacetic acid (TCA) for 1 hour at 4°C, 
washed five times with H2O, and dried at room temperature. Next, plates were stained 
with SRB solution (0.4% (w/v) Sulforhodamine B (Acros Organics, Geel, Belgium) in 
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1% acetic acid) for 15 minutes at room temperature. Excess dye was then removed by 
washing four times with 1% (v/v) acetic acid, and dried again at room temperature. 
Finally, the protein-bound dye was dissolved in 10 mM Tris base solution for optical 
density determination at 492 nm using a microplate reader (Tecan Spectrafluor, 
Salzburg, Austria). 
Growth inhibition curves, expressing growth inhibition as the percentage of control 
absorbance, were generated for each drug alone and in combination. IC50 values, defined 
as the drug concentration that inhibits cell growth by 50%, were calculated by fitting the 
data to a sigmoid dose-response curve using GraphPad Prism software (San Diego, 
CA). The percentage of cell survival was converted to fraction affected (Fa), defined as 
[100 - % growth inhibition]/100, and these data were used to determine the nature of the 
interaction between oxaliplatin and ML323.  
Calcusyn software (Biosoft, Cambridge, UK) was used for the study of the 
pharmacological interaction between oxaliplatin and ML323. This program uses the 
median drug effect principle of Chou and Talalay (Chou and Talalay, 1984) to 
determine the combination index (CI), which quantitatively describes if the interaction 
between two drugs is antagonistic (CI ≥ 1.2), additive (0.8 < CI < 1.2) or synergistic (CI 
≤ 0.8) (Table 5). An antagonistic effect is observed when the combination of two drugs 
is less effective than the single drugs. An additive effect results when the combination 
of two drugs is equivalent to the sum of treatment with those drugs individually. A 
synergistic effect occurs when the effect of two drugs in combination is greater than the 
sum of individual effects of those drugs (Bijnsdorp et al., 2011). Calcusyn software was 
used to determine the CI values at a range of 0.01 < Fa < 0.99, and to produce median-
drug effect plots (Fa vs CI) for each cell line. Since experimental conditions with a Fa 
lower than 0.5 are generally considered as less therapeutically relevant (Bijnsdorp et al., 
2011), CI values at Fa of 0.5, 0.75, and 0.9 were averaged for each experiment, and this 
value was used to calculate the mean between experiments. The resulting CI was used 
to determine if the combination of both drugs resulted in an antagonistic, additive or 
synergistic effect. 
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3.4. FLUORESCENCE MICROSCOPY TECHNIQUES 
3.4.1. Immunofluorescence 
Cells expressing GFP- or YFP-tagged fluorescent proteins were fixed with 3.7% 
formaldehyde (Sigma) in PBS for 30 minutes and coverslips were mounted onto 
microscope slides (Zuzi) using Vectashield aqueous mounting medium containing 4′,6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories) to visualize the nuclei. To 
detect biotinylated proteins by fluorescence microscopy we used streptavidin, a 
bacterial protein with strong affinity for biotin, fluorescently labeled with AlexaFluor 
594. 
Detection of endogenous or ectopic proteins with non-fluorescent tags (e.g. Myc or 
Xpress epitopes) was carried out by immunofluorescence (IF). Cells were fixed with 
3.7% formaldehyde in PBS for 30 minutes and permeabilized with 0.2% Triton X-100 
(TX-100, Sigma) for 10 minutes. Following a blocking step with 3% bovine serum 
albumin (BSA, Sigma) in PBS for 1 hour, the primary antibodies were diluted in 
blocking solution, and applied for 1 hour. After washing twice with PBS, and adding 
BSA 3% for 1 minute, cells were incubated for 1 hour with the corresponding 
fluorescently-labelled secondary antibody diluted in blocking solution. After washing, 
coverslips were mounted onto microscope slides (Zuzi) using Vectashield with DAPI 
(Vector Laboratories). Details about the antibodies used for immunofluorescence are 
provided in Table 6. 
 
Table 5: Simplified CI values and their interpretation following the method of 
Chou-Talalay: A CI value below 0.8 indicates a synergistic effect. A CI value 
between 0.8 and 1.2 represents an additive effect. A CI value higher than 1.2 
indicates antagonism. 
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Table 6: List of antibodies used for immunofluorescence.
 
 
3.4.2. Live cell microscopy 
293T cells were grown in 35mm ibiTreat µ-dish slides (Ibidi) were transfected, and 24 
hours later cells images were collected using Zeiss Apotome 2 fluorescence microscope 
with 40X objective.  
3.4.3. Microscopes 
Slides were examined at the SGIKER Analytical and High-Resolution Microscopy in 
Biomedicine Facility (UPV/EHU) using different microscopes: 
For standard visualization, a Zeiss Axioskop fluorescence microscope was used, and 
images were taken with a Nikon DS-Qi1Mc digital camera and the NIS-Elements F 
software. For confocal image acquisition, an Olympus Fluoview FV500 microscope 
was used, and images were taken with Olympus FV-Viewer software. For live cell 
analysis, Zeiss Apotome 2 fluorescence microscope was used, and images were taken 
with ZEN 2 software. 
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3.4.4. Image analysis for quantification of FK2 fluorescence and 
53BP1 foci 
3.4.4.1. Quantification of FK2 (conjugated ubiquitin) fluorescence 
5 or 10 microscopy fields per sample were captured with a 40X objective using a 
fluorescence Zeiss Axioskop microscope both for GFP (green channel) and FK2 (red 
channel). Fluorescence levels in the nuclei of at least 50 cells per sample were 
quantified using the “mean grey value” (MGV) measurement option of Fiji software 
(Schindelin et al., 2012). Background fluorescence was substracted. FK2 intensity in 
GFP-positive cells was normalized to the intensity in nontransfected cells. To ensure 
unbiased results, the analysis was carried out in a “blind” manner, by masking the 
identitiy of the samples prior to image acquisition and quantification. 
3.4.4.2. Quantification of 53BP1 foci 
Between 5 and 10 microscopy fields were captured per sample with a 40X objective 
using a fluorescence Zeiss Axioskop microscope for GFP (green channel) and 53BP1 
(red channel). At least 100 GFP-positive cells per sample were analysed and cells were 
classified as positive (more than 5 53BP1 foci) or negative (5 or less foci). Finally, the 
percentage of positive cells was calculated. As above the analysis was carried out in a 
“blind” manner. 
3.5. TECHNIQUES FOR RNA ANALYSIS 
3.5.1. RNA isolation 
To isolate total RNA, cells were lysed by pipeting up and down with 500 µl Trizol 
(Thermo Fisher Scientific), and incubated for 5 minutes at room temperature. Next, 100 
µl chloroform were added, and tubes were vigorously shaken and incubated for 2-3 
minutes at room temperature. Samples were centrifuged at 12000 g for 10 minutes at 
4°C. The aqueous phase was transferred to a clean microcentrifuge tube before adding 
250 µl isopropanol, mixed and incubated for 10-15 minutes at room temperature. The 
interphase containing genomic DNA was subsequently used for the analysis of DNA 
adducts (section 3.5.4). Samples were centrifuged at 12000 g for 10 minutes at 4°C, and 
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the supernatant was carefully removed. The RNA pellet was washed twice with 70% 
ethanol. Finally, the RNA pellet was air dried and resuspended in 20 µl RNAse free 
H2O, and immediately put on ice. The RNA quantity and quality were determined using 
a NanoDrop, and the A260/A280 ratio > 1.8 was used as a purity criterion for all 
samples. RNA samples were stored at -80°C until use. 
3.5.2. cDNA synthesis 
Complementary DNA (cDNA) was synthesized using the Dynamo cDNA Synthesis Kit 
for qRT-PCR (Thermo Fisher Scientific). The total reaction volume for reverse 
transcription was 20 µl and contained 10 µl of 2x RT buffer, 300 ng of random 
hexamers, 800 ng of RNA, and 2 µl of M-MuLV RNAseH + reverse transcriptase. The 
reactions were incubated at 25°C for 10 min for primer extension, at 37°C for 30 min 
for cDNA synthesis, and at 85°C for 5 min for reaction termination. The cDNA 
solutions were diluted 10-fold and stored at −20°C. 
3.5.3. qRT-PCR 
Primers and probes to specifically amplify USP1 (Hs00163427_m1), UAF1 
(Hs00368247_m1) and Human GAPDH Endogenous Control (4326317E) were 
obtained from Applied Biosystems Assay-on-Demand Gene expression products. The 
qRT-PCR reaction was performed in a 25-μl volume containing TaqMan Universal 
master mix (Applied Biosystems). All reactions were performed in duplicate using an 
ABI PRISM 7500 Sequence Detection System instrument (Applied Biosystems). 
Samples were amplified using the following thermal profile: 50°C for 2 minutes, 95°C 
for 10 minutes, 40 cycles of denaturation at 95°C for 15 seconds followed by annealing 
and extension at 60°C for 1 minute. Amplifications were normalized to GAPDH. The 
fold change was calculated by the ΔΔCT method (Livak and Schmittgen, 2001) and 
results were plotted as 2 -ΔΔCT. 
3.5.4. Analysis of DNA adducts using quantitative extra-long PCR 
(XL-PCR) and Taqman assays 
Genomic DNA samples were then analyzed using an extra-long PCR (XL-PCR) assay, 
followed by quantification with Taqman assays. The XL-PCR assay is based on the fact 
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that DNA adducts can block DNA polymerases, thus interfering with the DNA 
replication and decreasing the yield of PCR product. Using long PCR amplicons 
improves the sensitivity of the assay. The amplified target sequence used in our assay is 
part of the β-globin locus. XL-PCR was performed using the specific GeneAmp XL-
PCR Kit (Applied Biosystems), starting from 100 ng of template DNA. The 
amplification of a 17.7-kb region of the β-globin gene was performed using the specific 
primers listed in Table 7. XL-PCR was initiated at 70ºC by the addition of the rTth 
DNA polymerase, followed by 25 cycles of 94ºC for 15 seconds, 68ºC for 12 minutes. 
There was a final extention for 10 minutes at 72ºC. All the PCR reactions were 
performed in a GeneAmp-PCR-9700 machine (Applied Biosystems). Following XL-
PCR, the reaction products were diluted ten-fold and quantified using TaqMan assays in 
the ABI PRISM-7500 instrument, using specific primers and probes listed in Table 7 
and the same program than in section 3.5.3. A standard curve was generated by serial 
dilution of XL-PCR-amplified products from genomic DNA extracted from untreated 
samples to calculate the amount of amplification of each sample. 
Table 7: Primers and probes for XL-PCR and TaqMan reactions. 
 
3.6. TECHNIQUES FOR PROTEIN ANALYSIS 
3.6.1. Protein extraction 
HeLa or 293T cells from 6-well plates were washed once with ice-cold PBS, lysed by 
scrapping in 100 µl lysis buffer (supplemented with Na3VO4, PMSF, a protease 
inhibitor cocktail (PIC) (Roche) and N-ethylmaleimide (NEM)). Samples were 
incubated for 30 minutes in a rotating platform at 4°C, centrifuged at 13000 rpm for 10 
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minutes at 4°C, and the supernatant was transferred to a clean microcentrifuge tube. 
Protein concentration was determined using the Lowry method. 
Protein extraction from pancreatic cancer cell was carried out by resuspending the cells 
in 60 µl RIPA lysis buffer (supplemented with Na3VO4, PMSF and a PIC (Roche)). 
Lysates were centrifuged at 13000 g for 10 minutes at 4°C. Supernatants were 
transferred to a clean microcentrifuge tube, and protein concentration was determined 
using the Bradford method. 
3.6.2. Protein quantification  
3.6.2.1. Lowry method 
Protein concentration was determined using the modified Lowry method with a Bio-Rad 
Protein Assay kit. Bovine serum albumin (BSA) was used as a standard. Briefly, 
Reagent A + Reagent S were mixed at 50:1 a ratio and 25 µl were added to the diluted 
protein or BSA. Subsequently, 200 µl of Reagent B were added on top, and the mix was 
incubated 15 minutes at room temperature. Absorbance was measured at 750 nm in a 
microplate reader (PowerWave340). 
3.6.2.2. Bradford method 
Protein concentration of pancreatic cancer cells was determined using the Bradford 
method with the Bio-Rad Protein Assay Dye Reagent Concentrate. BSA was used to 
prepare the standard curve. 200 µl of BioRad dye reagent were added to diluted protein 
samples or BSA and incubated for 5 minutes at room temperature. Absorbance was 
measured at 600 nm in a microplate reader (Tecan Spectrafluor, Salzburg, Austria).  
Following quantification, the concentration of protein samples was adjusted with lysis 
buffer to ensure identical loading. Finally, 6X Protein Loading Buffer or 4X Sample 
Buffer (Thermo Fisher Scientific) were added and samples were heated at 95°C for 5 
minutes. 
 
51 
Materials and methods
  
3.6.3. Immunoprecipitation using GFP-trap magnetic beads 
Magnetic GFP-Trap (GFP-Trap®_M, Chromotek) beads were used for the 
immunoprecipitation of GFP-fusion proteins from cellular extracts. GFP-Trap®_M 
contains a GFP-binding protein (GBP) covalently coupled to the surface of magnetic 
beads, which enables an efficient isolation of any protein of interest fused to GFP or its 
derivates, including YFP (Rothbauer et al., 2008) using a magnet. GFP or YFP-
transfected cells grown in 10 cm plates were washed with PBS, scrapped in 1 ml IP 
Lysis Buffer (Pierce) containing PMSF and protease inhibitors (Pierce), and incubated 
for 30 minutes on ice with extensive pipeting every 5-10 minutes. Cell lysates were 
centrifuged at 13000 rpm for 10 minutes at 4°C, and the supernatant was transferred to a 
clean tube. A 100 µl aliquot was mixed with 6X Protein Loading Buffer, boiled at 95°C 
for 5 minutes and stored to use it as whole cell extract (WCE). The remaining lysate 
was mixed with equilibrated GFP-Trap®_M beads and incubated for 3 hours in a 
rotating platform at 4°C. Magnetic beads were washed twice with 500 µl ice-cold lysis 
buffer. Finally, the beads were resuspended in 60 µl 1X protein loading buffer, boiled at 
95°C for 5 minutes, and stored at -20°C. 
3.6.4. Immunoblot 
3.6.4.1. SDS-PAGE (Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis) 
Polyacrylamide gels were polymerized between two glass plates in a gel caster, with a 
comb inserted at the top to create the sample wells (10 or 15). Gels were divided into: 
• An upper stacking gel of low polyacrylamide percentage, where the proteins 
are concentrated at a narrow line migrating towards the anode. 
• A resolving gel of higher polyacrylamide percentage (between 8 and 15%) 
with smaller pores where the proteins were separated according to their 
molecular weight.  
Protein samples (20-40 µg per well) were resolved in a Bio-Rad MiniPROTEAN Tetra 
Cell vertical electrophoresis system at constant amperage in 1x Running buffer for 
approximately 1 hour and 30 minutes. BenchMark Pre-Stained Protein Ladder (Thermo 
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Fisher Scientific) or Precision Plus Protein All Blue Standard (Bio-Rad) were loaded as 
protein standards to determine the size of the proteins under analysis. 
3.6.4.2. Transfer and blocking 
Following electrophoresis, proteins were transferred from the gel to either a 
nitrocellulose (Bio-Rad) or a polyvinylidene difluoride (PVDF) (Bio-Rad) membrane. 
Transference was performed using the Bio-Rad Mini Trans-Blot® Cell transfer system 
in 1x transfer buffer for 1-2 hours at 100 V and 4°C. Membranes were stained with 
Ponceau S (Sigma) to check the successful transfer of the proteins. Following protein 
transfer, membranes were blocked with 5% (w/v) non-fat dry milk powder in TBS-T for 
1 hour at room temperature with gentle shaking.  
3.6.4.3. Antibody incubation and detection 
Membranes were then incubated with the primary antibody (Table 8) diluted in blocking 
solution for either 1 hour at room temperature or overnight at 4°C with gentle shaking. 
Membranes were washed thrice for 5 minutes with TBS-T or PBS-T and subsequently 
incubated with the corresponding horseradish peroxidase (HRP)-labeled (Table 8) in 
blocking solution for 1 hour at room temperature with gentle shaking. Membranes were 
washed again as described above. 
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Table 8: List of antibodies used for immunoblotting. The β-actin or α-tubulin 
antibodies are used as protein loading controls.  
 
Membranes were developed with Pierce ECL Plus Western Blotting Substrate or 
SuperSignal West Femto Chemiluminescent Substrate (Thermo Fisher Scientific) using 
the Bio-Rad Chemi-Doc imaging software. 
3.7. PULLDOWN OF ENDOGENOUS UBIQUITINATED 
PROTEINS USING bioUb 
3.7.1. The bioUb strategy 
Mass spectrometry (MS)-based proteomics is one of the most commonly used 
approaches for the large-scale identification of ubiquitin modified proteins. However, 
the low levels at which endogenous ubiquitinated proteins are usually present within the 
cell, makes identification of ubiquitinated proteins under physiological conditions a 
challenging task (Mayor and Peng, 2012). A key step is to sufficiently enrich the 
ubiquitin-conjugated material prior to the MS analysis. In this regard, the laboratory of 
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Dr. Ugo Mayor (Department of Biochemistry, UPV/EHU) has developed a new 
strategy, based on biotin tagging, for the efficient in vivo isolation of ubiquitin 
conjugates (Franco et al., 2011). This approach, termed bioUb, has so far allowed the 
purification and enrichment of ubiquitinated proteins from Drosophila (Franco et al., 
2011) and mice (Lectez et al., 2014), as well as from human cell lines (Min et al., 2014). 
The bioUb approach relies on the in vivo expression of the E. coli BirA biotin ligase 
fused to a synthetic linear polyubiquitin construct (Ub6-BirA). Each ubiquitin moiety in 
the construct bears a 16 amino acid long BirA recognition sequence, and can therefore 
be biotinylated by BirA. In the transfected cells, a precursor polypeptide with six 
ubiquitin molecules fused to BirA is produced. This precursor can be digested by the 
endogenous DUBs, allowing the release of BirA and the individual ubiquitin moieties 
fused to the BirA recognition sequence. Then, BirA biotinylates the ubiquitin 
molecules, thus generating a pool of biotinylated ubiquitin (bioUb) within the cell. The 
bioUb can then be incorporated into endogenous protein substrates by the action of the 
cellular ubiquitination machinery. bioUb-conjugated proteins can be isolated and 
enriched using avidin-beads (Figure 21). The strong interaction between avidin and 
biotin (Marttila et al., 2000) allows the use of very stringent washes (Franco et al., 
2011), resulting in the removal of interacting proteins and purifying only the 
ubiquitinated material and a few endogenously biotinylated carboxylases. The 
biotinylated material can then be subjected to MS or immunoblot analysis (Franco et al., 
2011; Lectez et al., 2014; Min et al., 2014; Ramirez et al., 2015). 
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Figure 21: The bioUb approach. A chain of six ubiquitin moieties containing the 
BirA recognition sequence (underlined) fused to BirA is produced as a precursor 
polypetide. The The target sequence for biotinylation is underlined, with the 
lysine where the biotin is attached highlighted in red. Endogenous DUB enzymes 
process the precursor polypeptide releasing the free biotinylatable ubiquitin 
moieties and the BirA enzyme. BirA recognizes the target sequence and 
conjugates a biotin molecule to it generating a pool of biotinylated ubiquitin 
(bioUb). The biotinylated ubiquitin is then conjugated to protein substrates by the 
cellular ubiquitination machinery. Biotinylated material (essentially ubiquitinated 
proteins) is purified using avidin beads. Modified from (Franco et al., 2011). 
3.7.2. bioUb protocol: preparation of cell extracts and purification of 
biotinylated proteins  
13.5x106 293T cells were plated in 15 cm dishes. 24 hours after plating, cells were 
transfected with siRNA against USP1 or siCTRL (as detailed in section 3.3.3.2.). Next 
day, cells were transfected (as described in section 3.3.3.1) with the pCAG-bioUb-BirA 
plasmid encoding bioUb-BirA or, as a negative control of biotinylation, with the pCAG-
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BirA plasmid, which encodes BirA. Immediately after transfection, growth medium was 
supplemented with 50 µM biotin (Sigma). Next day, cells were collected in 7 ml of 
PBS, 1 ml was separated for immunoblot and the remaining cells were pelleted at 1500 
rpm for 5 minutes at 4ºC.  
For pulldown, cell pellets were resuspended in 2,9 ml lysis buffer (8 M urea, 1% SDS, 
50 mM NEM and protease inhibitor mixture) and then left in a rotator at 4ºC for 20 
minutes. Lysates were centrifuged for 5 minutes at 16100g at 4ºC. Supernatants were 
applied to PD10 desalting columns (GE Healthcare), which were previously 
equilibrated with 25 ml of binding buffer containing 3 M urea (Sigma), 1 M NaCl 
(Sigma), 0,25% SDS (Sigma) and 50 mM NEM (Sigma) diluted in PBS. Afterwards, 
PD10-eluates (except 50 µl that were kept for monitoring the inputs by SDS-PAGE), 
were incubated in a roller with 150 µl of NeutrAvidin agarose beads suspension 
(Thermo Fisher Scientific), respectively for 1 hour at room temperature and 2 additional 
hours at 4ºC. Unbound material (flow through, FT) was recovered by spinning down 
beads at 233 g (1000 rpm) for 2 minutes. Beads were then subjected to stringent washes 
with six different washing buffers (WB) for 5 minutes at room temperature. The number 
and order of washes were as follows: two times with WB1 (8 M Urea, 0.25 % SDS), 
three times with WB2 (6 M Guanidine-HCl), 1 time with WB3 (6.4 M Urea, 1 M NaCl, 
0.2 % SDS), three times with WB4 (4 M Urea, 1 M NaCl, 10 % Isopropanol, 10 % 
Ethanol, 0.2 % SDS), 1 time with WB1, 1 time with WB5 (8 M Urea, 1 % SDS) and 
three times with WB6 (2 % SDS). All buffers were prepared in PBS (Thermo Fisher 
Scientific). Guanidine-HCl, isopropanol and ethanol were provided by Sigma, Panreac 
and Merck, respectively. Elution of the material bound to the beads was performed by 
heating the beads in a dry bath at 95 ºC in 4X Laemmli buffer (250 mM Tris-HCl pH 
7.5, 40 % Glycerol, 4 % SDS, 0.2 % Bromophenol blue) and 100 mM Dithiothreitol 
(DTT). The volume of elution buffer employed was half the volume of the NeutrAvidin 
agarose beads suspension used. Samples were centrifuged for 2 minutes at 16160 g to 
separate beads from the eluted material. Samples were then analyzed by electrophoresis, 
immunoblot or subjected to MS analysis. 
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3.7.3. Silver staining 
In order to check the amount of purified material, 10 % of the eluted material was 
analysed by silver staining. Stainings were performed using the SilverQuest kit (Thermo 
Fisher Scientific) according to manufacturer’s instructions. Briefly, gels were fixed in a 
40 % Ethanol/10 % Acetic acid solution for 1 hour at room temperature. Then, they 
were incubated with a sensitizing solution (30% ethanol and 10% SilverQuest kit 
sensitizer) to improve protein reactivity toward silver ions, and thus enhance the protein 
staining. After removing excess of sensitizing solution with H2O, gels were incubated 
with a staining solution containing 1% SilverQuest kit stainer and subsequently washed 
with H2O to remove silver excess. Silver ions were then reduced to metallic silver using 
developing solution (10% SilverQuest kit developer and 1 drop SilverQuest kit 
developer enhancer) until proteins were detected. 
3.8. IDENTIFICATION OF bioUb-ENRICHED ENDOGENOUS 
UBIQUITINATED PROTEINS USING MASS 
SPECTROMETRY  
The identification of ubiquitinated proteins was performed at the General Proteomics 
Service (SGIker) of the University of the Basque Country (UPV/EHU) using mass 
spectrometry based on a label-free quantification (LFQ) strategy. Eluted fractions from 
biotin pulldown experiments were trypsin-digested and extracted peptides run into a 
mass spectrometer as described in section 3.8.2. Mass spectra were then analysed using 
the MaxQuant software (Cox and Mann, 2008), with which protein identification and 
quantification of protein abundance were obtained.  
3.8.1. General aspects of mass spectrometry  
For MS-based proteomics (Figure 22), proteins extracted from cells or tissues are loaded 
into a gel and digested with specific proteases, such as trypsin. Next, peptides derived 
from proteins are separated by chromatography and analysed in a mass spectrometer, 
where they are ionized and separated according to their mass-to-charge ratio (m/z) 
(Steen and Mann, 2004). After assessing the m/z of the peptides, these ion precursors 
can be subjected to a second stage of fragmentation in the fragmentation chamber in 
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order to obtain additional information about the amino acid sequence (Steen and Mann, 
2004). This is known as a tandem MS (MS/MS). The ion precursor and corresponding 
fragment ions are then analyzed using software that compares the experimental MS data 
with the theoretical mass of the proteins in a database. As the amino acid sequence of 
each protein is unique, so are the peptide fragments obtained by its proteolytic cleavage. 
Thereby, calculating the mass of each peptide, their sequence and the proteins they 
come from can be identified. 
 
Figure 22: Flow chart of a typical proteomics experiment. Cells or tissues are 
loaded in a gel and digested with specific proteases (trypsin). Next, peptides are 
separated by chromatography and loaded into the mass spectrometer. Peptides 
are there ionized and separated according to their m/z and finally, real peptide 
mass is compared with the information from databases in order to identify the 
proteins. 
3.8.2. In-gel trypsin digestion and peptide extraction 
Proteins eluted from the biotin pull-down were fractionated in a precast gradient 
NuPAGE 4-12% Bis-Tris Gel (Thermo Fisher Scientific) and visualized with Colloidal 
Blue (Thermo Fisher Scientific). Each gel lane was cut into 4 slices (Figure 23), the 
avidin band was removed and proteins were subsequently subjected to in-gel trypsin 
digestion as previously described (Osinalde et al., 2015). Briefly, proteins were reduced 
and alkylated by incubating with 10 mM DTT for 45 minutes at 56 ºC, and with 55 mM 
chloroacetamide (CAA) for 30 minutes at room temperature in darkness. Proteins were 
digested by incubating with trypsin overnight at 37 ºC and finally, resulting peptides 
were extracted from the gel, dried down in a vacuum centrifuge and stored at -20 ºC. 
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Peptide mixture was resuspended in 0.1 % formic acid previous to the LC-MS/MS 
analysis. 
 
Figure 23: Gel cutting for trypsin digestion and (LC)-MS/MS analysis. Eluted 
proteins from biotin pull-down were loaded in a gel and stained with Colloidal 
Blue. Then, each lane was cut into 4 slices and the avidin bad was discarded. 
3.8.3. Liquid chromatography (LC)-MS/MS analysis 
Proteomic analyses were carried out using an EASY nLC-100 liquid chromatography 
system interfaced with a Q Exactive mass spectrometer (Thermo Fischer Scientific) via 
a Nanospray Flex ion source. Acidified peptides were loaded onto an Acclaim 
PepMap100 pre-column (75 µm x 2 cm, Thermo Fisher Scientific) connected to an 
Acclaim PepMap RSLC (50 µm x 15 cm, Thermo Fisher Scientific) analytical column. 
Peptides were eluted using a 45 minutes linear gradient of 2% - 40% acetonitrile in 
0.1% formic acid at a flow rate of 300 nL min-1 onto the nanoES Emitter (Thermo 
Fisher Scientific). Q Exactive was operated in a top-10 data-dependent mode. Survey 
scans were acquired at a resolution of 70 000 (m/z 200) and fragmentation spectra at 17 
500 (m/z 200). Precursors were fragmented by higher energy C-trap dissociation (HCD) 
with normalized collision energy of 28 -. The maximum ion injection time was 120 ms 
for both survey and MS/MS scans, whereas AGC target values of 3x106 and 5x105 were 
used for survey and MS/MS scans, respectively. Repeated sequencing of peptide was 
minimized by excluding the selected peptide candidates for 45 seconds. 
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3.8.4. Data processing and bioinformatics analysis 
Acquired raw data files were searched against the UniProt human database version 
2015_09 (with 42129 sequence entries) using the Andromeda search engine from the 
MaxQuant software (version 1.5.3.17) (Cox and Mann, 2008; Cox et al., 2011) in which 
the spectra originated from the different samples corresponding to the same biological 
replica were combined. Mass tolerance of precursor and MS/MS spectra were set to 8 
and 20 ppm, respectively. Enzyme specificity was set to trypsin, allowing for cleavage 
N-terminal to P and between D and P with a maximum of 2 missed cleavages. 
Carbamidomethylation of C was set as fixed modification whereas oxidation of M, 
protein N-terminal acetylation, and K GlyGly (not C-term) were selected as variable 
modifications for database searching. Match between runs option was enabled with 1.5 
minutes match time window and 20 minutes alignment window to match identification 
across samples. The minimum peptide length was set to 7 amino acids. The maximum 
FDR at peptide and protein levels were specified as 0.01. Normalized spectral protein 
intensities (LFQ intensity) were calculated using the MaxLFQ algorithm.  
MaxQuant output data was analyzed with the Perseus module (version 1.5.6.0) 
(Tyanova et al., 2016). Initially, all contaminants, reverse hits and proteins with no 
unique peptides or intensity were removed. Only proteins that were quantified in two or 
three biological replicates of at least one of the conditions were kept for further analysis 
included in the LFQ analsys. Subsequently, missing values were replaced with values 
from a normal distribution (width 0.3 and down shift 1.8). Two-sided t test was 
performed to identify statistically significant changing proteins. The statistical tests 
were corrected for multiple hypotheses testing using permutation-based FDR, and the 
parameters were chosen to provide sufficient input in the subsequent analysis 
(FDR = 0.05 and 250 randomizations). 
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3.9. SUPPLEMENTARY MATERIALS AND METHODS 
3.9.1. PCR reactions and programs 
PCR reaction A      PCR program A 
Component Volume(µl) 
H2O 40.50 
10× PfuUltra II reaction 
buffer 
5.00 
dNTPs (10 mM) 1.00 
DNA template (≈80 ng/μl) 1.00 
Forward primer (10 µM) 1.00 
Reverse primer (10 µM) 1.00 
PfuUltra II fusion HS DNA 
polymerase 
0.50 
TOTAL 50.00 
  
Temperature Time Nº Cycles 
95°C 2 min 1 
95°C 20 sec 
30 55°C 20 sec 
72°C 15 sec/kb 
72°C 3 min 1 
4°C ∞  
 
Materials and methods
62 
  
PCR reaction B      PCR program B 
Component Volume (µl) 
H2O 38.00 
10× QuikChange Lightning Buffer 5.00 
QuikSolution reagent 1.50 
dNTP mix 1.00 
DNA template (≈50 ng/μl) 1.00 
Forward primer (100 ng/µl) 1.25 
Reverse primer (100 ng/µl) 1.25 
QuikChange Lightning Enzyme 1.00 
TOTAL 50.00 
 
 
PCR reaction C      PCR program C  
Component Volume (µl) 
H2O 17.24 
10× QuikChange Multi 
reaction Buffer 
2.5 
QuikSolution reagent 0.5 
dNTP mix 1.00 
DNA template (≈50 ng/μl) 1.26 
Forward primer (100 ng/µl) 0.75 
Forward primer (100 ng/µl) 0.75 
QuikChange Multi Enzyme 1.00 
TOTAL 25.00 
Temperature Time Nº Cycles 
95°C 2 min 1 
95°C 20 sec 
18 55°C 10 sec 
72°C 30 sec/kb 
72°C 5 min 1 
4°C ∞  
Temperature Time Nº Cycles 
95°C 2 min 1 
95°C 20 sec 30 
55°C 30 sec 
65°C 4 min 
65°C 5 min 1 
4°C ∞  
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3.9.2. Solutions 
Tris-Acetic-EDTA (TAE) 50X 
2 M Tris base 
0.05 M EDTA 
0.05% Acetic acid (v/v) 
 
Agarose gel 
1.5 % Agarose (w/v) 
0.01% Ethidium bromide (v/v) 
1X TAE 
 
DNA loading buffer 
0.2% Orange G (w/v) 
40% sucrose (v/v) 
 
1X PBS (pH 7.6) 
137 mM NaCl 
2.7 mM KCl 
1.8 mM KH2PO4 
8.1 mM Na2HPO4 
 
6X Protein Loading Buffer 
350 mM Tris-HCl pH 6.8 
34.4% Glycerol (v/v) 
10% SDS (w/v) 
10% β-mercaptoethanol (v/v) 
0.06% Bromophenol blue (w/v) 
 
Tris Buffered Saline-Tween 20 (TBS-T) (pH 7.6) 
20 mM Tris base 
137 mM NaCl 
0.1% Tween 20 
 
RIPA protein lysis buffer 
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25mM Tris-HCl (pH 7.6) 
150mM NaCl 
1% NP-40 
1% sodium deoxycholate 
0.1% SDS 
 
Protein lysis buffer 
10 mM NaH2PO4 (pH7.2) 
1 mM EDTA 
1 mM EGTA 
150 mM NaCl 
1% NP-40 (v/v) 
10 mM β-glycerophosphate 
10 mM PMSF 
10 mM Na3VO4 
PIC (Roche) 
50 mM NEM 
 
Running buffer 
0.25 mM Tris base 
1.92 mM Glycine 
1% SDS 
 
Transfer buffer 
120 mM Tris base 
40 mM Glycine 
20% Methanol 
 
Stacking gel for SDS-PAGE 
63 mM Tris HCl pH6.8 
0.1% SDS (v/v) 
5% Acrylamide  
0.1% TEMED 
0.1% APS 
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Resolving gel for SDS-PAGE 
376 mM Tris HCl pH8.8 
0.1% SDS (v/v) 
Acrylamide (variable %) 
0.04% TEMED 
0.1% APS 
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4. Results 
4.1. INSIGHTS INTO THE REGULATION OF USP1 BY 
PHOSPHORYLATION AND AUTOCLEAVAGE 
Phosphorylation and autocleavage are two key regulatory mechanisms for USP1. 
However, several aspects of this regulation are either controversial or not completely 
understood. Therefore, in this section we aim to gain further insight into these aspects. 
4.1.1. Phosphorylation of USP1 at serine 313 is dispensable for the 
formation and activity of USP1/UAF1 complex 
The serine 313 (S313) residue is well established as a USP1 phosphorylation site 
(Cotto-Rios et al., 2011b). At the time this Thesis was initiated, several controversial 
findings regarding the identity of UAF1-binding motif in USP1 (Garcia-Santisteban et 
al., 2012; Villamil et al., 2012b) had raised the question of how relevant S313 
phosphorylation might be for the formation and activity of the USP1/UAF1 complex in 
a cellular context.  
To address this question, we generated non-phosphorylatable (S313A) and 
phosphomimetic (S313D) mutant versions of USP1, and tested their ability to interact 
with UAF1 using a previously described relocation assay (Garcia-Santisteban et al., 
2012) based on the nuclear accumulation of UAF1 induced by USP1 co-expression. By 
using fluorescently-tagged proteins, the results of the assay can be observed both in live 
and in fixed cells.  
Figure 24A shows the results of the relocation assay in live cells. Different versions of 
GFP-tagged USP1 (WT, S313A and S313D) or the YFP-empty vector were co-
transfected together with mRFP-tagged UAF1 into 293T cells. As expected, UAF1-
mRFP was predominantly located in the cytoplasm when co-expressed with YFP 
(negative control), and relocated to the nucleus when co-expressed with GFP-USP1 
(Garcia-Santisteban et al., 2012), as a result of their interaction. Importantly, both GFP-
USP1S313A and GFP-USP1S313D were able to relocate UAF1-mRFP to the nucleus, 
suggesting that both mutants are still able to interact with UAF1 (Figure 24A). Similar 
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results were obtained after cell fixation (Figure 24B). In line with these results, co-
immunoprecipitation (co-IP) analysis showed that both GFP-USP1S313A and GFP-
USP1S313D co-immunoprecipitated with Xpress-tagged UAF1 as efficiently as wild type 
GFP-USP1 (Figure 24C), confirming the result of the relocation assay. 
 
Figure 24: UAF1 binds the non-phosphorylatable S313A mutant version of USP1 
in cell-based assays. A Images of live 293T cells co-expressing UAF1-mRFP with 
YFP (vector), GFP-USP1WT, GFP-USP1S313A or GFP-USP1S313D. UAF1-mRFP is 
cytoplasmic when co-expressed with YFP, but relocates to the nucleus when co-
expressed with GFP-USP1WT, GFP-USP1S313A and GFP-USP1S313D. B. Images of fixed 
293T cells co-transfected as in A. DAPI was used to counterstain the nucleus (DNA 
panels). C. Results of GFP-trap co-IP analysis in 293T cells. Xpress-UAF1 readily co-
immunoprecipitates with GFP-USP1wt, GFP-USP1S313A and GFP-USP1S313D. A section 
of the membrane stained with Ponceau is shown to gauge protein loading. WCE, 
whole cell extract. 
UAF1 binding promotes USP1 stability (Cohn et al., 2007). Thus, we next compared the 
effect of UAF1 co-expression on the levels of the different USP1 S313 mutants. As 
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shown in Figure 25, a dramatic increase in the level of all the GFP-USP1 variants tested 
was observed upon co-transfection with Xpress-UAF1. Of note, the increase in USP1 
levels was accompanied by the appearance of a lower molecular weight band that most 
likely corresponds to the amino-terminal fragment of USP1 resulting from its 
autocleavage at the G670/G671 site (Huang et al., 2006). The appearance of this 
autoclevage product reflects the catalytic activation of USP1 induced by UAF1 binding. 
These results indicate that the S313A or S313D USP1 mutants are not impared in their 
ability to undergo UAF1-induced stabilization or catalytic activation. 
 
Figure 25: UAF1 stabilizes and activates a non-phosphorylatable S313A mutant 
version of USP1. Immunoblot analysis of 293T cells transfected with GFP-USP1WT, 
GFP-USP1S313A and GFP-USP1S313D, alone (−) or in combination with Xpress-UAF1 
(+).The lower molecular weight band in (+) samples corresponds to the well-
characterized N-terminal fragment that results from USP1 autocleavage and 
reflects catalytic activation of USP1 by UAF1. The shorter C-terminal fragment is 
not detected because it does not have GFP. UAF1 co-expression stabilized and 
activated GFP-USP1 wild type, GFP-USP1S313A and GFP-USP1S313D to a similar 
extent. 
These findings indicate that phosphorylation at S313 is not critical for USP1/UAF1 
complex formation and activity in a cellular context. 
The S313A mutation has been reported to drastically reduce the activity of USP1 on an 
artificial fluorogenic substrate in in vitro assays (Villamil et al., 2012b). We tested the 
effect of this mutation on the ability of the USP1/UAF1 complex to deubiquitinate one 
of its physiological substrates: monoubiquitinated PCNA (UbPCNA).  
To this end, 293T cells were co-transfected with plasmids encoding Xpress-UAF1 and 
either GFP-USP1 wild type, GFP-USP1S313A or GFP-USP1S313D. As a negative control, 
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we included a catalytically inactive mutant (C90S) version of USP1, which bears a 
mutation in one of the residues of the catalytic triad. Co-transfected cells were treated 
with hydroxyurea (HU), a drug that induces PCNA monoubiquitination (Huang et al., 
2006) (Figure 26A). As expected, (Figure 26B), wild type USP1, but not USP1C90S, 
decreased the levels of HU-induced PCNA monoubiquitination. Importantly, both S313 
mutants were able to reduce PCNA monoubiquitination. Nevertheless, the ratio of 
ubiquitinated to non-ubiquitinated PCNA (UbPCNA/PCNA ratio) was repeatedly 
observed in several independent experiments to be slightly higher in cells expressing 
GFP-USP1S313A and slightly lower in cells expressing GFP-USP1S313D in comparison to 
cells expressing wild type GFP-USP1. From these results, we conclude that 
phosphorylation at S313 is not necessary for USP1-mediated PCNA deubiquitination in 
HU-treated cells, although it might contribute to modulate this activity.  
 
Figure 26: USP1-mediated PCNA deubiquitination is not abrogated by the S313A 
mutation. A. Immunoblot of 293T cells left untreated (UT) or treated with 4 mM 
hydroxyurea (HU) for 24 h to induce PCNA monoubiquitination. Using an anti-
PCNA antibody, mononubiquitinated PCNA (UbPCNA) was detected as a band 
migrating around 10 kDa above the non-ubiquitinated form (PCNA). B. On the left, 
a representative example of immunoblot analysis of HU-treated 293T cells co-
expressing Xpress-UAF1 with different GFP-USP1 variants. A short-exposure image 
showing both PCNA and UbPCNA, as well as a cropped image showing only 
UbPCNA with longer exposure time are shown. The ratio of ubiquitinated to non-
ubiquitinated PCNA (UbPCNA/PCNA ratio) was determined by densitometry 
analysis of the immunoblot bands. The graph on the right shows the results (mean 
and SEM) of 7 independent experiments. The UbPCNA/PCNA ratio was similar in 
cells expressing Xpress-UAF1 with GFP-USP1WT, GFP-USP1S313A and GFP-USP1S313D, 
but higher in cells expressing the catalytically inactive GFP-USP1C90S. 
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4.1.2. USP1 autocleavage at the G670/G671 diglycine motif occurs 
most likely in cis 
Autocleavage of USP1 at G670/G671, a diglycine motif that resembles a ubiquitin 
linkage, was originally described as a mechanism that inactivates USP1 to allow for 
robust PCNA ubiquitination after UV-induced DNA damage (Huang et al., 2006). This 
autocleavage event can also occur in the absence of UV treatment (Cohn et al., 2007; 
Huang et al., 2006). In line with these reports, we have consistently observed that GFP-
USP1WT, but not the catalytically inactive GFP-USP1C90S, readily undergoes cleavage 
when co-expressed with Xpress-UAF1 in 293T cells (see e.g. immunoblot in Figure 
26B). This observation provides a convenient experimental system to further investigate 
USP1 autocleavage.  
One aspect about USP1 autocleavage that remains to be elucidated is whether this 
cleavage event occurs intramolecularly (in cis) or intermolecularly (in trans) (Figure 
27A). The three-dimensional structure of USP1 has not been solved, and the 
autocleavage motif lies within a non-conserved inserted domain whose structure cannot 
be reliably modeled using other USPs as template. Thus, it remains unknown if the 
cleavage site of a USP1 molecule can reach the catalytic site of the same molecule for 
the cleavage to occur in cis.  
In an attempt to shed some light on this issue, we devised the experiment illustrated in 
Figure 27B. We generated a mutant with alanine substitutions at the G670/G671 
cleavage site (USP1GG/AA). It has been shown that USP1GG/AA maintains its catalytic 
activity (Huang et al., 2006; Oestergaard et al., 2007) and, in fact, we found that it 
efficiently deubiquitinates UbPCNA when co-transfected with Xpress-UAF1 in 293T 
cells (not shown). However, USP1GG/AA cannot undergo autocleavage in cis. On the 
other hand, the catalytically inactive mutant (USP1C90S) does not undergo autocleavage. 
We reasoned that, if USP1 autocleavage occurs in trans, USP1GG/AA molecules could 
cleave USP1C90S molecules when expressed together. 
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Figure 27: Experimental design to test if USP1 autocleavage at the G670/G671 
motif occurs in cis or in trans A. Representation of USP1 showing the catalytic 
triad (C90/H593/D751, green spheres) and the autocleavage site (G670/G671, 
blue spheres). Below, potential cis/trans autocleavage modes. B. Experiment 
used to assess the cleavage mode. The C90S and GG/AA mutants (mutated 
residues in red) are unable to undergo cis autocleavage. If autocleavage occurs 
in trans, co-expression of both mutants could lead to cleavage of GFP-USP1C90S 
by GFP-USP1GG/AA. 
To test this hypothesis, GFP-USP1GG/AA and GFP-USP1C90S were either individually or 
simultaneously co-expressed with Xpress-UAF1 in 293T cells. GFP-USP1WT was used 
as a positive control. As shown in Figure 28, simultaneous co-expression of GFP-
USP1GG/AA and GFP-USP1C90S did not result in cleavage. It remains certainly possible 
that, in this experimental setting, GFP-USP1GG/AA and GFP-USP1C90S molecules did not 
come into close enough proximity for cleavage to occur in trans and, therefore, our 
results do not completely exclude the possibility of USP1 trans cleavage. Nevertheless, 
our findings support the view that the regulation of the USP1/UAF1 complex by USP1 
autocleavage involves a cis cleavage event. 
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Figure 28: USP1 autocleavage does not appear to occur in trans. Immunoblot 
analysis of 293T cells co-expressing Xpress-UAF1 with the indicated GFP-USP1 
constructs. No cleavage was observed upon co-expression of GFP-USP1C90S and 
GFP-USP1GG/AA, suggesting that trans cleavage does not occur. 
In summary, in this section, we provide further insight into the two major regulatory 
mechanisms of USP1/UAF1 complex: we show that phosphorylation at USP1 serine 
313 is not necessary for USP1/UAF1 complex formation or activity, and that USP1 
autocleavage occurs most likely in cis.  
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4.2. CONFIRMATION AND FINE MAPPING OF THE USP1/UAF1 
INTERACTION INTERFACE 
As mentioned above, the identity of the UAF1 binding region(s) in USP1 has been a 
matter of some controversy (see Figure 13). Our group mapped the UAF1-binding site 
to a motif comprising USP1 residues 420-520 (Garcia-Santisteban et al., 2012), 
whereas, another research group latter mapped the UAF1-binding site to USP1 amino 
acid segment 235-408 (Villamil et al., 2012b). 
In this section, we aim to solve the controversy about the UAF1-binding sites in USP1. 
Furthermore, we also made an effort to fine-map the specific residues that contribute to 
USP1/UAF1 interaction. It is important, in our opinion, to obtain as much detailed 
information as possible on the USP1/UAF1 binding interface, because disrupting the 
USP1/UAF1 complex might represent a future therapeutic strategy in cancer treatment.  
4.2.1. Side-by-side comparison of the two reported UAF1-binding sites 
in USP1 
In an attempt to gauge the contribution of the two proposed UAF1-binding regions of 
USP1 in a cellular context, we carried out a side-by-side test to compare the USP1(420–
520) and USP1(235–408) segments using the UAF1 nuclear relocation assay. The 235-
408 segment contains the USP1 nuclear localization signals (NLSs) and the S313 
phosphorylation site. It must be noted that only a phosphomimetic S313D mutant 
version of this was reported by Villamil et al, to interact with UAF1 in vitro (Villamil et 
al., 2012b). 
We used the constructs schematically represented in Figure 29: (i) full-length wild type 
USP1, (ii) the previously described USP1(420-520) fused to one of USP1 NLSs to 
ensure its nuclear accumulation (Garcia-Santisteban et al., 2012), (iii) S313 wild type 
and S313D versions of USP1(235–408) and (iv) S313 wild type and S313D versions of 
a USP1 fragment lacking the 420–520 motif (USP1(del420-520)). 
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Figure 29: Schematic representation of the USP1 constructs used for the UAF1-
relocation assay. The two UAF1 binding sites reported, the NLSs, and the S313 
phosphorylation site are indicated. S/D indicates that both wild type (S) and 
phosphomimetic (D) variants of the 313 residue were tested. 
YFP- or GFP-tagged versions of these USP1 variants were co-expressed with UAF1-
mRFP in 293T cells and the percentage of cells showing nuclear (N), 
nuclear/cytoplasmic (N/C) or cytoplasmic (C) localization of UAF1-mRFP was 
determined. Figure 30A shows representative examples and the results of three 
independent assays are represented in Figure 30B. In line with our previous findings 
(Garcia-Santisteban et al., 2012), full-length USP1 and the USP1(420–520) fragment 
induced a complete relocation of UAF1-mRFP to the nucleus. In contrast, UAF1-mRFP 
remained largely cytoplasmic when co-expressed with the other USP1 variants tested, 
including USP1(235–408)S313D and USP1(del420-520)S313D. These results indicate that 
USP1 amino acid motif 420–520 is both necessary and sufficient for UAF1 binding in a 
cellular environment. 
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Figure 30: Side-by-side comparison of two reported UAF1-binding sites in USP1 
using a nuclear relocation assay. A. Confocal images showing representative 
examples of the results using the UAF1 nuclear relocation assay. 293T cells were 
co-transfected with UAF1-mRFP and the different GFP or YFP-tagged-USP1 
constructs. UAF1-mRFP clearly relocates to the nucleus when co-expressed with 
GFP-tagged USP1 full length and USP1(420–520), but not with the remaining 
deletion mutants. B. Graph showing the results of a semiquantitative analysis of 
the nuclear relocation assay. Slides were coded and the nuclear (N), 
nuclear/cytoplasmic (N/C) or cytoplasmic (C) localization of UAF1-mRFP was 
determined in at least 100 cells per slide. The results (mean and SEM) of three 
independent experiments are shown in the graph. 
The failure of USP1(235–408)S313D to induce UAF1-mRFP nuclear relocation contrasts 
with the reported ability of this fragment to interact with UAF1 in vitro (Villamil et al., 
2012b). We thought that these contrasting findings might result from competition 
between UAF1 and other proteins for binding to this USP1 fragment, an event that may 
occur in a cellular environment, but not in in vitro assays with purified proteins. Since 
the 235–408 motif overlaps with USP1 NLSs, we hypothesized that competition with 
the nuclear import machinery might prevent UAF1 binding to this motif (Figure 31A). 
To test this possibility, we generated a variant of the USP1(235–408) fragment, termed 
USP1(235-408)NLSm + NLS. As illustrated in Figure 31A, this variant bears inactivating 
mutations in USP1 NLSs (Garcia-Santisteban et al., 2012) that would prevent importin 
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binding. To induce nuclear localization of this fragment, we used a heterologous NLS 
from the SV40 large T antigen (SV40NLS) fused to its amino terminus. USP1(235-
408)NLSm + NLS and the phosphomimetic USP1(235-408)NLSm + NLS/S313D remained unable 
to induce UAF1-mRFP relocation to the nucleus (Figure 31B). Although the possibility 
that the NLS-inactivating mutations might also interfere with UAF1 binding cannot be 
formally ruled out, these results suggest that the inability of USP1(235–408) fragment to 
promote UAF1 relocation cannot be ascribed to competition with the nuclear import 
machinery. 
 
 
Figure 31: Lack of UAF1 binding by the USP1(235-408) fragment is not due to 
competition with the nuclear import machinery. A. Cartoon illustrating the 
hypothesis that UAF1 and importins might compete for binding to the USP1(235–
408) segment. Below, schematic representation of the constructs used to test this 
hypothesis. USP1(235-408)NLSm + NLS bears NLSs mutations, and its nuclear 
localization is mediated by an SV40 NLS fused to its amino terminus. S313 wild 
type and S313D phosphomimetic mutants of this construct were tested in the 
UAF1 nuclear relocation. B. Confocal images showing representative examples of 
the assay. Mutation of USP1 NLSs does not faciliate in UAF1 binding to the 235–
408 segment. 
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4.2.2. The “Fingers” subdomain is the UAF1-binding site in USP1  
Considering the crucial role of UAF1 as activating cofactor, not only for USP1, but also 
for USP12 and USP46 (Cohn et al., 2009; Faesen et al., 2011), we reasoned that the 
critical UAF1-binding sequences would be conserved among these different DUBs. In 
order to test this possibility, we used CLUSTALW2 to align USP1, USP46 and USP12 
amino acid sequences (Figure 32). The USP1 420–520 segment was found to be 
homologous to a central amino acid segment in USP12 and USP46. Therefore, we 
decided to carry out a deletion analysis followed by cell-based interaction assays to 
determine if this central motif mediates the binding of these other DUBs to UAF1. 
Taking into account the high sequence similarity between USP12 and USP46, here we 
limited our analysis to USP46. 
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Figure 32: Alignment of USP1, USP46 and USP12 amino acid sequences using CLUSTALW2. USP1 aminoacid segment 420–520 and the homologous 
regions of USP46 and USP12 are highlighted in blue. An “*” (asterisk) indicates positions which have a single, fully conserved residue. A “:” (colon) indicates 
conservation between groups of strongly similar properties as below. A “.” (period) indicates conservation between groups of weakly similar properties as 
below. 
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As shown in Figure 33A, three deletion mutants of USP46 tagged with GFP were 
generated: an amino-terminal fragment (1–164), a central fragment (165–259), 
homologous to USP1(420–520), and a carboxy-terminal fragment (243–366). In 
agreement with a previous report (Urbé et al., 2012), we found that USP46-GFP is a 
cytoplasmic protein (Figure 33B). Thus, the SV40 NLS was fused to its amino terminus 
in order to force its nuclear import and carry out the UAF1-mRFP relocation assay 
(Figure 33B). This assay, (Figure 33C) as well as a subsequent co-IP analysis (Figure 
33D), revealed that the UAF1-binding motif of USP46 lies within the 165–259 
fragment. Thus, homologous amino acid sequences in USP1 and USP46 mediate 
binding to UAF1. 
 
Figure 33: Homologous amino acid motifs mediate binding of USP1 and USP46 to 
UAF1. A. Schematic representation of GFP-tagged USP46 deletion mutants. A 
heterologous NLS (SV40 NLS) was fused to the amino terminal end of each 
fragment. B. Confocal images of 293T cells showing that USP46-GFP is 
cytoplasmic, but relocates to the nucleus when fused to the SV40 NLS. The 
localization of co-expressed UAF1-mRFP parallels that of the DUB. C. Confocal 
microscopy images show that nuclear relocation of UAF1-mRFP is induced by full 
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length (FL) and the 165–259 fragment, but not by the 1–164 or the 243–366 
fragments. D. GFP-trap co-IP analysis of 293T cells, showing that Xpress-UAF1 co-
immunoprecipitates with full-length USP46 and with the 165–259 fragment  but 
not with the other two fragments tested. The dotted line indicates that the panel 
is a composite of two images from a single exposure of the same gel. WCE, whole 
cell extract. A section of the membrane stained with Ponceau is shown to gauge 
protein loading. 
At the time we carried out these experiments, no data about the three-dimensional 
structure of USP1, USP12 or USP46 were available. Therefore, we used the SWISS-
MODEL web tool (http://swissmodel.expasy.org/) to model the structure of the catalytic 
domains of these DUBs using the structure of USP7 catalytic domain (Hu et al., 2002) 
as a template. This model revealed that the UAF1 binding motifs of USP1 and USP46 
map to their “Fingers” subdomains (Figure 34).  
 
Figure 34: The UAF1 binding domain in USP1 and USP46 corresponds to the 
“Fingers” subdomains of these DUBs. Modeled structure of USP1 (left) and USP46 
(right) catalytic domains using SWISS-MODEL and the USP7 structure 1NB8 
(http://swissmodel.expasy.org/) as a template. The “Thumb”, “Palm” and 
“Fingers” subdomains are indicated. The UAF1-binding sites are highlighted in red 
(USP1 residues 420–520) or blue (USP46 residues 165–259). 
4.2.3. Fine-mapping of the UAF1/USP1 interaction 
Our next goal was to identify the specific USP1 and UAF1 residues that contribute to 
their binding. This detailed characterization of the USP1/UAF1 interaction represents a 
necessary first step for future attempts to disrupt this interaction as a therapeutic 
strategy in cancer.  
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4.2.3.1. Identification of USP1 residues that contribute to UAF1 binding 
We hypothesized that critical residues for UAF1 interaction would be conserved in the 
“Fingers” subdomain of UAF1-binding DUBs, but not in the “Fingers” subdomain of 
other DUBs, such as USP7, that have not been reported to bind UAF1. We also 
reasoned that, since the front of the “Fingers” subdomain represents the primary site for 
ubiquitin binding (Hu et al., 2002, 2005), residues at the back of the “Fingers” would be 
more likely to be involved in the USP1/UAF1 interaction. 
First, we used a relocation assay to confirm that USP7 “Fingers” subdomains (residues 
314-411) does not bind UAF1. The USP7(Fingers)-GFP fragment was found to be 
predominantly cytoplasmic (not shown), and, thus, the SV40 NLS was added to its 
amino terminus in order to force its nuclear localization. As shown in (Figure 35), 
UAF1-mRFP remained in the cytoplasm when co-expressed with [NLS]-
USP7(Fingers)-GFP, confirming the lack of interaction. 
 
Figure 35: USP7 “Fingers” subdomain does not bind UAF1. UAF1 relocation assay 
in 293T showing that a [NLS]-USP7(Fingers)-GFP fragment does not induce nuclear 
relocation of UAF1-mRFP, indicating lack of interaction. 
We applied CLUSTALW2-based alignment to compare the sequence of the “Fingers” 
subdomains of USP1, USP46 and USP7. In addition, a hypothetical three-dimensional 
model of the USP1 catalytic domain based on homology with USP7 structure 1NB8 (Hu 
et al., 2002) was used to deduce amino acid position. As illustrated in Figure 36, we 
selected four USP1 residues (Arg439, Leu441, Leu446, and Ser494) that are relatively 
well conserved in USP46, but not in USP7, and would be exposed at the back of the 
“Fingers” subdomain. We generated a mutant, termed GFP-USP14m, in which these four 
residues were replaced with the corresponding USP7 residues 
(R439Q/L441K/L446R/S494A). 
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Figure 36: Description of the experimental mutations introduced into the USP1 
“Fingers” subdomain. CLUSTALW2-based sequence alignment of the “Fingers” 
subdomains of USP1, USP46 and USP7. Letters are colored according to the 
physicochemical properties of the represented residue 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/help/faq.html). Grey arrowheads 
indicate residues whose properties are similar in USP1 and USP46, but different in 
USP7. Below, a model of the USP1 catalytic domain based on homology with USP7 
structure 1NB8 (Hu et al., 2002) is shown as a surface representation. The 
“Fingers” subdomain is colored cyan and both front and back views of the “open 
right hand” are shown. As explained in the text, we hypothesized that USP1 
residues conserved in USP46 but not in USP7, and located on the “back” side of 
the “Fingers” subdomain, might be particularly relevant for UAF1 binding. Four 
USP1 residues that fulfill these requirements (R439, L441, L446 and S494) are 
indicated by black arrowheads in the alignment and highlighted in dark red in the 
model. 
Somewhat disappointingly, using the nuclear relocation assay we found that GFP-
USP14m was still able to bind UAF1 (Figure 37). 
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Figure 37: The USP14m mutant binds UAF1. Confocal microscopy images of 293T 
cells showing that GFP-USP1WT and GFP-USP14m are equelly able to promote 
nuclear relocation of UAF1-Mrfp. 
While our manuscript describing these findings (Olazabal-Herrero et al., 2016) was 
under review, the three-dimensional structure of the UAF1/USP46 complex bound to 
ubiquitin was published (Yin et al., 2015) (Figure 38). In line with our results, their 
structural data independently revealed that the UAF1 binding site in USP46 corresponds 
to the “Fingers” subdomain of the DUB. Other groups have later confirmed these results 
(Dharadhar et al., 2016; Li et al., 2016). 
 
Figure 38: UAF1/USP46/ubiquitin complex. UAF1 is coloured blue (the β-
propeller and ancillary domains in dark blue, and the Sumo-like domain in light 
blue), USP46 is coloured ivory and ubiquitin is coloured orange. The model reveals 
that USP46 “fingertips” directly bind to the top center of the β-propeller of UAF1. 
Adapted from (Yin et al., 2015). 
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Taking advantage of their structure data, Yin et al identified four amino acid residues on 
the tips of the “Fingers” subdomain of USP46 (E186, R181, L183 and E237) engaged in 
the interaction with UAF1. They called this group of residues the “ERLE” motif. The 
ERLE motif is conserved in USP12 (E190, R185, L187 and E241) and USP1 (E444, 
R439, L441 and E516) (Figure 39). 
 
Figure 39: The ERLE pattern that contributes to UAF1 binding in USP46, USP12 
and USP1. Homology models of USP12 and USP1 compared to USP46 structure 
illustrate conservation of key amino acid residues involved in UAF1 interaction. 
The pattern of four amino acid residues is circled including E186, R181, L183 and 
E237 in USP46; E190, R185, L187 and E241 in USP12 and E444 and R439, L441 and 
E516 in USP1. Adapted from (Yin et al., 2015). 
As illustrated in Figure 40, the ERLE motif of USP1 includes two of the residues (R439 
and L441) that we introduced in the USP14m mutant. The most critical residue in the 
ERLE motif, however, turned out to be E444. In fact, Yin et al found that a USP1E444K, 
mutant or the equivalent USP46E186K mutant are unable to bind UAF1, and have their 
deubiquitinase activity abrogated (Yin et al., 2015). The equivalent mutation in USP12 
(E190K) was not tested. 
 
Figure 40: Comparison of the amino acids in USP1 “Fingers” subdomain mutated 
by our group (black arrowheads) and Yin et al (orange arrowheads). The most 
critical amino acid for the interaction with UAF1 (E444) is highlighted in red.  
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To independently confirm and extend their results, we generated plasmids encoding 
GFP-USP1E444K, YFP-[NLS]-USP46E186K and YFP-[NLS]-USP12E190K. Using the 
nuclear relocation assay, we found that the three mutants were unable to relocate UAF1 
to the nucleus (Figure 41), thus confirming that these single point mutations efficiently 
disrupt the interaction of the three DUBs with UAF1. 
 
Figure 41: The USP1E444K, USP46E186K and USP12E190K mutants do not interact with 
UAF1. Representative examples of 293T cells showing that the USP1E444K, 
USP46E186K and USP12E190K mutants have lost their ability to induce nuclear 
relocation of Xpress-UAF1. 
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4.2.3.2. UAF1 residues that contribute to DUB binding 
Guided by the structural information, Yin et al also generated a triple UAF1 mutant, 
(UAF13M) bearing three mutations in the β-propeller domain (K214E/W256A/R272D) 
that was unable to bind USP1 and USP46 (Yin et al., 2015). In order to independenlty 
validate and further refine their findings, we generated three different Xpress-tagged 
UAF1 mutants: UAF13M, UAF12M (K214E/W256A), and UAF1K214E (Figure 42A). We 
confirmed that these mutations did not alter the cytoplasmic localization of UAF1 
(Figure 42B).  
 
Figure 42: Schematic representation of UAF1 mutants and their localization. A. 
The WD-repeats of UAF1 are highlighted in blue and the Sumo-like domains 1 and 
2 (SLDs) are depicted in pink. The mutations are indicated with a red asterisks. B. 
Confocal microscope images of 293T cells showing cytoplasmic localization of 
Xpress-tagged UAF1 mutants. 
Using the nuclear relocation assay (Figure 43), we found that all the tested mutants, 
including the single point mutant UAF1K214E were unable to bind USP1, USP46, and 
USP12. 
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Figure 43: A single point mutation (K214E) in UAF1 is enough to disrupt 
interaction with USP1, USP46 and USP12. Confocal microscopy images of 293T 
cells showing that Xpress-tagged UAF13M, UAF12M and UAF1K214E do not relocate  
to the nucleus when coexpressed with GFP-USP1, or YFP-[NLS]-USP46 YFP-[NLS]-
USP12. 
In summary, we conclude that the E444 residue in USP1, and the K214 residue in 
UAF1 are crucial in the formation of the USP1/UAF1. 
4.2.4. Assesing the functional effect of the mutations that disrupt 
USP1/UAF1 interaction 
Using mostly in vitro experiments, Yin et al showed that mutations that disrupt UAF1 
binding prevented the catalytic activation of USP46 and USP1 (Yin et al., 2015). To 
further extend these findings in a cellular setting, we investigated how the single 
mutations USP1E444K and UAF1K214E affect the activity of the USP1/UAF1 complex in 
cells using two different readouts: (i) USP1 autoclevage and (ii) the ability to counteract 
HU-induced PCNA ubiquitination. 
As shown in Figure 44A, USP1E444K did not undergo autocleavage when co-expressed 
with UAF1WT and, conversely, USP1WT did not undergo autocleavage when co-
expressed with UAF1K214E (Figure 44B). Thus, consistent with the previous in vitro data, 
our findings indicate that these mutations abrogate catalytic activation of USP1 by 
UAF1 in cells. 
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Figure 44: Autocleavage analysis of USP1E444K and UAF1K214E mutants. A. 
Immunoblot analysis showing that USP1E444K mutant does not undergo UAF1-
induced autocleavage. B. Immunoblot analysis showing that UAF1K214E mutant 
does not induce USP1 autocleavage. In these experiments GFP-tagged USP1 
constructs and Xpress-tagged UAF1 constructs were used. USP1C90S was included 
as a negative control. 
On the other hand, UbPCNA levels were not decreased in cells co-expressing 
USP1E444K with UAF1WT (Figure 45A) as expected. Surprisingly, very low levels of 
UbPCNA were repeatedly observed in cells co-expressing USP1WT with UAF1K214E 
(Figure 45B). This was a puzzling observation, as we have shown above that UAF1K214E 
is unable to bind and catalytically activate USP1. 
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Figure 45: Analysis of PCNA ubiquitination in cells expressing USP1E444K and 
UAF1K214E mutants. Top, representative examples of immunoblot analysis of 293T 
cells co-transfected with the indicated plasmids and treated with 4 mM HU for 24 
h. The dotted line indicates that the panel is a composite of two images from a 
single exposure of the same gel. The UbPCNA/PCNA ratio was determined by 
densitometry analysis of the immunoblot bands, and the graphs below show the 
results (mean and SEM) of 3 independent experiments. A. Co-expression of GFP-
USP1E444K with Xpress-UAF1WT did not reduce HU-induced ubPCNA. B. Co-
expression of GFP-USP1WT with Xpress-UAF1K214E reduced HU-induced UbPCNA. 
Our unexpected findings with the UAF1K214E mutant raised the following question: does 
overexpressed “free” USP1 counteract PCNA monoubiquitination in a manner that does 
not require UAF1 binding and that is independent of its deubiquitinase activity?  
To answer this question, we expressed GFP-USP1WT and the catalytically inactive 
mutant GFP-USP1C90S either alone or with wild type UAF1 in 293T cells. We found 
that, indeed, the levels of monoubiquitinated PCNA were clearly reduced in cells 
expressing GFP-USP1WT and, more surprisingly, also in cells expresing GFP-USP1C90S 
alone (red square) (Figure 46). Of note, when co-expressed with UAF1, only wild type 
USP1 reduced UbPCNA level.  
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Figure 46: Overexpression of GFP-USP1WT or GFP-USP1C90S alone decreases PCNA 
monoubiquitination. Left, immunoblot analysis of 293T cells co-transfected with 
the indicated plasmids and treated with 4 mM hydroxyurea (HU) for 24 h. When 
expressed alone, both GFP-USP1WT and the catalytically inactive GFP-USP1C90S 
decrease HU-induced PCNA monoubiquitination (red square). In contrast, when 
co-expressed with Xpress-UAF1, only GFP-USP1WT decreases UbPCNA. The 
UbPCNA/PCNA ratio was determined by densitometry analysis of the immunoblot 
bands, and the graph on the right show the results (mean and SEM) of 3 
independent experiments. 
In summary, mutations that interfere with USP1/UAF1 binding prevent UAF1-mediated 
enzymatic activation of USP1 (as indicated by the lack of autocleavage). However, 
“free” USP1 may decrease PCNA monoubiquitination independently of its 
deubiquitinase activity, suggesting a previously undescribed “non-catalytic” effect of 
USP1 on the ubiquitination of PCNA. 
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4.3. USP1/UAF1 IN CANCER 
Although USP1 is not a frequently mutated gene in human tumors, the cancer mutation 
database COSMIC includes a number of USP1 mutations whose biological effect has 
not yet been tested. On the other hand, the USP1/UAF1 complex is emerging as a 
potential target in cancer therapy (García-Santisteban et al., 2013), but USP1 inhibitors 
have only been tested in a very limited set of tumor models.  
In this section, we first identify two novel readouts to evaluate USP1/UAF1 cellular 
activity. Then we apply these readouts, as well as previoulsy-established assays to 
investigate the functional consequences of several cancer-related USP1 mutations. 
Finally, we evaluate the effect of the USP1 inhibitor ML323, alone or in combination 
with the chemotherapeutic agent oxaliplatin, in a preclinical model of pancreatic cancer-
derived cells.  
4.3.1. Novel functional readouts to study USP1 activity in cells: general 
ubiquitin deconjugation and blockade of 53BP1 foci formation 
A few physiological targets of USP1, such as PCNA, FANCD2 and ID2, have been 
identified (Huang et al., 2006; Nijman et al., 2005b; Williams et al., 2011). The ability 
to reverse the monoubiquitination of these three targets is frequenlty used as readout to 
study USP1 deubiquitinating activity in cells. Using commercially available reagents, 
we were unable to unambiguosly detect FANCD2 and ID2 monoubiquitination by 
immunoblot. In contrast, UbPCNA was clearly and reproducibly detected and thus, the 
ability to reverse PCNA monoubiquitination is used throughout this Thesis as a readout 
for USP1 activiy. However, our data (section 4.2.4.) suggest that overexpression of 
“free” USP1 can also decrease UbPCNA levels through a mechanism independent from 
its enzymatic activity.  
We thought that this “non-catalytic” effect migth complicate the functional 
characterization of some cancer-related USP1 mutants. Thus, we set out to discover 
novel cellular readouts for monitoring USP1 activity to complement the analysis of 
PCNA ubiquitination. 
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We focused on two events that occur in cells that suffer DNA double-strand breaks 
(DSBs). On one hand, we studied the formation of nuclear ubiquitin-containing foci that 
reflect the recruitment of ubiquitinated proteins to the sites of DNA damage (Messick 
and Greenberg, 2009). To this end, we used the FK2 antibody, a well-validated reagent 
that specifically recognizes conjugated, but not free, ubiquitin (Fujimuro et al., 1994). 
On the other hand, we studied the ubiquitination-dependent recruitment of 53BP1 to 
foci (Huyen et al., 2004). As a negative control, we studied the phosphorylation-
dependent recruitment of γH2AX to foci, an ubiquitin independent event (Fernandez-
Capetillo et al., 2004; Rogakou et al., 1998). 
We used the radiomimetic drug neocarzinostatin (NCS) as a genotoxic agent to induce 
DSBs. As shown in Figure 47, and consistent with previous reports (Bencokova et al., 
2009; Morris et al., 2012; van Wijk et al., 2012), NCS (100ng/ml for 4 h) induced a 
dramatic increase in the number of FK2, 53BP1 and γH2AX nuclear foci.  
 
Figure 47: Ubiquitinated proteins, 53BP1 and γH2AX accumulate in nuclear 
damage foci after NCS treatment. Immunofluorescence analysis of untreated 
(UT) or neocarzinostatin (NCS)-treated 293T cells. A. Staining with the FK2 
antibody that recognizes conjugated ubiquitin. B. Double staining with anti-
53BP1 (red) and anti-γH2AX (purple).  
Next, 293T cells were transfected with GFP-USP1WT alone or co-transfected with 
Xpress-UAF1 plus GFP-USP1WT or GFP-USP1C90S. As a negative control, GFP fused 
to the SV40 NLS ([NLS]-GFP) was included. Transfected cells were either left 
untreated or treated with NCS and anti-FK2 immunofluorescence was performed. 
Strikingly, co-expression of GFP-USP1WT and Xpress-UAF1 resulted in a drastic 
reduction in the FK2 signal in the nucleus of untreated cells (Figure 48A), and 
 
Results
93 
  
completely prevented the formation of FK2-positive foci in NCS-treated cells (Figure 
48B). Importantly, none of these effects were noted in cells expressing the NLS-GFP 
control, GFP-USP1WT alone, or in cells co-expressing GFP-USP1C90S with Xpress-
UAF1.  
 
Figure 48: Overexpression of the USP1/UAF1 complex decreases general 
ubiquitin conjugation in the nucleus. A. Left, confocal microscopy images of FK2 
immunostaining in 293T cells transfected with the indicated expression plasmids. 
The nucleus of a representative transfected cell per sample is circled by a dotted 
line. Using ImageJ, the intensity of the FK2 signal in the nucleus of at least 50 
transfected cells with similar GFP expression levels was quantified per sample. 
Each dot in the graph (rigth) represents the intensity of the FK2 signal in the 
nucleus of a single cell, and the bar indicates the median. The data shown 
correspond to one experiment. Two independent experiments were performed, 
with similar results. Overexpression of USP1/UAF1 induces a drastic decrease in 
FK2 staining. B. Confocal microscopy images show FK2 immunostaining in 293T 
cells transfected as in A., and treated with 100 ng/mL neocarzinostatin (+ NCS) for 
4 h. Almost not nuclear FK2 staning is detected in NCS-treated cells 
overexpressing USP1/UAF1. 
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On the other hand, overexpression GFP-USP1WT and Xpress-UAF1 completely blocked 
the recruitment of 53BP1 into NCS-induced foci (Figure 49). YFP-USP3, a DUB 
previously shown to interfere with 53BP1 recruitment (Sharma et al., 2014), was 
included as positive control in this experiment. 53BP1 recruiment was not reduced in 
cells expressing the [NLS]-GFP control, GFP-USP1WT alone, or in cells co-expressing 
GFP-USP1C90S and Xpress-UAF1.  
 
Figure 49: Effect of USP1/UAF1 overexpression on the recruitment of 53BP1 to 
DNA damage foci. Left, confocal microscopy images showing representative 
examples of 53BP1 immunostaining in 293T cells transfected with the indicated 
expression plasmids. Cells were treated with NCS (100 ng/mL) for 4 h before 
fixation. The graph (right) represents the percentage of cells showing more than 
five 53BP1 nuclear foci in each sample. The data shown correspond to the mean 
of three independent experiments, and error bars indicate the SEM. One hundred 
cells per condition were examined in each experiment. **p< 0.01 (Student's t-
test). 
As expected, overexpression of GFP-USP1 and Xpress-UAF1 did not interfere with the 
phosphorylation-dependent recruitment of γH2AX into NCS-induced nuclear foci. 
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Figure 50: Effect of USP1/UAF1 complex overexpression on γH2AX. Confocal 
microscopy images showing examples of γH2AX immunostaining in 293T cells 
transfected with the indicated expression plasmids and treated with NCS. 
USP1/UAF1 overexpression does not interfere with recruitment of γH2AX to DNA 
damage foci. 
In summary, these results indicate that co-expression of USP1WT and UAF1 promotes 
general ubiquitin deconjugation and blocks the recruitment of 53BP1 to DNA damage-
induced foci. Of note, unlike the “non-enzymatic” effect on PCNA described above, 
both effects are dependent on the expression of a catalitycally active USP1/UAF1 
complex. 
The dramatic effect of USP1/UAF1 complex overexpression on nuclear ubiquitin 
conjugation prompted us to test the possibility that overexpression of other nuclear 
DUBs of the USP family might have a similar effect. In vitro analyses have shown that 
USP members are generally promiscuous in terms of the type of the ubiquitin linkage 
that they can process (Faesen et al., 2011; Komander et al., 2009), but little is known 
about their substrate promiscuity in a cellular context. We reasoned that depletion of 
conjugated ubiquitin, as detected by FK2 immunofluorescence, could be useful to gauge 
the relative substrate promiscuity of DUBs. In this regard, although FK2 
immunostaining has been previously performed in cells overexpressing specific USPs, 
such as USP36 (Endo et al., 2009), USP29 and USP44 (Mosbech et al., 2013), USP16 
(Zhang et al., 2014), or USP26 and USP37 (Typas et al., 2015), a systematic 
comparison of how overexpression of several different USP family DUBs affects the 
FK2 signal has not yet been attempted, to the best of our knowledge. 
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To address this issue, we directly compared the levels of FK2 immunofluorescence 
signal in the nucleus of 293T cells overexpressing four different GFP-tagged or YFP-
tagged USPs (Figure 51A). Besides USP1, three nuclear USPs (USP3, USP7, and 
USP22) were tested. In these experiments, GFP-USP1 was co-expressed with Xpress–
UAF1 and [NLS]-GFP was used as a negative control. The intensity of FK2 
immunofluorescence in the nuclei of cells expressing the different USPs was 
normalized using the FK2 intensity in the nuclei of nontransfected cells from the same 
sample as a reference. The relative FK2 intensity was then plotted against the intensity 
of the nuclear GFP/YFP fluorescence (Figure 51B). Overexpression of the [NLS]-GFP 
control, YFP-USP3 or YFP-USP22 did not affect FK2 immunostaining, even at high 
expression levels, whereas a partial decrease in the intensity of the FK2 signal was 
noted in cells expressing moderate to high levels of YFP-USP7. In the case of 
USP1/UAF1, a drastic reduction in the FK2 signal was clearly evident even in cells 
expressing very low levels of GFP-USP1. FK2 immunofluorescence was also 
investigated in NCS-treated cells overexpressing these four different USPs. As shown in 
Figure 51C, FK2-positive foci were readily detected in cells expressing [NLS]-GFP, 
YFP-USP7, or YFP-USP22. In line with a previous report (Sharma et al., 2014), diffuse 
FK2 staining was observed, but no NCS-induced foci were observed, in cells expressing 
YFP-USP3. As described above, the FK2 signal was almost undetectable in cells 
expressing USP1/UAF1. These findings suggest that, when expressed at similar levels, 
the USP1/UAF1 complex shows higher substrate promiscuity than other nuclear DUBs 
in a cellular context. 
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Figure 51: Using depletion of conjugated ubiquitin as readout to compare 
USP1/UAF1 with other nuclear USPs. A. Confocal microscopy images show 
examples of FK2 immunostaining in 293T cells transfected with the indicated 
expression plasmids. B. Graph showing the intensity of FK2 signal in the nuclei of 
50 transfected cells per sample. Each dot in the graph represents a single cell. The 
FK2 fluorescence intensity was normalized to the intensity of the signal in the 
nuclei of nontransfected cells, and plotted against the YFP/GFP intensity. Trend 
lines were added with Excel. The data shown correspond to one experiment. 
Three individual experiments were carried out, with similar results. C. Confocal 
microscopy images show examples of FK2 immunostaining in 293T cells 
transfected as in A., and treated with 100 ng/mL NCS for 4 h. 
In summary, these results identify general ubiquitin deconjugation and blockade of 
53BP1 recruitment to foci as two novel readouts that can be used to investigate the 
functional effects of cancer-related USP1 mutations.  
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4.3.2. Functional effects of cancer-related USP1 mutations  
Some USP1 mutations detected in tumors (S475Y, D502N, and S575R) affect residues 
in/near the “Fingers” subdomain, and several others (G667A, L669P, K673T and 
A676T) cluster around the G670/G671 autocleavage site (Figure 52). 
 
Figure 52: Cancer-associated USP1 mutations in or near the “Fingers” subdomain 
or the G670/G671 autocleavage site. Schematic representation of USP1 domain 
structure showing “Fingers” subdomain in light blue and the dyglicine 
autocleavage site highlighted in pink. The position of seven cancer-associated 
USP1 mutations reported in the COSMIC mutation database is indicated in red. 
We investigated the effect of these seven mutations, using a battery of tests that 
included (i) ability to interact with UAF1 using the relocation assay, (ii) ability to 
undergo UAF1-induced autocleavage, (iii) ability to reverse HU-induced PCNA 
ubiquitination when co-expressed with UAF1, (iv) ability to promote general ubiquitin 
deconjugation, and (v) ability to prevent NCS-induced recruitment of 53BP1 to DNA 
damage foci. 
4.3.2.1. Functional characterization of cancer-related mutations in the USP1 
“Fingers” subdomain 
We selected two missense mutations in the “Fingers” subdomain residues (S475Y and 
D502N), which have been detected in endometrial carcinoma and melanoma samples, 
respectively (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/), and a third 
mutation, S575R, which is located just outside the “Fingers” subdomain but affects the 
most commonly mutated USP1 residue in tumors (Figure 52). We generated GFP-
USP1S475Y, GFP-USP1D502N and GFP-USP1S575R mutants. The results of the nuclear 
relocation assay showed that the three mutants are able to interact with UAF1 (Figure 
53).  
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Figure 53: UAF1 nuclear relocation assay of USP1 cancer-related mutations 
in/near the “Fingers” subdomain. Confocal images showing examples of 293T 
cells co-expressing the indicated plasmids. All the mutants tested are able to 
relocate UAF1 to the nucleus. 
These three “Fingers” mutants were also able to undergo UAF1-promoted autocleavage 
(Figure 54). 
 
Figure 54: Autocleavage analysis of USP1 cancer-related mutations in/near the 
“Fingers” subdomain. Immunoblot analysis of 293T cells transfected with the 
indicated GFP-USP1 variants, either alone (–) or in combination with Xpress–UAF1 
(+). All the mutants tested are able to undergo autocleavage when coexpressed 
with UAF1. 
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Interestingly, one of the tested mutations, S475Y, but not the other two mutations 
tested, abrogated the ability of USP1 to deplete conjugated ubiquitin (Figure 55A), 
prevent 53BP1 recruitment to DNA damage foci (Figure 55B) and reduce ubPCNA 
levels (Figure 55C). Thus, the USP1S475Y mutant seems to be unable to catalyze 
substrate deubiquitination despite being capable to bind to and and become activated by 
UAF1.  
 
Figure 55: Cellular activity assays to characterize the effect of USP1 cancer-
related mutations in/near the “Fingers” subdomain. A, B. Confocal microscopy 
images showing examples of FK2 and 53BP1 immunostaining in 293T cells co-
transfected with the indicated expression plasmids and treated with NCS (100 
ng/mL) 4 h before fixation. The nucleus of a representative cell in each sample is 
circled by a dotted line. GFP-USP1S475Y mutant was not able to deplete nuclear FK2 
staining (A) or block 53BP1 foci recruitment (B). C. Immunoblot analysis of 293T 
cells co-transfected with the indicated expression plasmids and either left 
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untreated (UT) or treated with 4 mM hydroxyurea for 24 h. The UbPCNA/PCNA 
ratio was determined by densitometry analysis of the immunoblot bands. The 
graph on the right shows the results (mean and SEM of three independent 
experiments). GFP-USP1S475Y mutant was not able to deubiquitinate PCNA.  
4.3.2.2. Functional characterization of cancer-related mutations near USP1 
autocleavage site 
We also analysed four mutations (G667A, L669P, K673T and A676T) that cluster 
within a ten amino acid segment encompassing the G670/G671 autocleavage site. We 
used site-directed mutagenesis to introduce each of these amino acid changes into GFP-
USP1, and we co-expressed these proteins with Xpress-UAF1 in 293T cells. None of 
these mutations disrupted USP1/UAF1 interaction, according to the results of the 
nuclear relocation assay (Figure 56). 
 
Figure 56: UAF1 nuclear relocation assay of USP1 cancer-related mutations near 
the autocleavage site. Confocal images showing examples of 293T cells co-
expressing the indicated plasmids. All the mutants tested are able to relocate 
UAF1 to the nucleus.  
Next, we evaluated the ability of these mutants to undergo UAF1-induced autocleavage. 
Immunoblot analysis (Figure 57) revealed that GFP-USP1G667A, GFP-USP1K673T and 
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GFP-USP1A676T were cleaved to a similar extent as wild type GFP-USP1. However, 
cleavage of the GFP-USP1L669P mutant was much less efficient. 
 
Figure 57: Autocleavage analysis of USP1 cancer-related mutations near the 
autocleavage site. Immunoblot analysis of 293T cells transfected with the 
indicated GFP-USP1 variants in combination with Xpress-UAF1. GFP-USP1G667A, 
GFP-USP1K673T and GFP-USP1A676T are cleaved as efficiently as wild type USP1, 
whereas GFP-USP1L669P is less efficiently cleaved. 
Remarkably, the four tested mutants, including USP1L669P, were able to deplete FK2 
signal (Figure 58A), block 53BP1 recruitment (Figure 58B) and decrease HU-induced 
PCNA ubiquitination (Figure 58C).  
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Figure 58: Cellular activity assays to characterize the effect of USP1 cancer-
related mutations near the autocleavage site. A, B. Confocal microscopy images 
showing examples of FK2 and 53BP1 immunostaining in 293T cells co-transfected 
with the indicated expression plasmids and treated with NCS (100 ng/mL) 4 h 
before fixation. The nucleus of a representative cell in each sample is circled by a 
dotted line. All the mutants tested were able to deplete nuclear FK2 staining (A) 
or block 53BP1 foci recruitment (B). C. Immunoblot analysis of 293T cells co-
transfected with the indicated expression plasmids and either left untreated (UT) 
or treated with 4 mM hydroxyurea for 24 h. The UbPCNA/PCNA ratio was 
determined by densitometry analysis of the immunoblot bands. The graph below 
shows the results (mean and SEM) of three independent experiments. All the 
mutants tested were able to deubiquitinate PCNA. 
In summary, we have identified two cancer-related mutations that affect USP1 function 
(S475Y) or regulation by autocleavage (L669P). 
4.3.3. Activity of the USP1/UAF1 inhibitor ML323 in pancreatic 
cancer cells 
Pancreatic cancer is a type of tumor with poor prognosis and limited therapeutic options 
(Vaccaro et al., 2011). Oxaliplatin, a platinum-based chemotherapeutic drug, is used to 
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treat pancreatic cancer patients, but resistance to this drug frequently arises (Chand et 
al., 2016). The USP1 inhibitor ML323 (Dexheimer et al., 2014), has been shown to 
reverse the resistance of non-small cell lung cancer (NSCLC) cell lines to the platinum-
based drug cisplatin (Liang et al., 2014). Thus, we decided to explore the possibility that 
inhibiting the USP1/UAF1 complex with ML323 could increase the sensitivity of 
pancreatic cancer cells to oxaliplatin. Most of the experiments described in this section 
were carried out at the Pharmacology laboratory of VUmc (Amsterdam), under the 
supervision of Drs. Elisa Giovannetti and Godefridus J. Peters. 
4.3.3.1. Confirmation of ML323-mediated inhibition of the USP1/UAF1 in cells 
ML323 has been reported to be a specific and potent inhibitor of the USP1/UAF1 
complex. Although the original report (Liang et al., 2014) included some data obtained 
in cells, most of the validation of ML323 was done using in vitro biochemical assays. 
Thus, we decided to further evaluate the cellular effects of ML323.  
First, we compared side by side the effect of ML323 with the effect of knocking down 
USP1 expression using small interfering RNA (siRNA) in 293T cells. We used a pool 
of three siRNA oligonucleotides that consistently reduces USP1 protein levels (Figure 
59A). USP1 knockdown led to an increase in the percentage of cells having more than 
five FK2-positive foci in the nucleus, and a similar effect was noted in ML323-treated 
cells (Figure 59B). On the other hand, both USP1 silencing and ML323 treatment 
induced the recruitment of 53BP1 into nuclear foci (Figure 59C).  
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Figure 59: Side by side comparison of the effect of ML323 with the effect of 
siRNA-mediated USP1 knockdown. A. Efficacy of siRNA-mediated USP1 
knockdown. 293T cells were transfected with a pool of three siRNAs targeting 
USP1 (siUSP1) or with scramble siRNA as a negative control (siCTRL). 48 h after 
transfection, immunoblot analysis of total protein exctracts was carried out 
using anti-USP1 antibody. B. Confocal microscopy images show representative 
examples of FK2 immunostaining in 293T cells transfected with siCTRL or siUSP1 
(left) or 293T cells untreated (UT) or treated with the USP1/UAF1 inhibitor 
ML323 (50µM) for 16h (right). The graphs represent the percentage of cells 
showing more than five FK2-positive nuclear foci in each condition. USP1 
knockdown or ML323 treatment lead to a significant increase of FK2 foci. C. 
Confocal microscopy images show representative examples of 53BP1 
immunostaining in 293T cells transfected or treated as in B. The graphs 
represent the percentage of cells showing more than five 53BP1-positive nuclear 
foci in each condition. USP1 knockdown or ML323 treatment lead to an increase 
of 53BP1 foci. In A and B, the graphs represent the data (mean and SEM) of four 
independent experiments. One hundred cells per condition were examined in 
each experiment. ns=non significant; *p < 0.05; **p< 0.01 (Student's t-test). 
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On the other hand, in order to gauge the potency of ML323 in a cellular context, we 
tested its capability to inhibit overexpressed USP1/UAF1. As shown above, co-
expression of GFP-USP1 and Xpress-UAF1 depleted conjugated ubiquitin (Figure 60A) 
and blocked NCS-induced recruitment of 53BP1 into nucelar foci (Figure 60B). Both 
effects were clearly reversed by ML323, demonstrating the inhibition of overexpressed 
USP1/UAF1. These observations strongly suggest that the endogenous USP1/UAF1 
complex would be effectively inhibited in cells treated with this compound. 
 
Figure 60: ML323 reverses the effect of USP1/UAF1 overexpression on nuclear 
ubiquitin conjugation and 53BP1 recruitment. Confocal microscopy images 
showing examples of FK2 (A) or 53BP1 (B) immunostaining in 293T cells co-
expressing GFP-USP1 and Xpress-UAF1. Twenty-four hours after transfection, cells 
were either left untreated or pre-treated with ML323 (50 μM) for 2 h. NCS (100 
ng/mL) was subsequently added to all samples for an additional 2 h. ML323 
efficiently reversed the effects of USP1/UAF1 overexpression. 
4.3.3.2. Expression of USP1 and UAF1 mRNA in pancreatic cancer 
The levels of USP1 mRNA have been reported to be significantly altered in different 
types of cancer (García-Santisteban et al., 2013). We used quantitative RT-PCR (qRT-
PCR) to investigate whether the levels of USP1 and UAF1 mRNA are altered in 
pancreatic cancer. We compared USP1 and UAF1 mRNA levels in normal pancreatic 
tissue (n=3) and pancreatic cancer tissue (n=5) We also measured USP1 and UAF1 
mRNA in two non-transformed human pancreatic ductal epithelial cell lines (HPDE and 
HPNE) and in 19 pancreatic cancer cell lines. As shown in (Figure 61A and B), USP1 
and UAF1 mRNA expression was higher in tumor tissues or tumor-derived cells than in 
normal samples.Interestingly, a strong correlation between USP1 and UAF1 expression 
was observed in pancreatic cancer cell lines (Figure 61C). Even if the number of tissue 
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samples analyzed here is limited, these data suggest that overexpression of the 
USP1/UAF1 complex may be a common event in pancreatic cancer, and thus, 
USP1/UAF1 inhibitors, such a ML323, might be an appropriate therapeutic option in 
this tumor type. 
 
Figure 61: USP1 and UAF1 mRNA expression is altered in pancreatic cancer. A. 
Box plot graph showing the relative USP1 and UAF1 mRNA expression normalized 
to GAPDH in normal tissue (n=3) or pancreatic cancer tissue (n=5). Error bars 
indicate the SEM.*p < 0.05.(Student’s t-test). B. Relative USP1 and UAF1 mRNA 
expression normalized to GAPDH in two non-transformed human pancreatic 
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ductal epithelial cell lines (HPDE and HPNE) and in 19 different pancreatic cancer 
cell lines compared to the average of three normal pancreas tissue samples. The 
relative mRNA levels were determined with the ∆∆Ct method using the normal 
tissue value as a reference. USP1 is depicted in red and UAF1 in green. Blue 
asterisks indicate the cell lines selected for the following experiments C. Scatter-
plot showing a strong co-relation between USP1 and UAF1 mRNA expression in 
pancreatic cancer. Pearson r=0.8283 and ***p<0.001 (Student´s t-test). 
Based on the qRT-PCR results, we selected three cell lines (Figure 61B, blue asterisks) 
with different expression levels of USP1 and UAF1 mRNA: PDAC-2 (low), PANC-1 
(intermediate) and PDAC-3 (high). The potential of ML323 as a therapeutic agent was 
evaluated in these three cell lines. 
4.3.3.3. ML323 acts synergistically with oxaliplatin in the pancreatic ductal 
adenocarcinoma PDAC-2 cell line  
We first evaluated the effect of single-drug treatments with ML323 or oxaliplatin. 
Sulforhodamine B (SRB) assays were used to generate cell growth inhibition curves and 
to determine the IC50 (concentration of drug required for 50% cell growth inhibition) of 
oxaliplatin and ML323 (Figure 62). 
 
Figure 62: Growth inhibition curves of PDAC-2, PDAC-3 and PANC-1 pancreatic 
cancer cell lines. Exponentially growing cells seeded in 96 well plates were treated 
with different concentrations of oxaliplatin (A) or ML323 (B), and SRB assays were 
performed 72 hours after drug exposure. Growth inhibition curves were 
generated, where each point represents mean ± SEM of at least 2 independent 
experiments. The dotted line represents the 50% of cell growth used to determine 
the IC50. 
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Table 9 summarizes the IC50 values obtained for oxaliplatin and ML323 (used as single 
drugs). In general terms, ML323 was less toxic than oxaliplatin, as indicated by higher 
IC50 values. In PDAC-2 cells, the IC50 for oxaliplatin was 0.55 µM, and no substantial 
growth inhibition was observed with ML323 alone (IC50=25 µM). In PDAC-3 cell, the 
IC50 values for oxaliplatin and ML323 were 0.43 µM and 15 µM respectively. Finally, 
in PANC-1 cells the IC50 values for oxaliplatin and ML323 were 0.17 µM and 3.9 µM 
respectively. In summary, PANC-1 cells exhibited the highest sensitivity to both 
oxaliplatin and ML323, whereas PDAC-2 was the most resistant cell line to these 
compounds. 
Table 9: Effect of the USP1/UAF1 inhibitor ML323 and the chemotherapy agent 
oxaliplatin as single-drugs in pancreatic cancer cell lines. The IC50 value for 
oxaliplatin and ML323 was calculated for each cell line as described in Figure 62. 
 
Next, in order to evaluate the potential synergistic effects of the combination between 
oxaliplatin and ML323, SRB assays were performed in cells treated with both drugs 
using a fixed ratio based on the IC50 values of the single drugs (Table 10, Ratio O:M). 
Figure 63 shows representative examples of growth inhibitory curves for oxaliplatin, 
ML323 or a combination of both drugs in each cell line. The combination IC50 values 
obtained in these experiments are presented in Table 10 (O(+M)). In PDAC-2 cells, the 
IC50 value for oxaliplatin combined with ML323 was 0.24 µM, substantially lower than 
the IC50 for oxaliplatin as single drug (0.55 µM). In PDAC-3 cells, the IC50 value for the 
combination was 0.31 µM, slightly lower than the IC50 for oxaliplatin as single drug 
(0.43 µM). Finally, in PANC-1 cells, the IC50 value for the combination (0.15 µM) was 
similar to the IC50 for oxaliplatin as single drug (0.17 µM). 
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Figure 63: Growth inhibition curves of PDAC-2, PDAC-3 and PANC-1 cell lines 
treated with oxaliplatin, ML323 or their simultaneous combination. 
Exponentially growing cells seeded in 96 well plates were treated with oxaliplatin, 
ML323 or a combination of both drugs (O+M). The combination treatment was 
carried out using a constant oxaliplatin:ML323 ratio (see Table 10). After 72 hours 
of drug exposure, SRB assays were performed. Representative examples of the 
growth inhibition curves obtained in each cell line are shown. The drug 
concentration on the x-axis of the growth inhibition curves for the combination 
treatment indicates oxaliplatin concentration. The dotted line represents the 50% 
of cell growth used to determine the IC50. 
To further analyse the interaction between oxaliplatin and ML323, the fraction affected 
(Fa) and the combination idex (CI) were calculated using CalcuSyn, and median-drug 
effect plots were generated (Figure 64). 
Table 10: Effect of the combination between oxaliplatin and ML323 in 
pancreatic cancer cell lines. Treatment with the two drugs in combination was 
carried out using a constant oxaliplatin:ML323 ratio (Ratio O:M) that was 
individually established for each cell line as the ratio of the IC50 values for each 
single drug. The IC50 values obtained in the combination treatments experiments 
are represented as (O(+M)). At least three independent experiments per cell line 
were carried out. 
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Figure 64: Median-drug effect plots for PDAC-2, PDAC-3 and PANC-1 cell lines 
treated with oxaliplatin, ML323 or their combination. Using Calcusyn, the effect 
of the combination of oxaliplatin and ML323 was compared to the effect of each 
drug to determine the combination index (CI) at a range of a Fa (Fraction-affected 
by the dose). The resulting CI values were plotted agains the Fa to produce the 
median-drug effect plot for each cell line. The dashed horizontal line represents a 
CI=1.  
Finally, CI values at Fa of 0.5, 0.75 and 0.9 were averaged for each experiment, and this 
value was used to calculate the mean CI between experiments (Figure 65 and Table 11). 
A mean CI higher than 1.2 indicates an antagonistic effect of the drug combination, a 
mean CI value between 0.8 and 1.2 indicates an additive effect, and if the mean CI 
value is lower than 0.8 the effect is considered synergistic (Bijnsdorp et al., 2011) 
(Table 5). A strongly synergistic effect was observed for the combination of oxaliplatin 
and ML323 in PDAC-2 cell line whereas PDAC-3 presented an additive effect and 
PANC-1 an antagonistic effect (Figure 65). These findings indicate that, as previously 
noted in preclinical models of NSCLC, the USP1 inhibitor ML323 may synergize with 
platinum-based drugs, and increase the sensitivity of some pancreatic cancer-derived 
cells to these compounds. 
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Figure 65: Mean CI values of the oxaliplatin+ML323 combination in PDAC-2, 
PDAC-3 and PANC-1. Dotted lines highlight the CI values (0.8 and 1.2) that 
establish the limits to identify each combination as synergistic (CI ≤ 0.8), additive 
(0.8 < CI < 1.2) or antagonistic (CI ≥ 1.2). 
4.3.3.4. Cellular changes associated to the treatment of pancreatic cancer cells 
with oxaliplatin and ML323 
In an attempt to identify cellular changes associated to the effect of the 
oxaliplatin+ML323 combination, we treated PDAC-2 and PDAC-3 cells with 
oxaliplatin, ML323, or a combination of both drugs as indicated above. After 72h of 
treatment, we analysed three different cellular phenotypes that could be affected by the 
drugs: (i) USP1 and UAF1 mRNA levels, (ii) USP1 protein levels and (iii) formation of 
DNA adducts.  
Table 11: The interaction between oxaliplatin and ML323. The combination index 
(CI) value was calculated at a full range of Fa values using CalcuSyn. The final CI 
value for each experiment was determined as the average of the CI at Fa = 0.5, 
0.75 and 0.9. At least three independent experiments per cell line were carried 
out, and the CI value indicated in the Table represents the mean of the final CI 
values of these experiments. According to the CI, the nature of the interaction 
between the drugs (Effect) was classified as synergistic (CI < 0.8), additive 
(0.8 < CI. < 1.2) or antagonistic (CI > 1.2). 
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USP1 and UAF1 mRNA levels were analysed by qRT-PCR and normalized to the 
levels in the untreated (UT) control sample. The most obvious change was an increase 
in the mRNA levels of both USP1 and UAF1 in PDAC-2 cells treated with the 
oxaliplatin+ML323 combination (Figure 66A). Interestingly, in PDAC-3 cells only the 
levels of USP1 mRNA, but not UAF1 mRNA, were increased by the 
oxaliplatin+ML323 combination (Figure 66B). 
 
Figure 66: Relative USP1 and UAF1 mRNA levels in PDAC-2 and PDAC-3 treated with 
oxaliplatin, ML323 or a combination of both drugs (O+M). Graphs show USP1 and UAF1 
mRNA expression levels in treated cells relative to untreated (UT) cotrols. USP1 and UAF1 
levels determined with the ∆∆Ct method and normalized with GAPDH. 
USP1 protein levels were also analysed by immunoblot. In PDAC-2 cells (Figure 67A), 
oxaliplatin treatment increased USP1 protein. Conversely, ML323 treatment clearly 
decreased USP1 levels, and appeared to counteract the increase induced by oxaliplatin. 
In PDAC-3 cells (Figure 67B), oxaliplatin did not appear to increase USP1 protein 
levels. A decrease in USP1 was detected in cells treated with ML323 (either as single 
drug or in combination with oxaliplatin). 
 
 
114 
Results
  
 
Figure 67: Protein levels in PDAC-2 and PDAC-3 cell lines treated with 
oxaliplatin, ML323, a combination of both drugs (O+M). Immunoblots showing 
the expression of USP1 protein and β-actin (loading control) in PDAC-2 and PDAC-
3 upon 72 h of treatment. 
Finally, we measured the formation of DNA adducts, a specific form of genetic lesions 
that consists on the covalent attachement of a chemical moiety to the DNA. In cells 
treated with platinum-based drugs, such as oxaliplatin, platinum-DNA adducts are 
formed, which interfere with replication and transcription, and eventually lead to cell 
death. Monitoring DNA adduct formation is frequently used as a method to assess the 
effectivity of platinum-based drugs (Stornetta et al., 2017). 
The amount of adducts in a DNA sample can be estimated by using a technique based 
on the amplifcation of a long target sequence by PCR, coupled to Taqman 
quantification (see section 3.5.4). The presence of DNA adducts interferes with the PCR 
reaction and reduces target amplification (Laws et al., 2001). We used this technique to 
analyse DNA extracted from PDAC-2 and PDAC-3 cells either untreated, or treated 
with oxaliplatin, ML323, or a combination of both drugs. 
As expected, oxaliplatin treatment consistently reduced target amplification compared 
to the UT sample (Figure 68A and B). ML323 as a single agent did not reduce target 
amplification indicating that this coumpound does not induce DNA adduct formation 
(Figure 68A and B). Cells treated with the oxaliplatin+ML323 combination had the 
lowest level of target amplification in PDAC-2 cell line, suggesting that the 
combination of oxaliplatin with ML323 induces more DNA adducts than oxaliplatin 
monotherapy (Figure 68A). In contrast, no significant differences between oxaliplatin 
and combination therapy were observed in PDAC-3 cell line (Figure 68B). 
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Figure 68: Evaluation of DNA adducts by XL-PCR. PDAC-2 (A) or PDAC-3 (B) cells 
were either left untreated (UT), or were treated with oxaliplatin, ML323 or a 
combination of both drugs (O+M) for 72h. XL-PCR was performed using primers 
specific for a target sequence in the β-globin gene. Then, TaqMan quantification 
of XL-PCR amplicons was performed using specific primers and probe. Graphs 
represent the percentage of amplification in treated samples relative to the 
untreated control of three different experiments (mean and SEM). ns=non 
significant; *p < 0.05; **p< 0.01 (Student's t-test). 
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4.4. SEARCHING FOR NEW USP1 SUBSTRATES USING bioUb 
Most cellular proteins are regulated by ubiquitination and are thus likely substrates of 
specific DUBs. However, only around a hundred human DUBs exist (Nijman et al., 
2005a). It is therefore reasonable to assume that each DUB may have a relatively wide 
repertoire of substrates. In the case of USP1, only a limited number of bona-fide targets 
(PCNA, FANCD2/FANCI and ID proteins) (Huang et al., 2006; Nijman et al., 2005b; 
Williams et al., 2011) have been identified. In order to gain a deeper understanding of 
USP1 biological function we decided to use the bioUb system (Franco et al., 2011) to 
discover novel proteins that are deubiquitinated by USP1. The data presented in this 
section have been obtained in close collaboration with Drs. Juanma Ramírez, Ugo 
Mayor and Nerea Osinalde (Department of Biochemistry and Molecular Biology, 
UPV/EHU). 
4.4.1. The bioUb system and mass spectrometry 
Our strategy was to combine the bioUb system together with USP1 silencing in 293T 
cells to identify proteins whose ubiquitination increases when USP1 is knocked down 
and thus, represent potential novel USP1 substrates (Figure 69). 
 
Figure 69: Strategy for the identification of new USP1 substrates using bioUb and 
MS. The strategy was based on the combination of the bioUb system with USP1 
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silencing. Biotinylated material was purified using biotin-avidin beads and 
analysed by MS. We used label-free-quantification (LFQ) to identify those hits that 
are more ubiquitinated when USP1 is silenced (circled by dark red in the volcano 
plot). 
First, we followed the workflow illustrated in Figure 70A to ensure that the system 
worked properly in 293T cells. Using immunoblot (Figure 70B) and 
immunofluorescence (Figure 70C), we confirmed that the expression of bioUb6-BirA 
plasmid was high enough to allow isolation of the ubiquitinated proteins in these cells 
for subsequent MS analysis. Importantly, USP1 was very efficiently silenced (Figure 
70B and C). As expected, an FK2 smear was observed in all samples, suggesting that 
ubiquitin conjugation occurred to a similar extent in all conditions, whereas 
incorporation of biotinylated ubiquitin was only observed upon bioUb6-BirA plasmid 
transfection (Figure 70B). 
 
Figure 70: Checking the efficiency of the bioUb/siUSP1 strategy in 293T cells. A. 
Workflow: on day 1, 293T cells were seeded. Next day, cells were left 
untransfected (UT) or transfected with siRNA scramble (siCTRL) or a pool of three 
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siRNAs against USP1 (siUSP1). On day 3, cells were transfected with bioUb6-BirA 
plasmid or left untransfected (UT) and biotin (50 µM) was added. Finally, on day 4, 
cells were subjected to protein extraction (B) or immunofluorescence analysis (C). 
B. Immunoblot analysis using anti-USP1, anti-Biotin and anti-FK2 (conjugated 
ubiquitin) antibodies. bioUb conjugation was efficient and USP1 silencing 
competent. C. Immunofluorescence analysis using Streptavidin-AF594 
(Streptavidin binds biotin) and anti-USP1 antibody. bioUb6-BirA plasmid was highly 
expressed and USP1 efficiently silenced. 
Once we ensured bioUb conjugation was efficient and USP1 silencing competent, we set 
up a larger-scale experiment, with three biological replicates, to carry out the 
purification of bioUb-tagged proteins following the workflow summarized in Figure 71. 
293T plated in 15 cm dishes were transfected with pCAG-BirA together with siCTRL 
as a negative control or pCAG-bioUb6-BirA plasmid together with siCTRL or siUSP1, 
respectively. The pCAG-BirA negative control corresponds to the control plasmid 
expressing only BirA enzyme in order to ensure that protein biotinylation is not 
induced. Biotin was added to the culture medium. Cells were collected 24 hours after 
plasmid transfection.  
 
Figure 71: The bioUb/siUSP1 experiment: from cells to biotin-avidin purification. 
Workflow: 293T cells were seeded in 15 cm dishes. Next day, cells were 
transfected with either siRNA scramble (siCTRL) or a pool of three siRNAs against 
USP1 (siUSP1). The third day cells were transfected with negative control BirA 
plasmid or bioUb6-BirA plasmid and biotin (50 µM) was added. Last day cells were 
collected. A small aliquot was used to check bioUb conjugation and USP1 silencing 
by immunoblot (IB) and the rest subjected to biotin-avidin purification and 
subsequent mass spectrometry (MS) analysis. 
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Immunoblot anslysis demonstrated efficient protein biotinylation and USP1 silencing in 
the three replicates (Figure 72).  
 
Figure 72: Monitoring bioUb conjugation and USP1 silencing in cells to be 
subjected to pulldown. Immunoblot analysis with anti-biotin and anti-USP1 
antibodies showing efficient conjugation of bioUb and efficient silencing of USP1 in 
the three triplicate samples that were subsequently subjected to biotin pulldown. 
The membranes were stained with ponceau to check protein loading. 
The remaining cells were processed under denaturing conditions, and subjected to biotin 
pulldown with NeutrAvidin agarose beads as described in section 3.7.2, in order to 
purify the ubiquitinated material. Analysis of the purified material by silver staining 
(Figure 73, left), and by anti-biotin immunoblot (Figure 73, right) indicated that the 
purification worked successfully.  
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Figure 73: Purification of biotinylated material. Left panel: Representative silver 
staining of the purified material from one of the triplicates. Equal amounts of BirA 
and bioUb6-BirA samples were analysed by SDS-PAGE, and stained with silver. 
Common bands between samples are expected to be composed mainly of 
endogenously biotinylated material, while the thick bands at around 40 kDa and 
below correspond to trimer, dimer and monomer forms of NeutrAvidin. The main 
high molecular weight smear observed in the experimental (bioUb6-BirA) but not in 
the control (BirA) samples corresponds to the isolated ubiquitinated material. 
Right panel: Representative anti-biotin immunoblot. 1:60 dilution of the input and 
flow-throught (FT) and 1:300 dilution of the elution, as indicated, were loaded. 
Finally, the proteins eluted from the biotin-avidin pulldown were identified by using 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Proteins 
known to be common contaminants (Keller et al., 2008), reverse hits and proteins with 
no unique peptides or intensity were removed. Altogether, 1410 different proteins were 
identified in the bioUb6-BirA+siCTRL (hereafter called siCTRL for the sake of 
simplicity) samples, and 1404 different proteins were identified in the bioUb6-
BirA+siUSP1 (hereafter siUSP1) samples. In total, 1449 different proteins were 
identified, and 1365 of those (95%) were present in both conditions (Figure 74). In 
principle, all these proteins have been modified by conjugation of biotinylated ubiquitin. 
 
Results
121 
  
Our next goal was to estimate the relative abundance of these proteins in the siCTRL 
and the siUSP1 samples, to identify those that may be differentially ubiquitinated in the 
absence of USP1. 
 
Figure 74: Venn diagram indicating the overlap between the proteins identified 
in siCTRL and siUSP1 samples. About 95 % of all the proteins identified were 
found in both samples (brown). 
To this end, we used the Label Free Quantification (LFQ) method (Wong and Cagney, 
2010). After confirming that each sample followed a normal distribution and that the 
correlation between samples was high, the siUSP1/siCTRL LFQ ratio (siUSP1(1+2+3 
replicates)/siCTRL(1+2+3 replicates) was calculated using the MaxLFQ algorithm. Of 
note only those proteins identified in two or three biological replicates of at least one of 
the conditions were included in the LFQ analsys.  
Proteins whose siUSP1/siCTRL ratio was higher than 2, with a p-value (two-sided t-
test) lower than 0.05, were considered to be significantly more ubiquitinated in the 
absence of USP1 (Figure 75). Reassuringly, the known USP1 substrate PCNA was 
identified as one of the proteins whose ubiquitination is significantly higher in the 
siUSP1 condition. 
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Figure 75: Volcano plot showing the proteins that appeared differentially 
ubiquitinated upon USP1 silencing. Proteins are ranked in a volcano plot. On the 
y axis, statistical p-value (-log10 p-value siUSP1/siCTRL LFQ intensity ratio). On the 
x axis, siUSP1/siCTRL ratio (log2 LFQ ratio siUSP1/siCTRL). Those proteins with a 
LFQ ratio higher than 2 (1 in log2 scale) and p-value less than 0.05 (1.30 in -log10 
scale) were considered to be more ubiquitinated when USP1 is silenced (indicated 
in red). 
In adition to PCNA, 10 proteins whose ubiquitination increases upon USP1 silencing 
were identified (Table 12). The list of potential novel USP1 substrates includes proteins 
involved in DNA repair (KIAA0101, RIF1), DNA transcription (POLR1A, TFAP4, 
HIST2H2AC), cell cycle regulation (CCND2, RIF1), Metabolism (MPI), ATP-related 
functions (ATP6V0A2), tRNA processing (TRMT6) and SUMOylation (UBA2). 
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Table 12: List of potential USP1 substrates. Gene names, Uniprot entry, the 
number of peptides including unique peptides identified for each protein, the 
siUSP1/siCTRL ratio and significance p-values are shown. 
 
4.4.2. Validation of MS-detected potential novel USP1 substrates by 
immunoblot 
Our next goal was to begin the validation of the potential novel USP1 substrates 
identified by MS. This validation can be carried out by direct immunoblot analysis 
using specific antibodies for the candidates. 
We searched the published bibliography on the candiates, and decided to start with the 
DNA-repair related proteins RIF1 and KIAA0101. RIF1 plays a crucial role in the 
choice between DSB repair by NHEJ or HR (Daley and Sung, 2013). On the other hand, 
KIAA0101, known as PAF15 (PCNA-Associated Factor) is a small protein that 
interacts with PCNA and plays a key role in the exchange from DNA replicative 
polymerase to translesion synthesis polymerase in TLS (Xie et al., 2014)d. Thus, from a 
biological point of view, these two proteins seemed like interesting candiates to begin 
the validation. 
We tested three commercially available anti RIF1 antibodies, but were unable to obtain 
consistent results. 
A commercially available anti-PAF15 antibody reproducibly identified a single clear 
band in immunoblots, although with an apparent molecular weight slightly higher than 
the predicted for PAF15. We decide to use this antibody to confirm that an ubiquitinated 
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form of PAF15 protein accumulates upon USP1 silencing. As shown in Figure 76, a 
single band of similar intensity was detected with anti-PAF15 antibody in the three 
input samples. After biotin-streptavidin pull-down, no bands were observed in the 
BirA+siCTRL or the bioUb6-BirA+siCTRL samples. In contrast, a single band (arrow) 
was detected in the bioUb6-BirA+siUSP1 sample. This band migrated with an apparent 
molecular weight approximately 30 kD higher than the band in the input samples. 
Attachment of one ubiquitin molecule increases a protein molecular weight in about ~10 
kDa, suggesting that more than one ubiquitin moieties have been attached in this case.  
 
Figure 76: Immunoblot validation of using anti-PAF15 antibody. A single band of 
similar intensity is detected in input samples. In the elution of the bioUb pulldown, 
a higher molecular weight band is observed, only in the siUSP1 sample, indicating 
that the ubiquitination of the detected protein is increased after USP1 silencing. 
The difference in size with respect to the “input” band suggests conjugation of 3 
ubiquitin moieties. 
In summary, using bioUb strategy followed by MS analysis, 10 novel potential USP1 
substrates have been identified, including the DNA damage-related proteins RIF1 and 
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PAF15. Although further experimental validation and analysis are required, our findings 
suggest potential novel roles of USP1 in the regulation of the DNA damage response. 
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4.5. SEARCHING FOR MOLECULAR MECHANISMS THAT 
MAY UNDERLIE THE FUNCTIONAL DIFFERENCES 
BETWEEN USP12 AND USP46 
Human deubiquitinases USP12 and USP46 are very similar proteins. As shown in 
Figure 77, the amino acid sequence identity between these proteins is 88%. The most 
prominent difference is the presence of 4 additional residues (MEIL) in the N-terminal 
of USP12 that are absent in USP46. Interestingly, USP12 and USP46 have been 
reported to share some cellular activities, but also to carry out unrelated functions. As a 
potential mechanism that migth underlie the functional differences between these two 
DUBs, we hypothesized that USP12 and USP46 could display differences in binding to 
their cofactors or other proteins. In this section, we used subcellular relocation assays to 
characterize the interaction of these DUBs with their cofactors UAF1 and WDR20, as 
well as with DMWD, a poorly characterized interactor of these DUBs. 
 
Figure 77: USP12 and USP46 alignment using CLUSTAL-OMEGA. USP12 and 
USP46 are almost equal in sequence with exception of 4 amino acids in the N-
terminal of USP12 that are not present in USP46 (red square). Letters are colored 
according to the physicochemical properties of the represented residue. An “*” 
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(asterisk) indicates fully conserved residues. A “:” (colon) indicates residues with 
strongly similar properties . A “.” (period) indicates residues with weakly similar 
properties as below. 
4.5.1. Analysis of USP12 and USP46 binding to UAF1 and WDR20 
using relocation assays 
Whereas UAF1 binding appears to be sufficient to activate USP1 (Cohn et al., 2007, 
2009), full enzymatic activation of USP12 and USP46 requires binding to both UAF1 
and WDR20 (Dahlberg and Juo, 2014; Kee et al., 2010). 
As shown in our previous work (Garcia-Santisteban et al., 2012; Olazabal-Herrero et al., 
2015) and in section 4.2., the nuclear relocation assay has proven to be a convenient and 
reliable approach to characterize the interaction of USP1, USP12 and USP46 with 
UAF1. Therefore, we decided to use a similar approach to characterize the interaction of 
USP12 and USP46 with WDR20. First, we confirmed that WDR20, like UAF1, is a 
cytoplasmic protein (Figure 78A). As previously detailed, unlike GFP-USP1, YFP-
tagged USP12 and USP46 were located in the cytoplasm. Therefore, a NLS was fused 
to the N-terminal of the DUBs to force their entry into the nucleus and test their ability 
to relocate their cofactors (Figure 78B). 293T cells were co-transfected with GFP-USP1, 
YPF-[NLS]-USP12 or YPF-[NLS]-USP46 together with either UAF1-mRFP or Myc-
tagged WDR20. As shown above (section 4.2.3.), GFP-USP1, YFP-[NLS]-USP46 and 
YFP-[NLS]-USP12 relocated UAF1 to the nucleus to a similar extent, suggesting that 
the three DUBs interact in a comparable manner with this cofactor (Figure 78C). On the 
other hand, GFP-USP1 did not induce relocation of Myc-WDR20, consistent with 
previous reports that these two proteins do not interact (Kee et al., 2010). Strikingly, the 
localization of YFP-[NLS]-USP12 and Myc-WDR20 drastically changed when these 
two proteins were co-expressed. As shown in Figure 78D, both proteins fully 
translocated to the plasma membrane where they co-localized. In marked contrast, a 
very limited relocalization of YFP-[NLS]-USP46 and Myc-WDR20 to the plasma 
membrane was noted. In fact, YFP-[NLS]-USP46 remained largely nuclear whereas 
Myc-WDR20 remained predominanlty cytoplasmic in co-transfected cells. These 
observations, which have been confirmed in HeLa cells (not shown), suggest that 
WDR20 binds more strongly to USP12 than to USP46.  
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Figure 78: Relocation assay to evaluate the interaction of USP1, USP12 and 
USP46 with the cofactors UAF1 and WDR20. A. 293T cells co-transfected with 
UAF1-mRFP and Myc-WDR20, showing cytoplasmic localization of both proteins. 
B. 293T cells co-transfected with GFP-USP1, YFP-USP12, YFP-USP46, YFP-[NLS]-
USP12 and YFP-[NLS]-USP46. C and D. Relocation assay in 293T cells co-transfected 
with UAF1-mRFP or Myc-WDR20 together with USP1 or NLS-fused USP12 and 
USP46.  
4.5.2. Analysis of the binding of DMWD, a WDR20 paralog, to USP12 
and USP46 
In 2009, Sowa and co-workers published the first global DUB interactome analysis by 
using a large-scale proteomic approach (Sowa et al., 2009). In this analysis, they 
reported thousands of DUB-binding proteins, including several interactors of USP12 
and USP46. One of the USP12 or USP46 interactors reported by Sowa et al, a protein 
termed DMWD (dystrophia myotonica WD-repeat containing protein) called our 
attention, because we noted that this protein has a high sequence similarity (53% of 
identity) with WDR20 (Figure 79). 
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Figure 79: WDR20 and DMWD alignment using CLUSTAL-OMEGA. WDR20 and 
DMWD share a 53% of sequence identity. Letters are colored according to the 
physicochemical properties of the represented residue. An “*” (asterisk) indicates 
fully conserved residues. A “:” (colon) indicates residues with strongly similar 
properties . A “.” (period) indicates residues with weakly similar properties as 
below. 
The gene encoding DMWD is located in chromosomal region 19q13.32, and is one of a 
group of genes whose expression is disregulated by the expansion of a CTG repeat 
sequence that causes dystrophia myotonica (DM), a neuromuscular disease primarily 
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characterized by progressive muscle weakness (Ranum and Day, 2004). In the global 
proteomics analysis by Sowa et al., DMWD appeared as bound to USP12, USP46 and 
UAF1. These interactions, however, have not been validated in direct assays.  
We decided to use the relocation assay to validate and characterize the binding of 
DWMD to USP12, USP46 and UAF1. First, we assessed the localization of Myc-tagged 
DMWD in 293T cells, and found it to be cytoplasmic (Figure 80A, left). As above, we 
used YFP-[NLS]-USP12 and YFP-[NLS]-USP46 to test their ability ro relocate Myc-
DMWD. As a negative control, we included USP1, which was not reported to interact 
with DMWD (Kee et al., 2010; Sowa et al., 2009). In addition, we generated a nuclear 
version of DMWD, termed YFP-[NLS]-DMWD (Figure 80A, right), in order to test its 
interaction with UAF1. Then, we co-expressed Myc-DMWD or YFP-[NLS]-DMWD 
with GFP-USP1, YFP-[NLS]-USP12, YFP-[NLS]-USP46 or Xpress-UAF1. As shown 
in Figure 80B, no apparent relocation of the proteins was noted in cells co-expressing 
Myc-DMWD with GFP-USP1 or YFP-[NLS]-USP46 neither in cells co-expressing 
YFP-[NLS]-DMWD with Xpress-UAF1. In contrast, a partial relocation of YFP-[NLS]-
USP12 to the plasma membrane was observed when co-expressed with Myc-DMWD. 
Of note, this relocation was less pronounced that the one induced by Myc-WDR20. 
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Figure 80: Relocation assay to evaluate the interaction of USP1, USP12, USP46 
and UAF1 with DMWD. A. Confocal images of 293T cells expressing Myc-DMWD 
or YFP-[NLS]-DMWD. B. Confocal images of 293T cells expressing Myc-DMWD or 
YFP-[NLS]-DMWD together with YFP/GFP tagged USP1, NLS-USP12 and NLS-USP46 
or Xpress-UAF1. 
These results, therefore, validate the interaction between USP12 and DMWD previously 
reported by proteomics. However, we could not confirm the interaction of DMWD with 
USP46 or UAF1. 
In summary, our findings unveil previously unknown differences in the binding of 
USP12 and USP46 to their cofactor WDR20 and to DMWD. 
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4.5.3. The amino terminal motif “MEIL” in USP12 contributes to 
binding to WDR20 and DMWD  
We hypothesized that the different binding of USP12 and USP46 to WDR20 and 
DMWD could be related to differences in their amino acid sequence. The most evident 
difference is a 4 amino acid motif (MEIL) present in the extreme amino-terminal end of 
USP12, but absent in USP46 (Figure 77). We generated a version of YFP-[NLS]-USP12 
lacking this short motif, termed YFP-[NLS]-USP12delMEIL. 293T cells were transfected 
with Myc-WDR20 together with YFP-[NLS]-USP12 or YFP-[NLS]-USP12delMEIL. As 
shown in Figure 81A, the USP12 mutant lacking the MEIL motif remained mostly in the 
nucleus when co-expressed with WDR20, suggesting that deletion of the MEIL motif 
virtually abrogated USP12/WDR20 interaction. Similar results were observed regarding 
the USP12/DMWD interaction (Figure 81B).  
These observations suggest that the 4 amino acid motif MEIL at the amino-terminal end 
of USP12 significantly contributes to its interaction with WDR20 and DMWD, thus 
explaining why USP46, which lacks this motif, has a weaker or undetectable interaction 
with these proteins. 
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Figure 81: The MEIL motif in the N-terminal of USP12 contributes to the 
interaction of USP12 with DMWD and WDR20. Confocal images of 293T cells co-
transfected with NLS-fussed USP12 wild type or the mutant version lacking the N-
terminus YFP-[NLS]-USP12delMEIL and Myc-WDR20 (A) or Myc-DMWD (B). Deletion 
of the MEIL motif drastically reduces the ability of USP12 to relocate to the 
plasma membrane when co-expressed with WDR20 or DWMD. 
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5. Discussion 
Since the discovery of ubiquitin in 1975 (Goldstein et al., 1975), the field of protein 
ubiquitination has developed into a very active area of research. Over the last 
decades, most attention has been devoted to the enzymes that mediate the 
attachment of the ubiquitin to the target substrates, particularly to E3 ligases. More 
recently, the enzymes that reverse ubiquitination, the DUBs, have also attracted 
considerable research interest. It has been found that DUBs participate in essential 
cellular processes, and alterations in DUB function have been linked to various 
human diseases, including cancer (Fraile et al., 2012). However, our understanding 
of the function and regulation of DUBs lies behind that of E3 ligases. 
The human genome encodes approximately 100 DUBs (Nijman et al., 2005a). In this 
Thesis, we have studied three human DUBs (USP1, USP12 and USP46) that share a 
common regulatory mechanism: its enzymatic activity requires binding to the 
cofactor UAF1 (Cohn et al., 2007, 2009). 
Most of the work described here relates to USP1, which is emerging as a potential 
therapeutic target in cancer. First, focusing on the regulation of this DUB by 
phosphorylation, autocleavage and binding to UAF1, we clarify standing 
controversies and deepen into the details of these mechanisms. We also describe 
how cancer-related mutations in USP1 may affect its regulation and cellular 
activity. Next, we examine the effect of a novel USP1/UAF1 inhibitor, ML323, in 
cellular models of pancreatic cancer. Finally, we apply a novel approach, termed 
bioUb, followed by quantitative proteomics and identify potential novel targets of 
USP1. 
Regarding USP12 and USP46, two DUBs with a very high sequence similarity but 
some disparate functions, we identify a potential molecular basis for the observed 
functional differences between these enzymes. 
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5.1. DEEPENING INTO USP1 REGULATION: SERINE 313 
PHOSPHORYLATION, AUTOCLEAVAGE AND UAF1-
INTERACTION 
Phosphorylation at Serine 313 (Cotto-Rios et al., 2011b; Villamil et al., 2012b), 
autocleavage at the G670/G671 diglycine motif (Huang et al., 2006) and interaction 
with UAF1 (Cohn et al., 2007) are critical events regulating USP1 function, but 
several aspects of these regulatory mechanisms are still controversial or remain to 
be elucidated. 
Phosphorylation of USP1 at residue S313 regulates USP1 stability (Cotto-Rios et al., 
2011b). It has also been reported to be necessary for UAF1 binding and activity in an in 
vitro experimental setting (Villamil et al., 2012b). In contrast to these in vitro data, our 
data using several cellular assays clearly indicate that phosphorylation of USP1 at S313 
is not essential for UAF1 binding or activity. We have demonstrated interaction of a 
non-phosphorylatable mutant USP1S313A with UAF1 using a nuclear relocation assays in 
live and fixed cells, as well as with co-IP. Our findings have been later independently 
confirmed by another group (Yin et al., 2015). The experimental approach we used, 
with ectopically expressed proteins, has certainly limitations, but is, in our opinion, 
closer to a physiological setting than in vitro assays with purified recombinant proteins. 
Therefore, we conclude that S313 phosphorylation of USP1 is not required for UAF1 
binding. 
Importantly, USP1S313A forms a functional complex with UAF1 in transfected cells. This 
is shown by the clearly increased levels and autocleavage of the USP1S313A protein 
when co-expressed with UAF1, which indicate stabilization and catalytic activation of 
the mutant DUB. Furthermore the USP1S313A/UAF1 complex is able to reverse 
monoubiquitination of endogenous PCNA. It must be stressed that our data do not rule 
out the possibility that S313 phosphorylation plays a (non-essential) role regulating 
USP1 activity. In fact, we noted that a phosphomimetic mutant USP1S313D showed a 
slightly increased ability to reverse PCNA ubiquitination.  
Autocleavage at the G670/G671 diglycine motif was originally reported to be induced 
by UV light (Huang et al., 2006). However, we noted that USP1 autocleavage is also 
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readily detected in untreated cells co-transfected with GFP-USP1 and Xpress-UAF1, 
probably as a result of the high levels of expression of the USP1/UAF1 complex. This 
observation provides a convenient experimental system to gain further mechanistic 
insight into this important regulatory mechanism. Our results, using a combination of 
USP1 mutants, suggest that USP1 autocleavage occurs intramolecularly (in cis) (Figure 
82). The three-dimensional structure of the USP1/UAF1 complex has not yet been 
solved and, since the autocleavage site lies within a non-conserved inserted domain (Ye 
et al., 2009), it is impossible to model this area of USP1 using other USPs as template. 
Nevertheless, based on our findings, we predict that the diglycine motif of a USP1 
molecule can reach its own catalytic site to undergo cleavage. 
 
Figure 82: Model representing the cis mode of autocleavage in USP1. 
The most important controversy at the beginning of this Thesis concerned the identity of 
the UAF1 binding motif in USP1. Using cell-based assays our group had initially 
mapped the UAF1-binding site to USP1(420-520) (Garcia-Santisteban et al., 2012). 
Later, Villamil et al, using in vitro assays with purified recombinant proteins, mapped 
the UAF1 binding site to USP1(235-408) (Villamil et al., 2012b), a region located 
within a non-conserved inserted domain (Ye et al., 2009) and containing the S313 
phosphorylation site.  
To address this controversy, we decided to compare side-to-side both potential UAF1 
binding sites. The results of this direct comparison further support our initial findings 
that the critical UAF1 binding site is USP1 420-520 amino acid motif. The reasons for 
the discrepancy between the data obtained in vitro and in cell-based assays are not clear. 
Since USP1 NLSs (Garcia-Santisteban et al., 2012) overlap with the S313 
phosphorylation site, we tested the possibility of competition between nuclear import 
receptors and UAF1 for binding to this region, but this does not appear to be the case. 
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It is important to note that the UAF1 binding region reported by Villamil et al. is not 
conserved in USP12 and USP46. In contrast, the 420-520 region is well conserved in 
the three UAF1-regulated DUBs. In fact, we demonstrate that the UAF1-binding motif 
of USP46 lies within the 165–259 fragment, a segment homologous to USP1(420-520). 
In silico modeling showed that USP1(420–520) and USP46(165–259) motifs lie within 
the “Fingers” subdomain of the DUBs. These data represented the first published report 
identifying the “Fingers” subdomains as the UAF1-binding site (Olazabal-Herrero et al., 
2015), and have been subsequently validated by the three dimensional structures of 
USP12/UAF1 and USP46/UAF1 complexes (Dharadhar et al., 2016; Li et al., 2016; Yin 
et al., 2015). 
5.2. FINE-MAPPING THE USP1/UAF1 INTERACTION  
In the context of the potential use of USP1 as a therapeutic target, it must be noted that, 
besides inhibiting its enzymatic activity with USP1 inhibitors, an alternative approach 
might involve interfering with the formation of USP1/UAF1 complex. To this end, 
knowing the molecular details of the USP1/UAF1 interaction is critical. Optimally, 
these details would be revealed by solving the three-dimensional structure of the 
USP1/UAF1 complex. However, this appears to be a challenging task that remains to be 
accomplished. As an alternative, we undertook a detailed mapping of the sequences 
involved in the USP1/UAF1 interaction.  
We started this mapping effort before any structural information on the DUB/UAF1 
complexes was available. Thus, we relied on two criteria to predict USP1 residues that 
might be important for UAF1 binding. On one hand, we reasoned that the critical 
residues would be conserved in USP12 and USP46, but not in other DUBs. On the other 
hand, since the front side of the “Fingers” subdomain of USPs usually engages in 
ubiquitin binding, we hypothesized that the critical residue(s) for binding to UAF1 
would most likely be located at the back of USP1 “Fingers”. Using these criteria, we 
selected and mutated four amino acids R439, L441, L446, S494. Disappointingly, we 
found that a quadruple mutant (USP14m) with mutations in these residues was still able 
to bind UAF1. 
When our paper with these data was under review, Yin et al published the structure of 
the USP46/UAF1 complex (Yin et al., 2015). Making use of this structural information, 
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these authors identified a group of 4 residues on the tips of the “Fingers” (what they 
called the ERLE motif) that are important for UAF1 interaction in USP1, USP12 and 
USP46 (Yin et al., 2015). In the case of USP1, the ERLE motif is formed by E444, 
R439, L441 and E516. In our view, it is remarkable that, even without having the 
support of structural information, the changes we had decided to introduce into our 
USP14m mutant included two residues in the ERLE motif (R439 and L441). 
Unfortunately we did not mutate E444, which turned out to be the most critical USP1 
amino acid for UAF1 interaction (Yin et al., 2015). 
Yin et al also identified three amino acid residues in the β-propeller domain of UAF1 
(K214/W256/R272) that are important for interaction with the DUBs (Yin et al., 2015). 
Building on these data, we found that a single point mutation in UAF1 (K214E) is 
enough to disrupt the interaction with the three DUBs. 
In summary, the data described in this Thesis (using cell-based assays) and data from 
other groups (using mostly in vitro assays) identify USP1 E444 and UAF1 K214 as 
critical residues for the USP1/UAF1 interaction. These findings provide information 
that may guide future attempts to disrupt the USP1/UAF1 complex as a therapeutic 
strategy.  
Disruption of the USP/UAF1 complex is expected to abrogate USP1 activity. We decide 
to test this assumption, which is mostly based on in vitro data (Yin et al., 2015), using 
our cellular assays. As expected USP1E444K and UAF1K214E mutations abrogate 
autocleavage. Also as expected, USP1E444K was unable to decrease UbPCNA levels. 
However, co-expression of USP1WT with UAF1K214E led us to make an unexpected 
observation: UbPCNA levels were consistently reduced in these cells. This was 
puzzling because overexpressed USP1WT is expected to be “free” (co-expressed 
UAF1K214E cannot bind to USP1 and endogenous UAF1 molecules would be unable to 
bind all overexpressed USP1 molecules), and thus catalytically inactive. This 
observation suggested that “free” USP1 was still capable of counteracting PCNA 
ubiquitination in a manner that would not require its catalytic activity. This was 
subsequently confirmed by showing that UbPCNA levels are reduced in cells 
expressing USP1WT alone, as well as in cells expressing the catalytically inactive mutant 
USP1C90S alone. 
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As a possible explanation for these findings, we propose the model shown in Figure 83. 
In this model, when USP1WT and UAF1 are co-expressed in cells, they form 
USP1/UAF1 complexes that deubiquitinate PCNA. When USP1C90S and UAF1 are co-
expressed they form catalytically inactive complexes that do not deubiquitinate PCNA 
Figure 83A. When either USP1WT or USP1C90S are expressed alone, they will be free 
and may prevent PCNA ubiquitination (rather than inducing its deubiquitination,) by a 
mechanism that does not require USP1 enzymatic activity. This mechanism requires the 
DUB to be “free” from UAF1, and might involve binding/sequestering a yet unknown 
protein (X) required for PCNA ubiquitination Figure 83B. Of note, this mechanism 
seems to be hampered in the case of the USP1E444K mutant, as cells overexpressing this 
mutant showed high levels of UbPCNA. If our model is correct, the E444K mutation, 
besides disrupting binding to UAF1, also disrupts binding to the “X” protein.  
In normal cellular conditions, every USP1 molecule is thought to be in complex with 
UAF1 (Cohn et al., 2007) and thus, the physiological relevance of our observation is 
still unclear. However, it must be noted that other DUBs, such as yeast Ubp6 (an 
homolog of human USP14) have also been reported to present a "non-catalytic” effect 
(Hanna et al., 2006). 
 
Figure 83: A proposed model for the “non-catalytic” effect of USP1 in the 
regulation of PCNA ubiquitination. In cells expressing a catalytically active 
USP1/UAF1 complex, UbPCNA undergoes deubiquitination. In cells 
overexpressing free USP1 (even the catalytically inactive C90S mutant), a “non-
catalytic” mechanism counteracts PCNA ubiquitination. 
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5.3. FUNCTIONAL CONSEQUENCES OF CANCER-RELATED 
USP1 MUTATIONS 
Around a hundred cancer-associated USP1 mutations are included in the COSMIC 
database. Some of these changes are non-sense or frameshift mutations that would most 
likely result in a non-functional allele, but most USP1 mutations lead to single amino 
acid substitutions whose effect is still unknown. Some of these missense mutations are 
located in/near the “Fingers” subdomain of USP1 (S475Y, D502N, and S575R), and 
several others are located in close proximity to USP1 autocleavage site (G667A, L669P, 
K673T and A676T). 
We used a panel of cell-based assays to test the functional consequences of these 
cancer-related USP1 mutations. We evaluated their ability to bind UAF1, to 
undergo autocleavage and to decrease UbPCNA levels. In addition, prompted by 
the observation of the potential “non-catalytic” effect of USP1 on PCNA 
ubiquitination, we decided to search for novel functional readouts. We examined 
two well-characterized DNA damage-related phenomena: the recruitment of 
ubiquitinated proteins (Messick and Greenberg, 2009), and of 53BP1 (Huyen et al., 
2004) into nuclear foci after cell treatment with the DSB-inducing agent NCS.  
We found that USP1/UAF1 overexpression resulted in a striking depletion of 
conjugated ubiquitin from the nucleus, as determined by FK2 immunostaining. Such a 
general ubiquitin deconjugation was not observed in the nuclei of cells expressing other 
DUBs, such as USP3 or USP22, but was noted (although to a lesser extent) in cells 
expressing high levels of USP7. Of note, USP1/UAF1 and USP7 have been reported to 
have higher enzymatic activity than other USPs in biochemical analyses with artificial 
substrates (Cohn et al., 2007; Faesen et al., 2011; Villamil et al., 2012a). Our data 
suggest that this higher in vitro enzymatic activity translates into higher promiscuity of 
these USPs when they are ectopically expressed in cells. Importantly, such promiscuity 
limits the usefulness of USP1/UAF1 overexpression experiments to explore the role of 
the complex in specific cellular pathways and to identify its physiological substrates. 
More generally, although the number of DUBs compared in our study is certainly 
limited, our findings suggest that potential promiscuity should be taken into account 
when the results of DUB overexpression screens are interpreted. 
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On the other hand, we also found that USP1/UAF1 overexpression completely blocked 
the recruitment of 53BP1 into NCS-induced foci. A similar effect has been reported by 
overexpression of other DUBs, such as USP3 (Sharma et al., 2014). Admittedly, it is not 
possible to establish to what extent general ubiquitin deconjugation by USP1/UAF1 
contributes to the observed blockade of 53BP1 recruitment. Thus, we cannot claim that 
the USP1/UAF1 complex plays a physiological role in regulating 53BP1 recruitment.  
Regardless of their physiological relevance, the general ubiquitin deconjugation and 
the blockade of 53BP1 recruitment by USP1/UAF1 represent two novel clear-cut 
readouts expanding the battery of tests that can be used to investigate the phenotypical 
consequences of USP1 mutations. Using this battery of tests, we have identified two 
cancer-related mutations that affect USP1 function (S475Y) or regulation by 
autocleavage (L669P). 
Cancer-related missense mutations that result in decrease deubiquitination activity have 
been identified in other DUBs, including USP7 (Huether et al., 2014). However, to the 
best of our knowledge, the S475Y substitution was the first cancer-related loss-of-
function missense mutation identified in USP1 (Olazabal-Herrero et al., 2016). 
Interestingly, the S475Y mutation abrogates substrate deubiquitination without 
impairing UAF1 binding or autocleavage. In our view, a plausible explanation for this 
finding would be that this mutation interferes with the binding of the ubiquitin moiety in 
substrates to the complex. Thus, substrate deubiquitination would be impaired, but 
autocleavage would be preserved.  
On the other hand, the L669P mutation severely reduces USP1 cleavage efficiency. This 
mutation is adjacent to the diglycine autocleavage motif. We hypothesize that this 
mutation might introduce a conformational change that hampers access of the cleavage 
site to the catalytic site. Importantly, USP1L669P is able to interact with UAF1 and 
clearly retains its ability to deubiquitinate substrates. This further demonstrates that 
autocleavage is not required for substrate deubiquitination, as already shown by the 
analysis of the experimental mutant USP1GG/AA (Huang et al., 2006, and our data not 
shown). It is tempting to speculate that, by disrupting the normal balance of USP1 
cleavage, this L699P mutation may contribute to tumorigenesis, and further experiments 
should address this possibility.  
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5.4. EFFECT OF THE USP1 INHIBITOR ML323 IN 
PANCREATIC CANCER CELLS 
The USP1/UAF1 complex is emerging as a potential therapeutic target in cancer 
(García-Santisteban et al., 2013). A major challenge in cancer therapy results from the 
development of drug resistance in tumor cells. Resistance may arise if cancer cells 
acquire an increased ability to repair or tolerate the DNA lesions induced by 
chemotherapeutic drugs, such as cisplatin or oxaliplatin, (Martin et al., 2008). It has 
been recently reported that the USP1 inhibitor ML323 (Dexheimer et al., 2014) may 
reverse cisplatin resistance in NSCLC cells (Liang et al., 2014). Here, we tested its 
effect in cellular models of pancreatic cancer. 
Most of the validation of ML323 as an specific and potent inhibitor of the USP1/UAF1 
complex has been done using in vitro assays (Liang et al., 2014). To further test the 
specificity of ML323, we compared the effect of the drug with siRNA-mediated USP1 
knockdown. Both siUSP1 and ML323 treatment increased the number of 53BP1 and 
FK2-positive foci. We noted that ML323 treatment resulted in a more pronounced 
increase in the number of FK2 or 53BP1 foci than USP1 knockdown. This observation 
might indicate that the drug has additional effects besides inhibiting USP1/UAF1, but it 
might as well simply reflect a more complete blockade of USP1/UAF1 function by 
ML323. Additionally, we demonstrate that ML323 has the potency to inhibit 
overexpressed USP1/UAF1. Altogether, the results of these preliminary tests made us 
confident that the endogenous USP1/UAF1 complex woud be competently inhibited in 
cells treated with ML323.  
The effect of inhibiting USP1 has only been tested in NSCLC cells. We have further 
extended this analysis to pancreatic cancer, a cancer type with very poor prognosis and 
limited therapeutic alternatives. 
Supporting the view that USP1 inhibition could represent a valid strategy in pancreatic 
cancer treatment, we found that USP1/UAF1 mRNA is commonly overexpressed in 
pancreatic cancer. Large scale analyses using microarray and RNAseq have shown that 
the mRNA levels of USP1 (García-Santisteban et al., 2013) and UAF1 
(https://www.oncomine.org/resource/login.html) are frequently increased in different 
cancer types. Consistent with these observations, our qRT-PCR data in a limited 
 
Discussion
143 
  
number of clinical samples as well as in a relatively large panel of pancreatic cancer 
derived cell lines indicate that overexpression of USP1 and UAF1 mRNA is also a 
common feature in this tumor type. Of note, expression of USP1 and UAF1 mRNA was 
higher in HPDE and HPNE non-transformed pancreatic cells that in normal pancreatic 
tissue (although lower than in most cancer-derived cell lines). This suggests that 
USP1/UAF1 mRNA levels may also increase during the establishment of cell cultures.  
Interestingly, we found a strong correlation between the expression of USP1 and UAF1 
in pancreatic cancer cell lines. The “non-catalyitic” effect of free USP1 on PCNA 
ubiquitination described above raised the possibility that overexpression of the DUB 
alone might have phenotypical consequences. Nevertheless, these findings would 
suggest that overexpression of a catalytically active USP1/UAF1 complex (requiring 
co-overexpression of the DUB and its cofactor) might confer additional selective 
advantage for tumor development.  
Three pancreatic cancer cell lines with different levels of USP1/UAF1 mRNA (PDAC-2 
(low), PANC-1 (intermediate) and PDAC-3 (high)). were selected to analyze the effect 
of oxaliplatin and ML323as single agents or in combination. 
Our data suggest that higher levels of USP1 and UAF1 mRNA do not predict a more 
beneficial effect of ML323, as it might be expected. Rather, our results suggest that the 
effect of the oxaliplatin/ML323 combination is related to the degree of resistance to 
oxaliplatin as single agent. Thus, the oxaliplatin/ML323 combination had a synergistic 
effect in the cell line showing the highest resistance to oxaliplatin (PDAC-2), but an 
antagonistic effect in the most oxaliplatin-sensitive cell line (PANC-1). PDAC-3 cell 
line showed an additive drug interaction. A similar correlation was previously observed 
in a broad panel of NSCLC cell lines treated with the combination of cisplatin (another 
platinum-based drug) and pimozide (another USP1 inhibitor) (García-Santisteban et al., 
2013). 
In an attempt to elucidate some cellular factors that might determine the effect of 
the oxaliplatin/ML323 combination, we examined the levels of USP1/UAF1, as 
well as the presence of DNA adducts.  
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USP1 mRNA levels have been reported to change (decreasing after 4 h and increasing 
after 16 h) in cisplatin-treated NSCLC cells (Sourisseau et al., 2016). In contrast, we 
found no significant change in the levels of USP1 or UAF1 mRNA after 72 h treatment 
with oxaliplatin or ML323 as single agents. The oxaliplatin/ML323 combination 
increased USP1 levels in both cell lines, as well as UAF1 mRNA levels in PDAC-2 
cells line. USP1 protein levels were increased by oxaliplatin treatment in PDAC-2 cell 
line, but not in PDAC-3. Interestingly, ML323 treatment (either as single drug or in 
combination with oxaliplatin) clearly decreased USP1 protein levels in both cell lines. 
In our view, the most firm conclusion that can be drawn from these results is that 
ML323, besides inhibiting USP1 activity, also decreases USP1 protein levels. Other 
USP1 inhibitors (SJB2-043 and pimozide), had been previously reported to decrease 
USP1 protein levels through proteasomal-mediated degradation (Mistry et al., 2013), 
but this effect had not been yet described for ML323.  
On the other hand, we found that the synergistic effect of the oxaliplatin/ML323 
combination observed in PDAC-2 cells correlates with a significant increase in the 
number of DNA adducts with respect to the oxaliplatin monotherapy. The relevance of 
this correlation needs to be further investigated using a larger panel of cell lines. 
Nevertheless, our findings are in line with previous data showing that synergistic effects 
of platinum-based drugs in combination with different agents are mainly dependent on 
an increase in platinum adduct formation (Avan et al., 2013; Xu et al., 2003). These 
findings in PDAC-2 cell line are illustrated in Figure 84. 
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Figure 84: The model proposed for explaining the synergistic effect observed in PDAC-2 cell 
line. 
In conclusion, although the number of cell lines analyzed is limited, our findings 
suggest that USP1 inhibition might contribute to reverse oxaliplatin resistance in 
pancreatic cancer by increasing the formation of platinum-DNA adducts. 
5.5. NOVEL USP1 SUBSTRATES RELATED TO DNA DAMAGE 
Given that only a few number of well-characterized USP1 substrates have been 
identified to date, we decided to search for novel targets. We used a recently-established 
system termed bioUb (Franco et al., 2011) to pull down endogenous ubiquitinated 
proteins, followed by mass spectrometry. We combined this system with siRNA-
mediated USP1 knockdown, and applied label-free quantification (LFQ) to identify 
endogenous proteins that are differentially ubiquitinated in USP1-silenced cells. 
Reassuringly, the known USP1 substrate PCNA turned out as one of the endogenous 
proteins showing increased ubiquitination after USP1 knockdown. Besides PCNA, we 
identified 10 novel potential USP1 substrates. We decided to begin the validation of 
these candidates, by focusing on RIF-1 and PAF15. These two proteins were 
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particularly interesting in our opinion because, like USP1, they have DNA damage-
related functions (Daley and Sung, 2013; Xie et al., 2014).  
Unfortunately, we have not yet been able to unambiguously validate these candidates 
due to technical difficulties with commercially available antibodies. On one hand, three 
different anti-RIF-1 antibodies did not provide convincing results in immunoblot 
analysis and no further validation of this protein has been yet attempted. On the other 
hand, using anti-PAF15 antibody, we have obtained encouraging, but not conclusive 
results. This antibody detected a clear single band. Interestingly, this band was detected 
in cell extracts from both control samples and siUSP1 samples, but only in the bioUb 
pulldown eluates from siUSP1 samples. Moreover, the molecular weight of the band 
detected in the pulldown eluates was higher, suggesting an ubiquitinated form of the 
detected protein. Therefore, it seems reasonable to assume that we are detecting a 
protein that shows increased ubiquitination when USP1 is silenced, i.e. a USP1 
substrate. However we cannot be absolutely confident that it is PAF15, since the size of 
the detected bands is higher that the predicted molecular weight of PAF15. 
In summary, our study significantly expands the repertoire of USP1 targets and may 
provide novel insights into the role of USP1 in the DNA damage response. However, 
these candidates need to be validated before being considered bona-fide USP1 
substrates. Our analysis serves as a pilot experiment to evaluate the possibility of 
applying a similar strategy to identify substrates for other DUBs in the context of the 
ProteoRed platform (Carlos III Networked Proteomics Platform).  
5.6. USP12/USP46: SIMILAR PROTEINS, DIFFERENT 
FUNCTIONS 
USP12 and USP46 are nearly 90% identical at the amino acid level. Furthermore, 
they share UAF1 and WDR20 as activating cofactors (Cohn et al., 2009; Dahlberg 
and Juo, 2014; Kee et al., 2010), as well as some substrates and interactors (Sowa et 
al., 2009). One might assume that USP12 and USP46 would play largely 
overlapping roles in the cell. Indeed, these two DUBs have functions in common, 
but they also display disparate activities in unrelated cellular processes. 
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Here we show that the functional differences between USP12 and USP46 correlate 
with differences in their binding to the cofactor WDR20 and to the interactor 
DMWD. Using relocation assays, we found that co-expression of YFP-[NLS]-
USP12 with WDR20 resulted in a striking relocation of both proteins to the plasma 
membrane. Such a relocation was also evident, although less pronounced, when 
YFP-[NLS]-USP12 was co-expressed with DMWD. In contrast, YFP-[NLS]-USP46 
remained largely nuclear when co-expressed with WDR20 and no effect was 
observed when co-expressed with DMWD. In our view, the different extent of this 
relocation suggests that USP12 and USP46 bind differently to WDR20 and DMWD. 
Further experiments (e.g. co-IP or in vitro binding assays to determine the 
dissociation constants of each interacting pair) should be carried out to confirm our 
observations. 
Interestingly, differential binding to these proteins may, in turn, be related to the 
presence (in USP12) or absence (in USP46) of a four amino acid motif (MEIL) at 
their extreme N-terminal end. Deleting this motif largely (although not completely) 
abrogates USP12/WDR20 and USP12/DMWD interaction, as detected using the 
relocation assay. The structure of a ternary US12/UAF1/WDR20 complex has been 
recently solved (Li et al., 2016), showing that several residues in USP12 “Palm” 
subdomain contribute to WDR20 binding. However, it is important to note that the 
analysis by Li et al. does not provide structural information on the extreme N-
terminal end of USP12, and thus, they cannot determine if this region (including the 
MEIL motif) engages in WDR20 binding. Based on our data and the data by Li et 
al., we propose the model illustrated in Figure 85. According to this model, two 
USP12 regions contribute to WDR20 binding: the “Palm” subdomain and the N-
terminal MEIL motif. Although no structural information of USP46/WDR20 
binding is available yet, we propose that USP46 (lacking the MEIL motif) binds 
WDR20 exclusively through the “Palm” subdomain. As a consequence, the 
USP46/WDR20 interaction would be weaker than the USP21/WDR20 interaction.  
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Figure 85: A proposed model for the binding of USP12 and USP46 to WDR20. 
WDR20 binds to the “Palm” subdomain and the MEIL motif of USP12. WDR20 only 
binds the “Palm” subdomain of USP46. 
It is presently unknown why the interaction with WDR20 or DMWD induces DUB 
relocation to the plasma membrane. A likely explanation might be exposure of a 
previously masked plasma membrane recruitment motif in either the DUB or the 
interacting partner. This relocation might represent a novel mechanism to regulate 
DUB activity. In this regard, it has been reported that only a fraction of the 
USP12/UAF1 complexes associate with WDR20 (Kee et al., 2010). Thus, we 
propose that different USP12-containing complexes, with different level of 
enzymatic activity and different subcellular localization exist in the cells: 
USP12/UAF1 complexes with partial activity distributed in the cytoplasm or the 
nucleus, and USP12/UAF1/WDR20 complexes with full enzymatic activity located 
at the plasma membrane. 
.
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6. Conclusions 
1. In a cellular setting, USP1 phosphorylation at serine 313 is not necessary for 
UAF1 biding neither for its deubiquitinase activity.  
2. Regulation of USP1 by autocleavage involves most likely an intramolecular 
(cis) cleavage event.  
3. The “Fingers” subdomain is the critical UAF1-interacting region of UAF1-
regulated DUBs. The USP1/UAF1 interaction can be disrupted by single 
point mutations of specific critical residues in the DUB (E444) or the 
cofactor (K214). 
4. Besides the well-characterized deubiquitination of PCNA by the USP1/UAF1 
complex, “free” USP1 might prevent PCNA ubiquitination independently of its 
deubiquitinase activity. 
5. Ectopic overexpression of the USP1/UAF1 complex leads to a general ubiquitin 
 deconjugation in the nucleus, and blocks 53BP1 foci recruitment to DNA damage. 
6. Both the function and the regulation of USP1 can be altered by cancer-related 
missense mutations. 
7. The USP1/UAF1 complex may represent a valid therapeutic target in pancreatic 
cancer: USP1 and UAF1 are overexpressed in this tumor type, and the USP1 
inhibitor ML323 increases oxaliplatin sensitivity in a relatively resistant 
pancreatic cancer cell line.  
8. Combining the bioUb approach with siRNA-mediated DUB silencing and label- 
 free  quantification-based  proteomics  constitutes  a  useful  strategy  to  search  for 
 novel  DUB  targets.  We  have  identified  10  novel  potential  USP1  substrates, 
 including the DNA damage-related proteins RIF1 and PAF15.
9. USP12 and USP46 bind differently to WDR20, and DMWD. This differential 
binding appears to be mediated by the presence/absence of a 4 amino acid motif 
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(MEIL) at their N-terminus, and may contribute to explain the previously 
observed functional differences between these two highly similar enzymes. 
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8. Supplementary tables 
Supplementary table 1: List of plasmids obtained from other researchers. The name of the 
plasmid, the provider and their respective research centers are detailed. 
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Supplementary table 2: Plasmids obtained by cloning. Information about the generated plasmid, the name of the insert, the template used, the 
cloning method, forward (F) and reverse (R) primers, the ligated vector and the restriction enzymes.  
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Supplementary table 3: List of primers used for PCR cloning. Primer names (Primer ID) 
and the corresponding nucleotide sequences in 5´ 3´ direction are indicated. 
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Supplementary table 4: List of plasmids mutated by site-directed mutagenesis. The name 
of the plasmid, the template used in the PCR, the amino acid substitution (Aa substitution) as 
well as the forward (F) and reverse (R) primers are indicated. 
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Supplementary table 5: List of primers used for mutagenesis. Primer names (Primer ID) 
and the corresponding nucleotide sequences in 5’  3’ direction are indicated. 
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Supplementary table 6: List of primers used for sequencing. Primer names (Primer ID), the 
corresponding nucleotide sequences, forward or reverse and the vector where they hybridize 
are indicated. 
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